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Abstract 
Atherosclerosis is a chronic inflammatory disease characterized by thickening of the arterial 
wall from accumulation of lipoproteins and immune cells within the vessel intima, forming a 
lipid-rich plaque. Macrophages play a central role in atherosclerosis progression through 
phagocytic removal of apoptotic cells in a process termed efferocytosis. With disease 
progression however, macrophage efferocytosis becomes defective and uncleared apoptotic 
cells undergo secondary necrosis and form a necrotic core that increases the risk of plaque 
rupture. Despite the importance of defective efferocytosis in atherosclerosis, little is known 
about how efferocytosis becomes impaired. The aim of this thesis was to characterize 
mechanisms regulating efferocytic clearance of apoptotic cells and to identify potential 
mechanisms that contribute to impaired efferocytosis in atherosclerosis. Using a combination 
of mass spectrometry and microscopy-based efferocytosis uptake assays, we identified Rab17 
as a regulator of apoptotic cargo trafficking to the recycling endosomes. Disruption of Rab17 
function using a dominant-negative mutant resulted in mis-trafficking of apoptotic cargo away 
from recycling endosomes and into the MHC class II loading compartment. We then examined 
the gene expression profile of macrophages from the aortas of patients undergoing open heart 
surgery to identify potential mechanisms driving defective efferocytosis. We found over 3,000 
differentially-expressed protein-coding genes in these macrophages, with particular 
enrichment in pathways involved in cholesterol handling, efferocytosis and efferosome 
maturation. Interestingly, we observed upregulation of the hematopoietic transcription factor 
GATA2, which has been shown by genetic linkage studies to be associated with coronary 
artery disease. By perturbing GATA2 expression in oxLDL-treated THP-1 human 
macrophages, we found that oxLDL-induced impairment in efferocytosis and efferosome 
maturation is dependent on GATA2. Our findings indicate that exposure to pro-atherogenic 
conditions induces upregulation of GATA2 expression, which specifically impairs efferocytic 
uptake of apoptotic cells and efferosome maturation. Our data shed new light on the process 
of macrophage efferosome maturation and how this process is impaired in atherosclerosis. We 
are also the first to describe a role for GATA2 in mediating oxLDL-induced impairment in 
efferocytosis. Therefore, GATA2 and other processes involved in dysregulation of efferosome 
maturation may be suitable therapeutic targets in human atherosclerotic disease. 
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Lay Abstract 
Atherosclerosis is a disease of the blood vessels involving the accumulation of cholesterol and 
cells of the immune system within the vessel wall. This results in the formation of an 
atherosclerotic plaque, which grows over time and may eventually rupture and cause a number 
of complications, including heart attack and stroke. A type of immune cell called macrophages 
can migrate into the atherosclerotic plaque and remove dying cells and debris from within the 
plaque in a process called ‘efferocytosis’. Macrophage efferocytosis helps limit the growth of 
the plaque. However, over time efferocytosis within the plaque becomes defective, and 
macrophages are no longer able to limit plaque growth leading to faster disease progression. 
In this thesis, we studied macrophages isolated from atherosclerotic plaques in human patients 
to understand how efferocytosis becomes defective in atherosclerosis. We first identified a new 
regulator of efferocytosis called Rab17, which helps the macrophage properly break down the 
dead cells and debris it takes up during efferocytosis. We then found that certain genes and 
pathways related to efferocytosis were dysregulated in the macrophages from patients. These 
included pathways related to how the macrophage processes excess cholesterol and how 
macrophages deal with the dead cells they take up. Finally, we identified a transcription factor 
(protein that regulates gene expression) that was associated with defective efferocytosis called 
GATA2. We found that an increase in the amount of GATA2 in the cell seemed to be required 
for macrophages to develop defective efferocytosis. Taken together, these results advance our 
understanding of atherosclerosis and uncovers a role for GATA2 in the development of 
atherosclerotic disease. 
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Chapter 1  
1 Introduction 
1.1 Efferocytosis and regulation of tissue homeostasis 
1.1.1 Overview of efferocytosis 
The removal of dying and dead cells in situ is essential in multicellular organisms for 
proper growth during embryogenesis and early development, and for maintenance of tissue 
homeostasis in adults.1,2 Cells that are senescent, damaged or have otherwise received an 
appropriate signal undergo a form of programmed cell death termed “apoptosis”.1,3 
Apoptosis involves a series of tightly regulated processes mediated by sequential activation 
of caspase enzymes that result in degradation of cellular compartments and packaging of 
cellular contents in plasma membrane-contained vesicles known as apoptotic bodies.2,4 
Apoptotic bodies must be efficiently removed in order to safely dispose of their contents 
and to avoid secondary necrosis, a process whereby uncleared apoptotic bodies leak their 
contents, which include a number of pro-inflammatory damage-associated molecular 
patterns (DAMPs), into the extracellular milieu and instigate a pathological inflammatory 
response.5,6 
Apoptotic bodies are removed by other cells through phagocytic uptake and intracellular 
degradation of the apoptotic contents.1 This process of phagocytic removal of apoptotic 
cells is known as “efferocytosis”.1,2 Efferocytosis is a highly conserved physiological 
process that is crucial for the maintenance of tissue homeostasis, play a role in 
organogenesis, tissue remodeling (e.g. bone growth, involution of mammary glands, etc.), 
tissue repair following injury, and, in certain species, during organ or limb regeneration.7–
9 Efferocytosis is a highly efficient process. Under normal conditions, uncleared apoptotic 
cells are rarely detectable in vivo, even in tissues undergoing high rates of cellular turnover 
such as the tonsils and thymus.10 
The importance of efferocytosis in tissue homeostasis is underscored by fact that defective 
apoptotic cell clearance appears to be a central feature of several inflammatory and 
autoimmune diseases, including systematic lupus erythematosus and atherosclerosis.10–12 
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1.1.2 Types of efferocytes in the body 
In higher mammals, including humans, dying cells within tissues are removed by either 
cells that are specially adapted for efferocytosis or by neighbouring cells for which 
efferocytosis is not a primary function depending on the specific tissue in question and the 
circumstances of cellular death.13,14 The professional phagocytes for which efferocytic 
removal of apoptotic cells is a primary function include macrophages and dendritic cells, 
of which macrophages in particular are thought to carry out the majority of efferocytosis 
across a diverse range of tissues within the body.3 However, many other cell types have 
been observed to possess limited efferocytic capacity and usually function to remove 
neighbouring apoptotic cells under specific circumstances.13 These so-called non-
professional phagocytes include epithelial cells, endothelial cells and fibroblasts.15–17 Non-
professional phagocytes are less efficient at apoptotic cell clearance, internalize apoptotic 
cells at a slower rate and lack the capacity to clear multiple apoptotic cells in rapid 
succession.18 
In certain immune-privileged sites where circulating immune cells cannot access, non-
professional phagocytes play an essential role in apoptotic cell clearance.19,20 One example 
of this is within the eye, where specialized epithelial cells known as retinal pigment 
epithelial cells efferocytose membrane-bound, rhodopsin-containing disc structures shed 
on a daily basis by photoreceptor cells.21 Mutations in efferocytic receptors involved in this 
process results in the development of retinitis pigmentosa, a progressive degenerative 
disease characterized by loss of photoreceptor cells and resultant visual impairment and 
loss.22 Another example of the role non-professional phagocytes within an immune-
privileged site is the clearance of apoptotic germ cells that arise in the process of 
spermatogenesis by Sertoli cells within the testes.20 The presence of non-professional 
phagocytes within these tissues highlights the importance of apoptotic cell clearance across 
all tissues in the body.13 
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1.1.3 Recognition and uptake of apoptotic cells 
1.1.3.1 Find-me signals 
Efferocytosis proceeds through a number of distinct stages, the first of which involves 
migration of an efferocyte to the apoptotic cell.23,24 Similar to the migration of immune 
cells towards pathogens and sites of infection, migration of efferocytes to apoptotic cells 
is dependent on a number of soluble chemoattractants, called “find-me” signals, that guide 
efferocyte migration in a concentration-dependent fashion.24 To date, four distinct find-me 
signals have been identifying: extracellular adenosine triphosphate (ATP) and uridine 
triphosphate (UTP), fractalkine (CX3CL1), lysophosphatidylcholine (lysoPC) and 
sphingosine-1-phosphate (S1P).23 These signals are generated following activation of 
executioner caspases that cleave a variety of structural components of the apoptotic 
cell.23,25 
The release of the extracellular nucleotides ATP and UTP occurs early in the execution 
phase of apoptosis.26 Caspase 3/7-mediated cleavage of pannexin-1 on the apoptotic cell 
surface leads to the opening of pannexin channels and release of cytosolic nucleotides into 
the extracellular environment.27 Macrophages and other phagocytes recognize ATP and 
UTP in the environment through the G-protein-coupled receptor (GPCR) P2Y2. P2Y2 
activation promotes myeloid cell vascular adhesion and motility, and genetic deletion of 
P2Y2 in mice delays the kinetics of apoptotic cell clearance in these animals.26 
Another find-me signal that is released relatively early on during apoptosis is 
fractalkine/CX3CL1.28 Fractalkine is an atypical chemokine that initially exists in a 
membrane-bound form and is cleaved to a soluble form through the activity of the metal 
metalloproteinases ADAM10 and ADAM17.29 Fractalkine is recognized by the receptor 
CX3CR1.28 Truman et al. found that soluble fractalkine is released by apoptotic Burkitt 
lymphoma cells and stimulated macrophage chemotaxis.28 In addition to acting as a find-
me signal for apoptotic cells, the CX3CL1-CX3CR1 signaling axis also appears to play an 
important role in promoting monocyte cell survival.30 Absence of either ligand or receptor 
results in decreased numbers of circulating monocytes in knockout mice and treatment of 
human monocytes ex vivo with fractalkine extended their survival.31,32 
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The other two known find-me signals, LysoPC and S1P, accumulate to physiologically-
relevant levels only later in apoptosis (4-12 hrs following induction).23 LysoPC was first 
described as a lymphocyte chemoattractant by Hoffman et al. in 1982.33 Caspase-mediated 
activation of phospholipase A2 drives the production of lysoPC from phosphatidylcholine 
found on plasma membranes.34 Peter et al. demonstrated that monocytes and macrophages 
recognize lysoPC using the GPCR G2A, and that knocking down G2A expression in 
macrophages inhibited cell migration in the presence of lysoPC.35 S1P is a lipid signal 
mediator with a diverse range of biological functions.23 During the process of apoptosis, 
S1P is generated by the activity of S1P kinase 2, which has been shown to be a target of 
caspase 1.36 S1P is recognized by five GPCR’s on a range of lymphocytes (S1PR1-S1PR5) 
and activation of these receptor drive lymphocyte migration under a variety of 
circumstances, including mediating migration of monocytes and macrophages in response 
to S1P release from apoptotic cells.24 
1.1.3.2 Eat-me signals 
Following migration of a phagocyte to the apoptotic cell through the action of find-me 
signals, the next step in efferocytosis is recognition of the apoptotic cell by the phagocyte.2 
This is achieved through recognition by the phagocyte of specific ligands on the surface of 
the apoptotic cells, called “eat-me” signals.23,37 A number of eat-me signals have now been 
identified, including exposure of phosphatidylserine (PS) on the outer leaflet of the plasma 
membrane, alterations in the glycosylation patterns on the apoptotic cell surface, changes 
in ICAM-1 epitopes on the cell surface, and exposure of the endoplasmic protein 
calreticulin on the cell surface.2,5 
Of these, PS exposure on the plasma membrane outer leaflet has been by far the most 
recognized and well-understood eat-me signal.38 In healthy cells, PS is sequestered on the 
cytoplasmic face of the plasma membrane through the activity of membrane flippases that 
actively shuttle PS from the outer leaflet to the inner leaflet.5,38 Segawa et al. were able to 
demonstrate that caspase 3/7-mediated cleavage of the ATP-dependent flippase enzyme 
ATP11C is required for PS exposure during apoptosis.39 In contrast, scramblase enzymes 
mediate movement of PS to the outer leaflet and Suzuki et al. showed caspase 3/7-mediated 
cleavage of the scramblase Xkr8 led to its constitutive enzymatic activity and drove PS 
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exposure.40 In a series of experiments using camptothecin- or anti-Fas-induced apoptosis 
of Jurkat T cells, Borisenko et al. demonstrated that the amount of PS exposed on the cell 
surface increased by >280-fold following induction of apoptosis and that a minimum 
threshold of an 8-fold increase in PS levels on the cell outer surface was required before 
macrophage-mediated efferocytosis would occur.41 In addition, it is also thought that a 
fraction of exposed PS becomes oxidized or otherwise modified and that this may increase 
its affinity towards certain efferocytic receptors.38 
Despite the requirement for significant PS exposure before efferocytosis can occur, healthy 
cells possess an additional means of safeguarding themselves against inappropriate 
efferocytosis in the form of so-called “don’t eat-me” signals that inhibit phagocytosis.1,23 
To date, just two such signals have been identified: CD47 and the recently recognized β2-
microglobulin (B2M) component of the major histocompatibility complex (MHC) class I 
molecule.42,43 CD47 is a surface protein that belongs to the immunoglobulin superfamily 
and interacts in cis with integrins and plays a role in immune cell migration and 
proliferation.44 In the context of efferocytosis, CD47 is recognized by the surface 
glycoprotein SIRPα expressed on the surface of phagocytes and the CD47-SIRPα signaling 
axis serves to inhibit phagocytosis of the CD47-expressing cell through phosphorylation 
of immunoreceptor tyrosine-based inhibitory motifs (ITIMs) on the cytoplasmic tail of 
SIRPα, which leads to the recruitment of the phosphatases SHP1 and SHP2.45,46 The 
activity of these phosphatase inhibits the accumulation of myosin II during phagocytic cup 
formation to inhibit phagocytosis.46 More recently, Barkal et al. described the expression 
of β2M on the surface of a range of human cancer cell lines and found that the level of 
β2M expression correlated with the degree of protection against macrophage-mediated 
phagocytosis.43 The authors found that β2M was recognized by the inhibitory receptor 
LILRB1 expressed on the surface of macrophages and β2M-LILRB1 signaling was 
sufficient to inhibit phagocytosis.43 
1.1.3.3 Efferocytic receptors 
Exposed eat-me signals on the surface of apoptotic cells are recognized by efferocytic 
receptors expressed on the surface of efferocytes, either directly or through bridging 
molecules that opsonize the apoptotic cell.3,46 Curiously, although there are only a few 
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recognized eat-me signals, these signals can be recognized by a wide range of efferocytic 
receptors and opsonins.1,3 The majority of efferocytic receptors function by binding to PS, 
either directly or through one or more opsonins. Among the efferocytic receptors that are 
capable of binding directly to PS are: member of the TIM family of receptors (including 
TIM-1, TIM-3 and TIM-4), brain angiogenesis inhibitor 1 (BAI1), Stabilin-2, members of 
the CD300 family of receptors and the receptor for advanced glycation end products 
(RAGE).47–51 Opsonin-dependent efferocytosis receptors include integrin αVβ3, the TAM 
family of receptors, which includes three members: Tyro-3, Axl and Mer, and integrin αXβ2, 
which was recently described by our lab  to participate in efferocytosis.52–54 The other eat-
me signals also have corresponding efferocytic receptors. Modified ICAM3 is recognized 
by CD14 on the phagocyte surface, calreticulin is recognized by low density lipoprotein 
receptor-related protein 1 (LRP1; CD91) with the complement molecule C1q acting as a 
bridging opsonin, while modified phospholipids, including oxidized PS, can be recognized 
to a limited extent by the class B scavenger receptor CD36.55–57 
Several bridging opsonins that recognize PS have been identified and work in concert with 
efferocytic receptors that do not directly recognize PS to mediate recognition of apoptotic 
cells.58 Hanayama et al. identified that the secreted glycoprotein milk fat globule-EGF-
factor 8 (MFG-E8) could bind to PS on the surface of apoptotic cells.59 The same group 
later found that in mice lacking MFG-E8, apoptotic lymphocytes in the spleen and lymph 
nodes were not efficiently cleared and the mice went on to develop autoimmune 
glomerulonephritis, underscoring the importance of this MFG-E8 in efferocytosis in vivo.60 
MFG-E8 is recognized by integrin αVβ3 and mediates αVβ3-dependent recognition of 
apoptotic cells.38 Two other opsonins, the vitamin K-dependent proteins Gas6 and protein 
S, are recognized by the TAM family of efferocytic receptors and mediate TAM receptor-
dependent apoptotic cell recognition.53,58 Protein S is produced by a wide variety of tissues 
across the body and is found as a circulating factor in the blood.53 In addition to its role in 
efferocytosis, protein S also plays an important role as a cofactor for protein C in the 
inactivation of factors Va and VIIIa in the extrinsic pathway of the coagulation cascade.53 
Gas6 is primarily produced by endothelial cells, vascular smooth muscle cells and in the 
bone marrow.53 Members of the TAM family have different affinities for each of these 
opsonins, with Gas6 preferentially binding to Axl and protein S binding preferentially to 
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Tyro-3 and MerTK.53 Two other potential opsonins that have been recently proposed to 
function cooperatively with the TAM family of receptors are the signaling proteins tubby 
and tubby-like protein 1 (TULP1), both of which are preferentially recognized by 
MerTK.61 Mice lacking either tubby or TULP1 have significantly impaired efferocytosis 
within the retina and develop a number of vision disorders as a result.62,63 Finally, our lab 
has recently identified a soluble form of the transmembrane glycoprotein CD93 (solCD93) 
as an opsonin that mediates integrin αXβ2-dependent efferocytosis.54 A summary of find-
me signals, eat-me/don’t eat me signals and their cognate receptors and opsonins is 
presented in Table 1.1.  
Table 1.1 List of find-me, eat-me and don't eat me along with their cognate opsonins 
and/or receptors. 
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1.1.4 Apoptotic cell internalization 
Following recognition of the apoptotic cell, it is subsequently internalized by the efferocyte 
for degradation and clearance.64 The process of apoptotic cell uptake is complex and there 
are probably multiple signaling pathways utilized by different efferocytic receptors. Peter 
Henson and others have suggested that the process of apoptotic cell uptake occurs through 
two distinct steps: binding of the apoptotic cell to the efferocyte and subsequently its uptake 
into the efferocyte in what has been termed the “tether-and-tickle” process.1,23,65 Tethering 
holds the apoptotic cell in place while the phagocyte forms an invagination within their 
plasma membrane called a “phagocytic cup” to mediate the engulfment of the apoptotic 
cell.66 Certain efferocytic receptors are able to mediate both apoptotic cell binding and 
uptake, while others, including CD14 and TIM4, are able to tether apoptotic cells but do 
not initiate their uptake.1 Indeed, it is believed that many efferocytic receptors that 
recognize and tether apoptotic cells require cooperative binding and signaling through 
integrins and other canonical phagocytic receptors to mediate apoptotic cell 
internalization.67,68 One example of this is the efferocytic receptor TIM-4, which utilizes 
β1 integrins as coreceptors in order to induce the necessary signal to initiate apoptotic cell 
internalization.69 
A complete discussion of the signaling pathways used by efferocytic receptors is beyond 
the scope of this thesis, but has been reviewed in detail by Elliot et al., Freeman et al. and 
others.46,58 However, signaling from efferocytic receptors appear to converge on the 
activation of several Rho guanosine triphosphatases (GTPases): Rac1, Cdc42 and RhoA, 
that drive formation of the phagocytic cup required to engulf and then internalize the target 
apoptotic cell.37 Rac1 in its active state is a crucial mediator of actin polymerization via the 
Scar/WAVE complex, which is required for formation of membrane extrusion and the 
phagocytic cup.70 Signaling from efferocytic receptors activate Rac1 through recruitment 
of several guanine nucleotide exchange factors (GEFs), in particular the Dock180-Elmo 
complex which is crucial for apoptotic cell uptake and highly evolutionarily conserved.37 
A number of other factors have also been found to participate in this process and drive 
Rac1 activation. Among these is CrkII, a member of the Crk family of adaptor proteins that 
are known to associate with Dock180.71 While a direct physical association between 
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Dock180 and CrkII appears not to be required for internalization of apoptotic cells, deletion 
of the CrkII homologue in C. elegans was sufficient to abrogate efferocytosis.72 An 
illustration of efferocytic receptor crosstalk and convergence at Rac1-Dock180-Elmo 
complex is presented in Figure 1.1. 
 
Figure 1.1 Convergence of efferocytic receptor signaling onto Rac1 activation. 
Efferocytic receptors (BAI1, integrin αVβ5, stabilin-2) utilize distinct signaling pathways 
that convergence on the activation of the Rho-GTPase Rac1. Activation of BAI1 results in 
recruitment of the Dock180-Elmo GEF complex, which directly activates Rac1. Signaling 
from integrin αVβ5 recruits focal adhesion kinase (Fak), which recruits the CrkII-
Dock180-Elmo complex using the scaffold protein p130Cas as a mediator. Stabilin-2 
signaling recruits the adaptor protein Gulp1, which is thought to mediate direct activation 
of Rac1 or enable cooperative signaling with integrin αVβ5 to drive Rac1 activation. Figure 
adapted from Penberthy & Ravichandran.37 
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Rac1 activity is antagonized by RhoA, which activates the Rac1 GTPase-activating 
proteins (GAPs) p190Rho-GAP and FilGAP to drive Rac1 inactivation.73 The contribution 
of RhoA to efferocytosis has been somewhat controversial since it plays different roles 
during phagocytic cup formation and phagocytic cup closure.70 While impairment of RhoA 
function results in impaired apoptotic cell clearance, there is evidence that its activity is 
required for phagocytic cup closure and internalization of the apoptotic cell.74,75 Indeed, it 
has been demonstrated that RhoA signaling through Rho-associated protein kinase 
(ROCK) drives activation of myosin II, which is crucial for actin contraction and functions 
to pull the engulfed apoptotic cell into the efferocyte.76 Using fluorescence resonance 
energy transfer (FRET)-based biosensors to examine the spatiotemporal dynamics of Rac1 
and RhoA activation, Kim et al. found that the ratio of Rac1/RhoA appeared to play a role 
in determining whether apoptotic materials were internalized by the efferocyte, with the 
authors suggesting that this served as an additional mechanism to prevent inappropriate 
efferocytosis.77 
1.1.5 Efferosome maturation 
Following closure of the phagocytic cup, the apoptotic cell is fully contained within a 
plasma membrane-derived vacuole, which then undergoes scission from the cell surface 
membrane to form an efferosome.70 The efferosome then undergoes a series of highly 
regulated biochemical modifications to efficiently degrade the internalized apoptotic cell 
in a remodeling process called efferosome maturation.64,70 Efferosome maturation is 
characterized both by sequential fusion with early and then late endosomes along with 
progressive acidification of the efferosomal lumen in order to drive the breakdown of 
apoptotic cargo.64 The regulation of efferosome maturation is complex but the most well-
defined mechanism driving this process is the sequential recruitment of the small GTPases 
Rab5 and Rab7 to the efferosome surface (see Figure 1.2).64 
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Figure 1.2 Sequential recruitment of the small GTPases Rab5 and Rab7 to the 
efferosome surface regulates efferosome maturation. 
Following apoptotic cell recruitment, Rab5 is recruited to the surface of the nascent 
efferosome, where it drives fusion between the efferosome and early endosomes to form 
the early efferosome. Fusion with early endosomes also mediates recycling of efferocytic 
receptors to the cell surface. Rab5 is then replaced on the efferosome surface by Rab7, 
marking the transition to the late efferosome. The late efferosome undergoes acidification 
and fusion with lysosomes, acquiring the lysosomal marker LAMP-1 as a result. Figure 
adapted from Kinchen & Ravichandran.64 
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One of the earliest maturation events following apoptotic cell internalization is recruitment 
of Rab5 to the nascent efferosome, a process that is driven by the Rab5 GEF Gapex-5.78 
Initially, activated Rab5 recruits another GEF, Rabex-5, which is thought to further recruit 
Rab5 and stabilize Rab5 on the surface of the efferosome.79 A series of Rab5 effectors are 
also recruited to the early efferosome, including: EEA-1, Vps-34 and Mon1a/b.79 EEA-1 
mediates fusion between the efferosome and early endosomes, which mediates trafficking 
to the recycling endosome and receptor recycling back to the cell surface.80 Vps-34 
functions as a phosphoinositide 3-kinase (PI3K) and mediates formation of 
phosphoinositide 3-phosphate (PI3P), which functions to both enhance Rab5 recruitment 
and mediate Rab7 recruitment to the efferosome downstream of Rab5 activation.81 
Mon1a/b displaces Rabex-5 and shuts down the Rab5 recruitment loop and also functions 
in complex with the vacuolar trafficking protein Ccz1 to recruit the tethering homotypic 
fusion and protein sorting (HOPS) complex.82,83 The Vps-39 subunit of HOPS complex 
possesses Rab7 GEF activity and this complex mediates the transition between Rab5 and 
Rab7 on the efferosome surface.83 
Replacement of Rab5 by Rab7 marks the transition from the early efferosome to the late 
efferosome.64,83,84 Rab7 effectors have crucial roles in driving remodeling events that result 
in apoptotic cell degradation. These mediators include Rab7-interacting lysosomal protein 
(RILP) and oxysterol-binding protein-related protein 1 (ORPL1), which together interact 
with the dynein/dynactin motor complex to drive trafficking of late efferosome along 
microtubules to the perinuclear region of the efferocyte.85–87 This movement is necessary 
for efficient fusion between late efferosomes and lysosomes, and the delivery of 
degradative lysosomal hydrolases into the efferosomal lumen.87,88 RILP further recruits 
V1G1, a subunit of the vacuolar ATPase (v-ATPase), which mediates v-ATPase assembly 
on the efferosome surface and drives efferosomal acidification and activation of lysosomal 
hydrolases to complete degradation of apoptotic cargo.89 
1.1.6 Cellular consequences of efferocytosis  
The hallmark of efferocytosis is the lack of an inflammatory response.1,2 Indeed, 
efferocytosis is considered to be either immunologically silent—meaning that efferocytes 
do not produce pro-inflammatory factors nor do they present apoptotic cell-derived 
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antigens or initiate an immunological response—or actively anti-inflammatory.1 
Additionally, the efferocyte must effectively deal with the added metabolic stress of 
internalizing an entire apoptotic cell and the contents thereof.1,90 In macrophages, 
efferocytosis leads to further reinforcement of a tissue remodeling/repair state. This is 
achieved through a positive feedback loop whereby engagement of efferocytic receptors 
drives the upregulation of the expression of both efferocytic receptors and certain 
opsonins.91  
Efferocytosis has a well-documented role in restraining the generation of inflammation.92 
Many of the receptors involved in efferocyte recruitment and apoptotic cell recognition 
themselves have been shown to suppress inflammation.58,92 For example, signaling from 
the fractalkine receptor CX3CR1 simultaneously induces production of proinflammatory 
cytokines while enhancing expression of both pro-survival signals such as the anti-
apoptotic protein Bcl-2 and anti-oxidant factors such as hemeoxygenase-1 (HO-1).32,93 In 
addition, almost every PS receptor has been shown to exhibit some degree of anti-
inflammatory activity. Signaling through both TIM-3 and MerTK have been shown to 
inhibit nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)-mediated 
expression of pro-inflammatory genes.94,95 Engulfment of apoptotic cells leads to 
activation of several nuclear factor family transcription factors in the efferocyte.96,97 
Activation of these transcription factors play a role in generation of an anti-inflammatory 
state through increasing the expression of several anti-inflammatory cytokines. Activation 
of liver X receptor (LXR)-α/β and peroxisome proliferator-activated receptor (PPAR)-δ 
downstream of apoptotic cell internalization drive the expression of TGF-β and IL-10.96,98 
Internalization of apoptotic cells imposes a significant metabolic load upon efferocytes, 
which must adapt accordingly to deal with this stress.1,90 Activation of LXR-α/β, in 
addition to dampening inflammation, also leads to upregulation of ATP-binding cassette 
transporter member 1 (ABCA1), which is a major transporter responsible for cholesterol 
efflux from the cell.99 Upregulation of ABCA1 (and the related cholesterol transporter 
ABCG1) has also been shown by Yvan-Charvet et al. to protect against excessive 
production of superoxides as a result of nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase 2 activation in response to apoptotic cell internalization.100 In addition 
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to cholesterol efflux and anti-oxidant activity, efferocytes are able to cope with cholesterol 
and lipid accumulation, which have been shown to exert a pro-apoptotic effect, through 
cell survival signaling through the PI3K/Akt axis and activation of anti-apoptotic proteins 
such as Bcl-2.101 Finally, due to the intake of excess carbohydrates and lipids from 
efferocytosis, mitochondrial function in efferocytes has been shown to be altered post-
apoptotic cell internalization. Park et al. demonstrated that mitochondrial membrane 
potential decreased post-efferocytosis in manner dependent on the mitochondrial 
membrane protein mitochondrial uncoupling protein 2 (Ucp2).102 More recently, Wang et 
al. demonstrated that dynamin related protein 1 (Drp1)-mediated mitochondrial fission in 
response to apoptotic cell internalization was required for increasing intracellular calcium 
levels, which the authors found to be required for efficient continuous uptake of multiple 
apoptotic cells by professional phagocytes.103 Similarly, Morioka et al. found that 
expression of glucose transporter 1 (Glut-1) was upregulated following efferocytosis and 
helped drive metabolic reprogramming of the efferocyte towards being glycolysis-
dominant.104 This transition was found by the authors to also be required for continuous 
efferocytosis.104 
 
1.2 Atherosclerosis and the role of macrophages 
1.2.1 Atherosclerosis 
Atherosclerosis is characterized by thickening of the arterial intima as a result of the 
accumulation of modified lipoproteins and immune cells beneath the vessel 
endothelium.105 The result of this accumulation is the formation of a lipid-rich plaque 
overlaid by a fibrotic cap, referred to interchangeably as an “atherosclerotic lesion” or 
“atheroma”.106,107 Atheromas cause stenosis of the arterial lumen, resulting in the 
constriction of blood flow to vital organs.105 Significantly, atheroma growth over time can 
result in weakening of the fibrotic cap and increased risk of plaque rupture.108 Rupture of 
the plaque results in the formation of a thrombus overlying the plaque. Within the coronary 
arteries, thrombus formation over a ruptured plaque may result in the occlusion of a vessel 
and a subsequent myocardial infarction. The thrombus can also break off from the inciting 
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plaque, travel through arteries and potentially lodge in the circulation, resulting in serious 
complications including ischemic stroke and critical limb ischemia.105,109 (See Figure 1.3 
for a summary of atherosclerotic plaque development). Atherosclerosis is the most 
common cause of cardiovascular disease (CVD) such as coronary heart disease and 
cerebrovascular disease, which together form the leading cause of death in Canada—
accounting for over 30% of all-cause mortality in the 2013 national census.110 
 
Figure 1.3 Pathogenesis and progression of atherosclerosis. 
Stages of atherosclerotic plaque progression. Lesions begin as pre-atherosclerotic fatty 
streaks characterized by accumulation of ApoB-containing lipoproteins and a number of 
immune cell types within the arterial intima. Next, proliferation of endothelial cells and 
smooth muscle cells of the artery results in the formation of a fibrous cap that overlies the 
lesion, leading to the formation of the established atherosclerotic lesion. Cell death and 
generation of chronic inflammation within the lesion results in the formation of a necrotic 
core and the thinning of the fibrous cap, increasing the risk of plaque rupture and forming 
a vulnerable plaque. Finally, disruption of fibrous cap integrity through either endothelial 
erosion or fibrous cap fissure results in the exposure of lesion contents to the circulation 
and the formation of a thrombus. Figure adapted from Moore & Tabas.111 
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Atherosclerosis is a prevalent disease and is found almost ubiquitously in individuals living 
in post-industrial nations.109,112 The influential Pathological Determinants of 
Atherosclerosis in Youth (PDAY) study has reported that among 2,876 U.S. subjects aged 
15-34, lesions were identified in all of the aortas and more than half of the coronary arteries 
of the youngest age group (15-19 years) and that lesions increased in both prevalence and 
extent with increasing age.112 The risk factors for atherosclerosis align closely with those 
identified for development of coronary artery disease by the Framingham Heart Study.113 
The most important risk factor for atherosclerosis development and progression was age, 
with older individuals possessing a greater lesion extent and more lesions that are 
considered to be vulnerable and prone to rupture and causing serious complications.112,113 
Other risk factors for atherosclerosis include: male sex, race (Southeast Asians are 
particularly prone to developing significant atherosclerotic disease), smoking and the 
components of metabolic syndrome (abdominal obesity, insulin resistance, hypertension 
and high triglycerides/low high-density lipoprotein [HDL] levels).113 Atherosclerosis has 
a clear genetic component as well, with certain monogenic disorders such as familial 
hypercholesterolemia raising the risk of significant atherosclerotic disease significantly 
and a multitude of allelic variants linked to increased risk of atherosclerosis.114 
Atherosclerosis is a complex and multi-faceted disease with a number of factors that 
contribute to its pathogenesis.105,115 The initiating event in atherosclerosis is thought to be 
the retention of apolipoprotein B (ApoB)-containing lipoproteins, in particular modified 
low-density lipoproteins (moLDLs) and lipoprotein remnant particles in the arterial 
intima.116 Regions of the arterial tree with disturbed laminar flow (e.g. where a single vessel 
branches into multiple vessels) are particularly prone to lipoprotein accumulation.117 
Damage to the vessel endothelium, for example resulting from decreased nitric oxide 
bioavailability and increased adhesion molecule expression on the endothelium as a result 
of smoking, is a further potentiating factor for lipoprotein accumulation and plaque 
formation.118 Disturbed or damaged endothelium upregulates cell surface adhesion 
molecules.118–120 These receptors promote infiltration of circulating immune cells, 
especially macrophages and T lymphocytes, into the developing lesion.121,122 There is also 
evidence that activated endothelial cells increase their expression of scavenger receptors 
that bind to moLDL and drive their trafficking across the endothelium and into arterial 
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intima via cholesterol transcytosis within individual endothelial cells.123,124 These 
pathological changes within the endothelium together result in accumulation of lipids and 
immune cells within the intima. 
Retention of lipoproteins in the intima results in increased endothelial activation, which 
drives further modification of retained lipoproteins and the generation of sterile 
inflammation.108,125 This state of inflammation results in the aberrant production of a 
number of chemokines and the recruitment of cells of the innate and adaptive immune 
system to the developing atheroma. These immune cells become retained within the 
atheroma and contribute to the generation of a highly pro-inflammatory atheroma 
microenvironment and a state of unresolved inflammation.115 The development of a 
chronic inflammatory state within the atheroma has two major consequences: 1) sustained 
endothelial activation resulting in further lipoprotein retention and modification, and 2) 
proliferation of vascular smooth muscle cells (VSMCs) into myofibroblasts, which form a 
fibrous cap that overlies the plaque.106,119 Persistent inflammation combined with growth 
of a necrotic core composed of foam cells and lipid-rich debris over time results in thinning 
of the fibrous cap and increased plaque vulnerability to rupture.108 Rupture results from 
endothelial fissure or erosion, two distinct processes that result in exposure of the pro-
thrombotic contents of the plaque to the circulation.126 There, phospholipids, tissue factor 
and other pro-thrombotic plaque contents react with platelets and fibrin to quickly form 
large thrombi that can rapidly occlude entire vessels.127  
For decades, a focus of therapeutic intervention in atherosclerosis has been LDL 
cholesterol reduction.128 Lowering the level of LDL in patients with a previous coronary 
event using statins along with ezetimibe and/or proprotein convertase subtilisin/kexin type 
9 (PCSK9) inhibitors has been shown repeatedly to confer a mortality benefit.129 However, 
even with reduction of LDL to optimal levels, the rate of further cardiovascular events is 
not completely eliminated.129,130 The remaining risk of a recurrent cardiovascular event, 
called the residual risk, has widely been believed to be attributable to the inflammatory 
component of atherosclerotic disease, which is not adequately addressed with LDL 
lowering therapy alone.130 The first indication that inflammation had a role in 
atherosclerotic disease in humans came from the Justification for the Use of Statins in 
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Primary Prevention: An Intervention Trial Evaluation Rosuvastatin (JUPITER) trial, which 
demonstrated that treating patients with low-to-normal LDL levels but high C-reactive 
protein (CRP) levels (not causative for atherosclerosis but potentially indicative of on-
going inflammatory processes) lowered their risk of a major cardiovascular event by 0.2-
0.6% over one year.131 More recently, the 2017 Canakinumab Antiinflammatory 
Thrombosis Outcome Study (CANTOS) trial was able to definitively show that in patients 
with a previous coronary event and optimally controlled LDL levels but high levels of high 
sensitivity CRP, treatment with canakinumab, a monoclonal antibody that inhibits IL-1β, 
could lower the risk of a recurrent cardiovascular event without affecting lipid levels.132 
CANTOS provides strong evidence that targeting inflammation is a viable strategy for 
treating atherosclerotic disease in humans.  
1.2.2 Role of macrophages in atherosclerosis 
Macrophages play a central role in the pathogenesis of atherosclerosis, both in efferocytic 
removal of apoptotic debris in early stage of disease and in retention, pathologic 
differentiation into lipid-laden foam cells and production of pro-inflammatory factors in 
late-stage disease.116,121,133 They are arguably the central inflammatory cell of the 
atherosclerotic plaque, acting as the major source of a number of key pathologic pro-
inflammatory cytokines including TNF-α, IL-6 and IL-1β.134 Macrophage content has been 
shown to be an indicator of atherosclerotic plaque progression, and in murine plaque 
regression models, decrease in lesional macrophage content is observed to correlate with 
the degree of disease regression.135,136 The number of circulating monocytes has also been 
found to be increased in mouse models of atherosclerosis, suggesting that atherosclerotic 
conditions have a systemic impact on hematopoiesis in addition to its local effects in the 
vasculature.32,137 
It is thought that activation of the endothelium in response to accumulation and 
modification (particularly oxidation) of lipoproteins in the underlying intima results in the 
release of chemokines such as CCL2 and CCL5 that recruit circulating monocytes to the 
site of the lesion.138 Importantly, blockage of either these chemokines or their cognate 
receptors abrogate monocyte migration into lesions and inhibit atherosclerosis 
progression.111 Simultaneously, activated endothelial cells express a number of cell surface 
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adhesion molecules, including P- and E-selectin, which interact with their cognate receptor 
on the cell surface of monocytes to induce monocyte rolling.117,139 The monocyte integrins 
very late antigen-4 (VLA-4) and lymphocyte function-associated antigen-1 (LFA-1) then 
bind to their respective ligands on activated endothelial cells, vascular cell adhesion 
molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) to mediate 
tethering and transmigration of the monocyte into the intima, where they proceed to 
differentiate into macrophages.111,121 
Initially, these macrophages play a protective role through the efferocytic removal of 
apoptotic cells and debris, thereby limiting the size and expansion of the early 
atheroma.140,141 However, a certain proportion of atheromas can progress to a more 
advanced pathologic state, characterized by a breakdown of the ability to efficiently 
efferocytose apoptotic cells (discussed in greater detail in Chapter 1.3).142 The 
accumulation of cholesterol within these macrophages, through both uptake of modified 
lipoproteins in the intima and efferocytosis of cholesterol-laden apoptotic cells drive the 
formation of foam cells, described in greater detail in Chapter 1.2.4.143 Within the lesional 
microenvironment, macrophages also experience inflammatory activation as a result of 
cholesterol loading and the chronic inflammatory state of the plaque microenvironment, 
described in detail in Chapter 1.2.3.13 
Within advanced atherosclerotic plaques, macrophages contribute to the development of 
necrotic cores and fibrous cap thinning, two features of vulnerable plaques.144 
Macrophages contribute to fibrous cap thinning through induction of vascular smooth 
muscle cell (VSMC) death through induction of VSMC apoptosis through engagement of 
their Fas death receptors and through the production of pro-apoptotic cytokines such as 
TNF-α.145 Another mechanism of macrophage-mediated thinning of the fibrous cap is 
through production of matrix metalloproteinases (MMPs), which degrade collagen that 
stabilizes the cap.144 In particular, macrophage production of MMP-2 and MMP-9 have 
been shown to be involved in fibrous cap thinning in mouse models of atherosclerosis.146 
Additionally, in mice lacking MMP-13, the collagen content of fibrous caps was found to 
be increased.147  
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Macrophages also contribute to the generation of necrotic cores, which serve to destabilize 
plaques and increase the risk of rupture, through two distinct mechanisms: apoptosis of 
advanced lesional macrophages, and a failure of surrounding macrophages to efferocytose 
these apoptotic cells.148,149 Macrophage cell death within advanced atherosclerotic lesions 
is the result of a combination of factors, including increased oxidative stress, activation of 
death receptors by ligands that exist uniquely within advanced lesions and signaling from 
Toll-like receptors (TLRs).126,150 Recently, endoplasmic reticulum (ER) stress pathways, 
and the unfolded protein response (UPR) pathway in particular, have been recognized as 
important contributors to macrophage cell death in atherosclerosis.144,151 Activation of the 
UPR mediator C/EBP-homologous protein (CHOP) is associated with lesion progression 
and with plaques with vulnerable features.151 Deletion of CHOP in animal models of 
atherosclerosis has been shown to protect against lesional cell death and formation of large 
necrotic cores.152 
An overview of the many roles played by macrophages in the development of 
atherosclerosis is provided in Figure 1.4. 
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Figure 1.4 Features characteristic of pathologic monocyte/macrophage function in 
atherosclerosis. 
Monocytes and macrophages play a central role in the pathogenesis of atherosclerosis. 
Activation of the endothelium overlying regions of lipoprotein accumulation results in 
persistent monocyte influx. Within the lesion, monocytes differentiate into macrophages, 
which produce pro-inflammatory cytokines and accumulate cholesterol through uptake of 
modified lipoproteins and efferocytosis of cholesterol-laden apoptotic cells. Excessive 
cholesterol accumulation results in the pathologic differentiation of macrophages into foam 
cells, which are retained within the plaque and fail to egress. In advanced atherosclerotic 
lesions, a combination of accelerated macrophage cell death and defective efferocytosis 
results in the formation of a large necrotic core. Generation of pro-apoptotic factors and 
matrix metalloproteinases by macrophages within advanced lesions also contributes to 
fibrous cap thinning. A combination of necrotic core formation and fibrous cap thinning 
increase the risk of plaque rupture and contribute to the vulnerable plaque phenotype. 
Figure adapted from Tabas (2009).144 
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1.2.3 Influence of the plaque microenvironment on macrophages 
The presence of a chronic inflammatory state is an important factor in the pathogenesis of 
atherosclerosis.115 There is ample evidence from gene expression studies of plaque-resident 
macrophages and in knockout mice that the presence of inflammation drives accelerated 
lesion progression and the absence or reduction of inflammation slows progression.150,153 
Inflammatory activation of macrophages within the plaque appears to be at least partially 
driven by signaling through the TLRs.126,154 In particular, TLR4 has been shown to bind 
oxidized LDL (oxLDL) cooperatively with CD36 to activate NF-κB signaling and 
expression of pro-inflammatory cytokines.155 Another pro-inflammatory pathway in 
atherosclerotic macrophages involves accumulation of free cholesterol within the 
macrophage cytoplasm which activates the Nod-like receptor pyrin domain containing 3 
(NLRP3) inflammasome, driving the subsequent production of IL-1β and IL-18.156 Bone 
marrow transplantation experiments using donor mice lacking NLRP3 results in decreased 
lesion size compared to transplantation with wild type bone marrow.157 An overview of 
pro- and anti-inflammatory signaling with atherosclerotic macrophages is presented in 
Figure 1.5. 
This aberrant activation of lesion-resident macrophages into an inflammatory phenotype 
has important consequences for the progression of atherosclerosis.133 Indeed, analyses of 
human atherosclerotic plaques have revealed a greater proportion of pro-inflammatory 
macrophages compared to tissue remodeling macrophages within progressing lesions, and 
in particular within vulnerable plaques.136 A number of studies have shown that 
experimental models of atherosclerosis regression, including delivery of an apoE-encoding 
adenovirus vector in Apoe-/- mice and transplantation of atheroma-laden aortic arch from 
Apoe-/- mice into recipient C57BL6 mice with varying levels of HDL, demonstrate that 
macrophage numbers and polarization state are significantly impacted.158,159 In these 
models of atherosclerosis regression, investigators have consistently found lower overall 
macrophage numbers within the atheromas and a greater proportion of tissue remodeling 
macrophages.135,158,159 
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Figure 1.5 Pro-inflammatory and anti-inflammatory signaling within lesion-resident 
macrophages. 
The atherosclerotic lesion microenvironment activates a number of pro-inflammatory 
signaling pathways that converge on NF-κB activation. Simultaneously, inflammatory 
activation is counterbalanced by anti-inflammatory signaling that upregulate pathways and 
receptors involved in response to cholesterol loading. Lipid ligands within the plaque, 
including oxLDL, minimally modified LDL (mmLDL) and lipoprotein(a) (LPa) induce 
signaling through TLRs and scavenger receptors to induce the generation of pro-
inflammatory cytokines, including RANTES (CCL5), KC (CXCL1) and MIP-1α (CCL3). 
Accumulation of free cholesterol within endosomes result in endosomal damage and 
activation of the NLRP3 inflammasome along with generation of IL-1β. Excess cholesterol 
also activates the UPR pathway of the ER stress response, leading to further pro-
inflammatory activation and ultimately cell apoptosis. Along with inflammatory activation, 
lipoprotein exposure also drives upregulation of ABCA1 and ABCG1, which mediate 
cholesterol efflux from the cell. Figure adapted from Moore & Tabas.111 
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Beyond the classical paradigm of the simple dichotomy between pro-inflammatory and 
tissue remodeling macrophage phenotypes, macrophages in vivo rarely fall nicely into 
either subset.160 As such, a number of unique atherosclerosis-associated macrophage 
subsets have been identified in murine models of atherosclerosis and in patients. Kadl et 
al. identified a Mox macrophage phenotype in murine macrophages treated with oxLDL, 
which demonstrated a distinct gene expression pattern characterized by upregulation of 
redox-regulatory genes driven by the transcription factor Nrf2.161 Boyle et al. identified 
another novel atherosclerotic macrophage subset that is associated with intra-plaque 
hemorrhage called hemorrhage-associated (HA)- or Mhem macrophages.162 The presence 
of heme and hemoglobin at the site of hemorrhage drives expression of heme oxygenase 1 
(HO-1) through activating transcription factor 1 (ATF-1).163 These macrophages also 
upregulate gene targets of LXR-α/β, including ABCA1. The net result is a macrophage 
subset that is highly resistant to oxidative stress and cholesterol loading.162,163 
1.2.4 Cholesterol uptake and foam cell formation 
Uptake of lipoproteins by macrophages within the atheroma results in accumulation of 
cholesterol esters within the macrophage, which is converted into free cholesterol by 
lysosomal acid lipase in the lysosome.164 Free cholesterol must be either removed from the 
cell through the cholesterol efflux transporters ABCA1 and ABCG1 or re-esterified and 
stored as cholesterol ester intracellularly as neutral lipid droplets.100,143 Excess intracellular 
free cholesterol results in macrophage inflammatory activation through the induction of 
ER stress, TLR4 signaling and inflammasome activation.151,157,165 Furthermore, delivery of 
excess cholesterol into the macrophage leads to enrichment of free cholesterol within the 
plasma membrane and may serve to enhance inflammatory signaling through cholesterol 
microdomain-mediated activation of pro-inflammatory signaling receptors.166 Thus, 
cholesterol loading of macrophages can further contribute to the generation of a chronic 
inflammatory state within the lesion. 
Accumulation of esterified cholesterol stored in both membrane-bound and free lipid 
droplets within the cytoplasm confers unto lesion-resident macrophages the “foamy” 
appearance first described by Nikolai N. Anichkov in his classic studies on cholesterol-fed 
rabbits in 1913.167 There is also evidence from electron microscopy studies of macrophages 
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from advanced atherosclerotic lesions demonstrating the presence of minimally degraded 
and fully intact moLDL within foam cell.168 
1.2.5 Generation of autoimmunity 
Beyond dysfunction of the innate immune system, there is growing evidence that impaired 
antigen presentation and autoimmunity also play a role in atherosclerosis.122,169 Strikingly, 
autoimmune disorders appear to be an independent risk factor for the development of 
atherosclerosis and CVD.11,170 In patients with systemic lupus erythematous (SLE) and 
rheumatoid arthritis, the incidence of CVD is significantly increased compared to age- and 
sex-matched controls from the general population.170 Similar patterns are observed in non-
autoimmune patients, where patients who develop IgG-isotype antibodies against plaque 
components develop more severe disease than those who remain immunologically 
quiescent.171 In animal models, these athero-reactive antibodies result in immune complex 
deposition within the vascular intima, further exacerbating inflammation in the atheroma, 
thereby hastening disease and destabilizing the plaque.172 Importantly, presentation of 
atheroma-derived antigens on MHC II, by cells such as macrophages, is a pre-requisite for 
antibody class-switch to IgG subtypes.173–175 This indicates that mis-presentation of 
atheroma antigens following ingestion of plaque components such as apoptotic foam cells 
has an important role in atheroma development. Indeed, T-cell-deficient nude mice fed a 
high-fat diet developed significantly smaller atheromas than controls.176 
The majority of T lymphocytes present within the atheroma are TH1 CD4+ cells.122,177 
These cells are likely atherogenic, as inhibition of TH1 polarization in Apoe-/- mice results 
decreases plaque burden. TH1 cells infiltrate the atheroma and contribute to the chronic 
inflammatory state of the atheroma including through IFN-γ production.122,178 
Furthermore, these T cells have a restricted repertoire and appear to respond specifically 
to a number of atheroma-specific antigens, including ApoB-100, native LDL and 
moLDL—particularly oxLDL.175,178 In advanced atheromas, antigen presentation is 
primarily carried out by macrophages and conventional dendritic cells that expression 
CD11b and CD11c, and which are pre-disposed to TH1 priming of CD4+ T cells through 
production of IL-12 and CCL17.179 Presentation of self-lipid antigens by the CD1 family 
of MHC I-like glycoproteins is another potential source of T cell activation in 
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atherosclerosis.180,181 CD1 molecules surveil the endocytic pathway and are capable of 
presenting both foreign- and self-lipid antigens to CD1-restricted T cells, in particular 
CD1d-restricted iNKT cells.182 While the role of endogenous lipid antigens in the 
pathogenesis of atherosclerosis is current poorly characterized, investigators have shown 
that administration of α-galactosylceramide (a synthetic antigen that activates iNKT cells) 
resulted in a 50% increase in plaque size in Apoe-/- mice.181 
1.2.6 Impaired inflammation resolution 
Resolution of an inflammatory response is a necessary step in maintenance of homeostasis 
and avoiding unnecessary tissue damage.65 However, in the setting of atherosclerosis, 
resolution of inflammation is impaired and instead a chronic, low-grade inflammatory state 
persists within the plaque microenvironment.65,121 Mediators of inflammation resolution 
include anti-inflammatory cytokines, other signaling molecules and transcription factors. 
The most prominent anti-inflammatory cytokines in atherosclerosis are TGF-β and IL-10.91 
IL-10 signaling induces expression of the suppressor of cytokine signaling 3 (SOCS3), 
which antagonizes the NF-κB signaling pathway and downregulates expression of a 
number of pro-inflammatory cytokines.144 IL-10 also induces expression of signal 
transducer and activator of transcription 3 (STAT3), a transcription factor that helps 
polarize macrophages into an anti-inflammatory phenotype.9 TGF-β, in contrast, appears 
to primarily act on T cells in the context of atherosclerosis and induces the migration and 
generation of regulatory T cells.183,184 Within the atherosclerotic plaque, macrophage 
production of both IL-10 and TGF-β have been shown to be reduced within advanced 
plaques.185 IL-10 levels in the serum are also lower in patients with coronary artery 
disease.186  
In addition to anti-inflammatory cytokines, inflammation resolution is also mediated by 
lipid specialized pro-resolving mediators (SPMs), including lipoxin A4, resolvin D1 and 
protectin D1.115 SPMs are generated through the activity of lipoxygenase (LOX) enzymes 
on arachidonic acid (AA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), 
and function through several mechanisms including the suppression of lipopolysaccharide 
(LPS)-mediated pro-inflammatory signaling.187,188 Variants in LOX enzymes have been 
associated with CVD and patients with CVD have lower levels of circulating SPMs 
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compared to healthy controls.189,190 Several experiments have shown that SPMs are 
produced following efferocytosis and during atherosclerotic lesion regression.144 Direct 
administration of a number of SPMs in mouse models of atherosclerosis have been shown 
to decrease the rate of plaque progression.191 Fredman et al. showed that SPMs are involved 
in atherosclerosis progression by demonstrating the ratio of SPMs, especially resolvin D1, 
and pro-inflammatory leukotriene B4 is decreased in advanced atherosclerotic plaques and 
in regions of plaque vulnerability in Ldlr-/- mice.192 
 
1.3 Efferocytic removal of apoptotic cells by macrophages 
in the atherosclerotic plaque 
1.3.1 Apoptosis in the atherosclerotic plaque 
Apoptosis is a key feature of progression in atherosclerosis.148 While pre-atherosclerotic 
and early atherosclerotic lesions contain few if any apoptotic cells, advanced 
atherosclerotic plaques have been shown to be relatively abundant in uncleared apoptotic 
cells.142 Several factors drive cell apoptosis within the atherosclerotic lesion, including 
oxidative stress, hypoxia, pro-apoptotic cytokines and the cellular response to cholesterol 
loading.13,118,149,193 All cells types present within the lesion experience apoptosis, and the 
death of these cells have differing impacts on plaque biology. Apoptotic death of 
endothelial cells and VSMCs, for example, is thought to destabilize the fibrous cap through 
removal of cells and collagen that form the structure of the cap, resulting in increased 
plaque vulnerability and risk of rupture.145 
The role of macrophage apoptosis on plaque progression appears to be more nuanced and 
may indeed exert opposing effects depending on the stage of plaque development (see 
Figure 1.6).140 In the early atherosclerotic lesion, macrophage apoptosis is thought to be 
protective against disease progression by removing cells from the plaque and reducing the 
generation of inflammation.140 Studies that transplanted the bone marrow of mice lacking 
the pro-apoptotic factors Bcl-2-associated X (Bax) or apoptosis signal-regulating kinase 1 
(Ask-1) into Ldlr-/- mice and feeding a high fat diet for 10-12 weeks resulted in an increase 
in total lesion area.194 In contrast, induction of macrophage apoptosis in later stages of 
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disease may be detrimental. In experiments using Chop-/- Apoe-/- mice, Thorp et al. showed 
that the rate of ER stress-induced apoptosis was decreased, and that plaque apoptosis and 
necrotic core formation was reduced in these mice.152 These results suggest that 
macrophage apoptosis occurring later during plaque progression leads to additional 
necrotic cell burden, potentially due to a lack of functioning efferocytic machinery in later 
stages of plaque development.152 
 
 
 
 
 
 
 
Figure 1.6 Macrophage apoptosis and efferocytosis in early and advanced 
atherosclerosis. (on opposite page) 
Macrophage apoptosis and efferocytosis have different impacts on plaque biology in early 
versus advanced atherosclerosis. (a) Within early atherosclerotic lesions, induction of 
macrophage apoptosis has a protective role. Apoptotic macrophages are quickly cleared by 
neighbouring healthy macrophages, limiting the capacity of that macrophage to contribute 
to the generation of inflammation and inducing an anti-inflammatory phenotype in the 
efferocyte characterized by release of the anti-inflammatory cytokines TGF-β and IL-10. 
(b) In advanced atherosclerotic lesions, in contrast, apoptotic macrophages are not cleared 
by neighbouring efferocytes and instead undergo secondary necrosis. This in turn drives 
disease progression through contributing to the formation and growth of a necrotic core 
within the lesion and the release of pro-inflammatory factors into the plaque 
microenvironment. Figure adapted from Tabas (2009).144 
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1.3.2 Evidence of defective efferocytosis in atherosclerotic disease 
Defective efferocytosis is a hallmark of advanced atherosclerotic lesions and the presence 
of impaired efferocytosis is associated with increased plaque vulnerability.195 The lack of 
efferocytic apoptotic cell clearance probably contributes more than any other single 
mechanism to necrotic core formation.144 Schrijvers et al. demonstrated the presence of 
uncleared terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling 
(TUNEL)+ necrotic cells within advanced atherosclerotic lesions in human carotid 
endarterectomy specimens while in the tonsils—a tissue with comparably high rates of 
apoptosis—very few uncleared apoptotic cells could be detected.142 This finding implies 
that defective efferocytosis drives the accumulation of necrotic cells in atherosclerosis and 
that this is a bona fide feature of advanced atherosclerosis in humans.142 
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Complementing observations in human plaque, numerous studies in mouse models of 
atherosclerosis have demonstrated that deletion of macrophage efferocytic effectors 
increase lesion necrotic core size and total lesional area.196,197 Boisvert et al. found that 
Ldlr-/- mice transplanted with bone marrow deficient in transglutaminase 2 (TG2), a co-
receptor of integrin αVβ3, had increased atherosclerotic lesion area and necrotic core 
size.196 Further evidence for the importance of integrin αVβ3 in efferocytosis within the 
atherosclerotic lesion came from studies using Mfge8-/- Ldlr-/- mice. MFG-E8 is the opsonin 
used by integrin αVβ3 to bind PS, and Mfge8--/ Ldlr-/- mice develop lesions with larger 
necrotic cores and also have higher levels of circulating pro-inflammatory cytokines, in 
particular IFN-γ.197 Further studies have also found that C1q, the opsonin used by LRP1 to 
bind calreticulin on the apoptotic cell surface, also plays a role in efferocytosis within the 
plaque.56,198 Deletion of C1q in Ldlr-/- led to the development of larger and more complex 
lesions.198 Finally, Thorp et al. demonstrated that mice expressing a tyrosine kinase 
defective MerTK mutant had increased numbers of free apoptotic cells and larger necrotic 
cores after 16 weeks of being on a high-fat diet.199 However, deletion of another member 
of the TAM family of receptors, Axl, did not appear to impact efferocytosis within the 
atherosclerotic plaque or plaque progression.200 A summary of these mechanisms that 
mediate macrophage efferocytosis within the atherosclerotic plaque is provided in Figure 
1.7. 
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Figure 1.7 Known efferocytic receptors and pathways utilized by macrophages in 
atherosclerosis. 
A number of efferocytic receptors and opsonins have been identified by in vivo studies in 
mouse models of atherosclerosis to be involved in macrophage efferocytosis of apoptotic 
cells within the atherosclerotic lesion. These include: integrin αVβ3 and its opsonin MFG-
E8 and co-receptor TG2, LRP1 and its opsonin C1q, and MerTK and its opsonins Gas6 
and protein S. Successful clearance of apoptotic cells induces the production of anti-
inflammatory cytokines by the efferocytosing macrophage, including TGF-β and IL-10. 
Figure adapted from Thorp & Tabas.201 
1.3.3 Consequences of defective efferocytosis 
Beyond insufficient apoptotic cell clearance and the development of secondary necrosis 
leading to necrotic core formation and release of pro-inflammatory factors, defective 
efferocytosis also has consequences related to a lack of inflammation resolution.65 As 
discussed previously in Chapter 1.2.6, efferocytosis induces an anti-inflammatory 
phenotype in macrophages that functions to partially counteract the chronic inflammatory 
microenvironment of the plaque.116 Impaired efferocytosis removes macrophage-derived 
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anti-inflammatory cytokines from the plaque and instead promotes further inflammatory 
activation within the lesion.  
Defective efferocytosis also leads to a reduction in the production of SPMs that normally 
help limit inflammation (discussed previously in Chapter 1.2.6) and increases the 
production of pro-inflammatory leukotrienes, which are synthesized from AA, the same 
substrate as a number of SPMs.192 Cai et al. found that engagement of MerTK receptor led 
to translocation of 5-LOX into the nucleus, where it drives production of the SPM lipoxin 
A4.202 The authors found that impaired MerTK signaling in the context of atherosclerosis 
reduced the level of lipoxin A4 production and instead increased production of the pro-
inflammatory leukotriene B4.202 
1.3.4 Known mechanisms leading to defective efferocytosis  
The molecular mechanisms that lead to defective macrophage efferocytosis in 
atherosclerosis remain poorly understood. One potential mechanism identified by Cai et 
al. involves cleavage of MerTK within the atherosclerotic plaque through the activity of 
the metalloproteinase ADAM17.202 The authors found that in Ldlr-/- mice expressing a 
cleavage-resistant MerTK variant, atherosclerotic plaques possessed smaller necrotic cores 
and thicker fibrous caps. In human carotid atherosclerosis, cleavage of MerTK from the 
cell surface of macrophages and the presence of the resultant soluble form of MerTK 
correlated with increased plaque necrosis and ischemic symptoms in these patients.203 
Separately, the same group found that MerTK cleavage also limited SPM production by 
macrophages and led to higher levels of circulating pro-inflammatory cytokines in mice.204  
Disruption of anti-phagocytic “don’t eat me” signals has also been shown to have an impact 
on atherosclerotic disease.10,205 Kojima et al. showed that blocking the anti-phagocytic 
molecule CD47 using antibodies in Apoe-/- mice led to restoration of efferocytosis within 
advanced atherosclerotic plaques and a resultant decrease in lesion necrotic core size.205 
Within the plaque, elevated levels of TNF-α appears to induce CD47 expression on VSMCs 
via activation of NF-κB signaling. In patient carotid endarterectomy specimens, CD47 was 
found to be elevated compared to non-atherosclerotic surrounding vascular tissue. This up-
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regulation of CD47 could be reproduced in a mouse model of atherosclerosis through 
feeding of a high fat diet in Apoe-/- mice.205 
Finally, macrophage cholesterol loading may impair efferocytosis through disruption of 
proper efferosome maturation.206 Free cholesterol accumulation in macrophages leads to 
the induction of several adaptive processes that could alter the regulation of intracellular 
trafficking and efferosome maturation. Huynh et al. showed that inhibition of cholesterol 
exit from lysosomes using the small molecule inhibitor U18666A resulted in impaired 
phagolysosome formation.206 The authors found that this defect was due to inactivity of 
Rab7 recruited to the late phagosome, leading to a failure to recruit the effector molecules 
RILP and ORLP1 which are required to drive migration of phagosomes towards the 
perinuclear region to permit efficient fusion with lysosomes.87,206 Another example of such 
an adaptive process is the increased biosynthesis of phospholipids, in particular 
phosphatidylcholine and phospholipid species with polyunsaturated acyl chains.207 Since 
the recruitment of many regulators of the maturation process depends on interactions with 
phospholipid species present in the efferosomal membrane, alterations to phospholipid 
synthesis may result in maturation defects–although this remains to be experimentally 
demonstrated.207 
 
1.4 Current limitations in our understanding of 
atherosclerosis  
1.4.1 Animal models of atherosclerosis and their limitations 
Due to the complexity of atherosclerosis and the slow rate of disease progression in 
humans, a range of small and large animal models have been developed to study the biology 
of this disease.208,209 Each model system carries distinct advantages and drawbacks and are 
typically used to study specific components of atherosclerotic disease (e.g. genetics, 
lipoprotein profiles, hemodynamics, etc.).208 
The most frequently used animal models of atherosclerosis are by far the murine models 
of atherosclerosis.210 Although the lipoprotein profile and lesion distribution in mice differ 
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from those in humans, many of the critical features of disease are preserved.208,210 The ease 
of genetic manipulation in mice and the relatively fast rate at which atherosclerosis develop 
in atherosclerosis-prone mice make them an attractive model organism for studying the 
impact of specific genes and proteins on disease pathogenesis. Mice are HDL monotypic 
animals, meaning that HDL is the dominant lipoprotein in their circulation. This makes 
mice naturally resistant to atherosclerosis.211 Mouse models of atherosclerosis therefore 
rely on generating a non-HDL based hypercholesterolemia. A number of murine model 
systems now exist for studying atherosclerosis, but the most well-known and best-studied 
models are the apoE-knockout and the LDLR-knockout animals.210 Deletion of apoE or 
LDLR inhibit cholesterol reverse transport and the animals develop hypercholesterolemia 
on a high fat diet as a result.208 
Despite the widespread use of Ldlr-/- and Apoe-/- mice in experimental investigations into 
the biology of atherosclerosis, there are still critical differences between human and mouse 
atherosclerosis that call into the question the extent to which the mouse is an accurate 
model of atherosclerotic disease.212,213 First, most mouse models of atherosclerosis never 
develop the vulnerable, rupture-prone plaque that drives atherosclerotic CVD in humans.210 
The distribution of lesions in the vasculature also differs significantly between mouse and 
human.117 Importantly, mice rarely develop significant atherosclerosis within their 
coronary circulation, instead preferentially developing atherosclerosis within the aortic 
root.117 This stands in contrast to humans, where the aortic root and ascending aorta are 
usually relatively spared from severe disease.214 Finally, mice do not possess the 
cholesteryl ester transfer protein (CETP), a serum transporter of cholesteryl esters and 
triglycerides that has been implicated in atherosclerosis in humans.215 
The small size of the mouse imposes an additional limitation on the extent to which 
important disease parameters such as hemodynamics may be measured in these animals. 
As such, a number of large animal models of atherosclerosis have been used.208 A full 
discussion of large animal models of atherosclerosis is beyond the scope of this thesis but 
is reviewed in detail by Getz & Reardon.208 We will briefly summarize the most important 
large animal models of atherosclerosis here. Amongst these are pigs, which spontaneously 
develop atherosclerosis on a high fat diet.216 A number of seminal studies on the impact of 
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vascular hemodynamics on atherosclerosis development and on endothelial activation in 
response to atherogenic stimuli have been performed in pigs.217 Pigs also do develop 
complex lesions in their coronary circulation and these plaques do experience vulnerability 
and rupture.218 Rabbits have also been used in the study of atherosclerosis. These animals 
are extraordinarily sensitive to cholesterol feeding and have been used in a number of 
studies on how the body’s circulating lipid profile changes with a high cholesterol diet.219 
Finally, non-human primates can also be used to study atherosclerosis. Although they are 
expensive and difficult to maintain, non-human primates have the most similar lipoprotein 
profile to humans of any model organism.220 Some of the first studies on plaque regression 
upon return to a low-fat diet was conducted in Rhesus monkeys.221 
1.4.2 Challenges of studying atherosclerosis in humans 
The majority of what is currently known about the biology of atherosclerosis and 
particularly its pathogenesis and progression is derived from studies in animal models of 
disease.128 In particular, studies in mice have generated much insight into the role of 
macrophages and other cell types in the atherosclerotic plaque.209 However, the degree to 
which these findings may be translated into the human context remains a topic of 
controversy.128,222 Indeed, a number of promising therapeutic targets identified through 
research on mouse models of atherosclerosis have not been borne out in humans.128 In a 
systematic review of disease-causing genes identified in mouse models of atherosclerosis 
and the association of the human orthologs of these genes with CVD, Pasterkamp et al. 
found few associations between genes found to be important in mice and human disease.213 
In contrast, von Scheidt et al. used the same approach but concluded that there was a 
significant overlap between genes found to be important for the pathogenesis of 
atherosclerosis in mice and genes that have been implicated in atherosclerosis and CVD in 
humans.210 To illustrate the stark differences that can be present between atherosclerosis in 
the mouse and in humans, a recent study by Gomez et al. found that IL-1β had a protective 
effect in advanced atherosclerotic plaques in Apoe-/- mice, which stands in contrast with 
the results of the CANTOS trial.223 
However, despite the sometimes questionable validity of animal models of atherosclerosis, 
it is technically difficult to study this disease in humans for a variety of reasons. First, 
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atherosclerosis develops over the course of decades in humans, making it very difficult to 
study disease progression.127 Second, obtaining plaque specimens for study in humans is 
difficult due to the anatomical location of these plaques.224 The most commonly used 
source of plaque material in human studies is plaque obtained from carotid 
endarterectomies.225–227 However, it has been established there are significant differences 
in macrophage gene expression between plaques isolated from different anatomical 
sites.228 Therefore, it is difficult to determine how representative the carotid plaque is of 
disease situated in other vessels. Finally, the ubiquitous nature of atherosclerosis in 
industrialized nations makes it difficult to identify individuals who are truly free of 
atherosclerosis that may be utilized as a control.229 Due to these factors, it is likely that the 
field will continue to rely on mouse models of atherosclerosis as the major means of 
studying atherosclerosis biology.  
 
1.5 Rationale, objective and aims 
1.5.1 Rationale 
Defective macrophage efferocytosis is widely acknowledged as a major driver of disease 
progression and plaque vulnerability in atherosclerosis. Despite this, relatively little is 
known about the molecular mechanisms that drive defective efferocytosis in the setting of 
atherosclerotic disease. The few mechanisms that have been identified to date have been 
described either in vitro or almost exclusively in mouse models of atherosclerosis. 
Therefore, we do not have a clear understanding of how efferocytosis becomes defective 
in human atherosclerotic disease. 
1.5.2 Objective 
The overall objective of this thesis is to explore gene expression in human atherosclerotic 
lesion-resident macrophages in order to identify potential genes and pathways that 
contribute to defective efferocytosis in human atherosclerosis. 
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1.5.3 Aims 
Our first aim, described in Chapter 3, was to gain a more complete understanding of how 
efferosome maturation is regulated in macrophages under homeostatic conditions. We 
employed ectopic expression of fluorescently labelled proteins in combination with bead-
based efferocytosis assays and live- and fixed-cell fluorescence microscopy to identify 
novel proteins that differentially regulate phagosome and efferosome maturation. 
Our second aim, described in Chapter 4, was to study the gene expression profile of human 
atherosclerotic macrophages to determine globally which pathways and cellular functions 
were dysregulated and specifically which pathways related to efferocytosis and apoptotic 
cell clearance were affected. This was accomplished using a microarray to analyze gene 
expression in macrophages isolated from aortic punch samples compared to macrophages 
derived ex vivo from peripheral blood monocytes from healthy donors.  
The final aim, described in Chapter 5, was to validate the role of a transcription factor 
identified in the previous aim as being potentially involved in driving efferocytic defects. 
This was done through generating stably-transduced macrophage cell lines that 
overexpressed or knocked down our protein of interest and using these cell lines in 
functional assays that test macrophage efferocytosis and efferosome maturation proceeds 
correctly. We also examined the upstream signaling pathways employed to drive 
upregulation of our protein-of-interest. 
1.6 Importance 
Atherosclerosis is the major pathological feature that contributes to CVD. In Canada, the 
impact of atherosclerotic CVD is so large that approximately 1 in 3 Canadians will be 
affected by atherosclerosis or one of its complications.110 Despite the importance of 
atherosclerosis, there are still gaps in our understanding of the biology of atherosclerosis 
in humans and a lack of therapeutic agents that completely eliminate the risk of CVD. As 
such, identification of specific defects in the efferocytosis of apoptotic cells that forms the 
overarching goal of this thesis has the potential to uncover novel therapeutic targets and 
approaches for atherosclerosis. 
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Chapter 2  
2 Materials and Methods 
2.1 Reagents, cell lines, plasmids/oligos, and antibodies 
2.1.1 Reagents 
RPMI, DMEM, Trypsin-EDTA and fetal bovine serum (FBS) were purchased from 
Wisent. Recombinant human M-CSF, GM-CSF, IFNγ and IL-4 were purchased from 
Peprotech. No. 1.5 thickness 8-mm round coverslips and 16% paraformaldehyde (PFA) 
were purchased from Electron Microscopy Supplies. Colloidal Coomassie Blue, 
PUREZOL RNA isolation reagent and iScript Select cDNA Synthesis Kit were purchased 
from Bio-Rad. Lympholyte-poly was purchased from Cedarlane Laboratories. Cell 
Proliferation Dyes eFluor 450 and eFluor 670 were purchased from eBioscience. 
Phosphatidylserine (PS), phosphatidylcholine (PC), biotin-phosphatidylethanolamine 
(biotin-PE), rhodamine-phosphatidylethanolamine (rhodamine-PE), cholesterol and 
BODIPY-cholesterol were purchased from Avanti Polar Lipids. Salmonella 
lipopolysaccharide (LPS), rAPID alkaline phosphatase, Polybrene Infection Reagent, 
mammalian protease inhibitor cocktail, Oil Red O, Nile Red, phorbol 12-myristate-13-
acetate (PMA), methyl-β-cyclodextran, TRITC-dextran, human IgG and the Anti-
Citrulline (Modified) Detection Kit were purchased from Sigma-Aldrich. Phusion DNA 
polymerase, FugeneHD, dithiobis[succinimidyl propionate], dithio-bismaleimidoethane,  
Permafluor mounting reagent, Fast SYBR Green master mix, EZ-link NHS-LC-biotin, 
CellTrace dyes and nitro blue tetrazolium chloride were purchased from Thermo Fisher. 
Restriction enzymes and T4 DNA ligase were purchased from New England Biolabs. 
Polystyrene beads, silica beads and silica-functionalized magnetic beads were purchased 
from Bangs Laboratories. Tissue-Tek OCT compound was purchased from VWR. 
Lipofectamine 3000 transfection reagent was purchased from Life Technologies. Polyjet 
In Vitro DNA transfection reagent was purchased from SignaGen Laboratories. Human 
plasma oxidized low density lipoprotein (oxLDL) was purchased from Alfa Aesar. Trypsin 
Enzymatic Antigen Retrieval Kit was purchased from Abcam. Vector DAB HRP substrate 
was purchased from Vector Laboratories. Cytoseal 60 was purchased from Thomas 
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Scientific. pHrodo Red Microscale Labeling Kit was purchased from Invitrogen. Normal 
rabbit and donkey sera were purchased from Jackson Immunoresearch. All other chemicals 
were purchased from Canada BioShop.  
2.1.2 Mice, cell lines and bacteria  
LDL receptor-deficient C57BL/6J mice were generously provided by Dr. Lillian Barra 
(Western University). THP-1 monocytes (ATCC TIB-202) were a gift from Dr. Joe 
Mymryk (Western University). Jurkat T cells (ATCC TIB-152) were a gift from Dr. Jimmy 
Dikeakos (Western University). J774.2 murine macrophage cells (ATCC TIB-67) were a 
gift from Dr. Sergio Grinstein (Hospital for Sick Children). HEK 293 cells (ATCC CRL-
1573) were a gift from Dr. David Litchfield (Western University). Escherichia coli DH5α 
and ML35 strains were gifts from Drs. John McCormick and Susan Koval, respectively 
(Western University). 
2.1.3 Plasmids and oligos 
PM-RFP, Rab5-GFP, Rab7-mCherry, TfR-GFP, TfR-mCherry and LAMP1-mCherry 
expression constructs were gifts from Dr. Sergio Grinstein (Hospital for Sick Children). 
pBabePuro-GATA2 (Addgene Plasmid #1285) was purchased from Addgene. pLVX-
IRES-ZsGreen1, pGFP-C-shLenti, pMD2.G and pDR8.2 were gifts from Dr. Jimmy 
Dikeakos (Western University). Human Rab17 cDNA was purchased from the Harvard 
PlasmID Repository. Primers and shRNA oligos were purchased from IDT. ON-
TARGETplus siRNA was purchased from Thermo Fisher.  
2.1.4 Antibodies 
Mouse anti-human LAMP-1 monoclonal IgG1 antibody (H4A3) and mouse anti-human 
GAPDH monoclonal IgG1 antibody (2G7) were purchased from Developmental Studies 
Hybridoma Databank. Rat anti-mouse MHC class II monoclonal IgG2b antibody 
(M5/114.15.2; eBioscience 14-5321-82) was purchased from eBioscience. Rabbit anti-
human Rab17 polyclonal IgG antibody (Proteintech 28274-1-AP) was purchased from 
Proteintech. Rabbit anti-human CD163 polyclonal IgG antibody (Abcam ab87099), mouse 
anti-human CD68 monoclonal IgG1 antibody (KP1; Abcam ab955) and rabbit anti-human 
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GATA2 polyclonal IgG antibody (Abcam ab153820) were purchased from Abcam. Rabbit 
anti-citrulline polyclonal IgG antibody (Sigma 07-377) was purchased as part of the Anti-
Citrulline (Modified) Detection Kit from Sigma-Aldrich. All fluorescent secondary 
antibodies were purchased as IgG F(ab’)2 fragments from Jackson ImmunoResearch.  
 
2.2 Cell culture 
2.2.1 Cell lines 
HEK 293 cells were maintained at 37 °C and 5% CO2 in DMEM media supplemented with 
10% FBS, L-glutamine and sodium bicarbonate, and buffered with 25 mM HEPES to a pH 
= 7.2. Cells were sub-cultured 1:5 by scraping once cells reached 80-90% confluency or 
approximately once every 3 to 4 days.  
J774.2 murine macrophage cells were maintained at 37 °C and 5% CO2 in RPMI media 
supplemented with 10% FBS, L-glutamine and sodium bicarbonate, and buffered with 25 
mM HEPES to a pH = 7.2. Cells were sub-cultured 1:5 by enzymatic digestion with 0.05% 
trypsin supplemented with 0.53 mM EDTA once cells reached 80-90% confluency or 
approximately once every 3 to 4 days.  
THP-1 human monocyte-like cells were maintained at 37 °C and 5% CO2 in RPMI media 
supplemented with 10% FBS, L-glutamine and sodium bicarbonate, and buffered with 25 
mM HEPES to a pH = 7.2. Cells were sub-cultured 1:5 or 1:10 through addition of fresh 
media once cells reached a concentration of 1×106 cells/mL. For differentiation into 
macrophages, cells are incubated with 100 nM PMA for 48-72 hrs. Differentiated THP-1 
cells are washed at least 1× with PBS to remove excess PMA prior to use in downstream 
assays.  
Jurkat human T lymphocyte-like cells were maintained at 37 °C and 5% CO2 in RPMI 
media supplemented with 10% FBS, L-glutamine and sodium bicarbonate, and buffered 
with 25 mM HEPES to a pH = 7.2. Cells were sub-cultured 1:5 or 1:10 through addition of 
fresh media once cells reached a concentration of 1×106 cells/mL. 
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2.2.2 Primary cells 
Primary human macrophages and dendritic cells were prepared from monocytes isolated 
from whole blood isolated from healthy adult donors with ethics approval from the Office 
of Human Research Ethics at Western University Health Sciences Research Ethics Board 
(HSREB Reference Number: 104010). Blood was collected through venipuncture into 
vacuum tubes coated with heparin and monocytes were isolated using Lympholyte-poly 
cell separation media (Cedarlane) according to the manufacturer’s instructions. Briefly, 
approximately 4 mL of blood was layered over an equal volume of Lympholyte-poly and 
centrifuged for 25 min at 500 ×g at 50% acceleration and zero deceleration. The monocyte 
layer was carefully removed using a transfer pipette to a clean 50 mL tube and resuspended 
in approximately 50 mL of PBS and subsequently centrifuged for 6 min at 300 ×g at full 
acceleration and deceleration. Monocytes were re-suspended in 200 µL of warm RPMI per 
well to fill of a 12-well plate. Sterile, acid-washed glass coverslips were placed into 12-
well plates and the monocyte suspension was pipetted onto coverslips. Cells were 
incubated for 1 hr at 37 °C and 5% CO2 to allow monocytes to adhere to glass and 
coverslips were washed 3× with PBS to remove any non-adherent cells. Cells were 
maintained in culture with RPMI supplemented with 10% FBS, L-glutamine and sodium 
bicarbonate, 10,000 U/mL penicillin, 10 mg/mL streptomycin and 25 µg/mL amphotericin 
B and buffered with 25 mM HEPES to a pH = 7.2. 
To generate dendritic cells, adherent monocytes were additionally supplemented with 
1000U/mL rhGM-CSF and 500U/mL rhIL-4 for 48 hrs. To generate macrophages, 
adherent monocytes were additionally supplemented with various cytokines and allowed 
to incubate for five days to induce cell differentiation and polarization. For M0 or M2 
macrophages, adherent monocytes were supplemented with 10 ng/mL rhM-CSF. For M1 
macrophages, adherent monocytes were supplemented with 20 ng/mL rhGM-CSF. 
Following the five-day incubation, culture media was replaced with fresh complete RPMI 
free of antibiotics and supplemented with the following combination of cytokines to induce 
specific macrophage polarization: M0 macrophages – 10 ng/mL rhM-CSF; M1 
macrophages – 20 ng/mL rhGM-CSF, 250 ng/mL LPS and 10 ng/mL IFNγ; M2 
macrophages – 10 ng/mL rhM-CSF and 10 ng/mL rhIL-4.  
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2.3 Molecular cloning 
2.3.1 Recombinant DNA preparation 
Recombinant expression vectors were prepared through restriction enzyme digestion and 
subsequent ligation of appropriate insert sequences and vector backbones (see Appendix 
A for a complete list of constructs used in this thesis). Briefly, a DNA insert consisting of 
the consensus coding sequence (CDS) of the gene of interest or simply the sequence of 
interest (in the case of shRNA inserts) were amplified using standard PCR with primers 
designed to add flanking restriction enzyme sites compatible with the multiple cloning site 
of the vector backbone. A list of all PCR primers used for cloning can be found in 
Appendix A. PCR reaction was run for 30 cycles with Phusion DNA polymerase (New 
England Biolabs) according to the manufacturer’s instructions.  
Subsequently, the insert and backbone were digested with appropriate restriction enzymes 
for 1 hr at 37 °C and gel purified using a 1% agarose gel and the Monarch Nucleic Acid 
Preparation Kit (New England Biolabs) according to the manufacturer’s instructions. 
Optionally, prior to gel purification, backbone DNA sequences can be dephosphorylated 
with rAPID alkaline phosphatase (Sigma-Aldrich) according to the manufacturer’s 
instructions. Purified cut insert and backbone were ligated at a ratio of 10:1 insert to 
backbone overnight at 16 °C with 20,000 U/mL T4 ligase. Ligated vectors were 
transformed into chemically-competent Escherichia coli DH5α cells by heat shock for 1 
min at 42 °C.  
Transformed E. coli were plated on LB agar supplemented with the appropriate selective 
antibiotic(s) and incubated overnight at 37 °C. Colonies appearing following incubation 
were screened by colony PCR where feasible and propagated in liquid LB media overnight 
at 37 °C and shaking at 200 RPM. Following overnight incubation, plasmids were 
harvested from cultures using the High-Speed Plasmid Mini Kit (Geneaid) according to the 
manufacturer’s instructions. Correct insertion of insert into backbone was confirmed by 
Sanger sequencing at the London Regional Genomics Centre.  
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2.3.2 Transfection of cell lines 
HEK 293 cells were transfected using Lipofectamine 3000 (Life Technologies) according 
to the manufacturer’s instructions. Briefly, cells were seeded at 30-40% confluency the day 
prior to transfection. Vector DNA and Lipofectamine 3000 reagent were prepared in 
separate tubes in serum-free RPMI media. Equal volumes of DNA and Lipofectamine 
reagent were combined and the mixture allowed to incubate for 5 min at room temperature. 
The entirety of the mixture was then added dropwise to the desired well of J774.2 cells to 
be transfected. The transfection mix was incubated with cells for 5-16 hrs at 37 °C and 5% 
CO2, after which it was replaced by fresh complete RPMI media and allowed to incubate 
for at least 12 hrs at 37 °C and 5% CO2 prior to use in downstream applications.  
J774.2 cells were transfected using FuGENE HD transfection reagent (Promega) according 
to the manufacturer’s instructions. Briefly, the DNA to be transfected was diluted in serum-
free media and FuGENE reagent was added to 3:1 transfection reagent to DNA ratio. The 
mixture was vortexed briefly and allowed to incubate for 10-15 min at room temperature. 
Following incubation, the transfection mixture was added to the well to be transfected and 
allowed to incubate for at least 16 hrs at 37 °C and 5% CO2 prior to use in downstream 
applications. 
2.3.3 Viral transduction of cell lines 
THP-1 macrophages were transduced using lentiviral vectors to establish cell lines stably 
expressing the gene or sequence of interest. Insert sequences cloned into an appropriate 
lentiviral transfer plasmid backbone were packaged into lentiviral vectors in HEK 293 cells 
using Polyjet In Vitro DNA Transfection Reagent (SignaGen Laboratories) according to 
the manufacturer’s instructions. Briefly, HEK 293 cells were seeded at 10-20% confluency 
on 10-cm dishes and allowed to proliferate to 50-60% confluency over approximately two 
days. A DNA mixture containing 5 µg of the lentiviral vector, 2 µg of the pMD2.G 
envelope plasmid and 5 µg of the pDR8.2 packaging plasmid in serum-free DMEM media. 
This mixture was combined with an equal volume of Polyjet reagent diluted in serum-free 
DMEM and allowed to incubate for 12 min at room temperature. Following incubation, 
the transfection mixture was added dropwise to HEK 293 cells. Cells were incubated for 
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three days at 37 °C and 5% CO2, with the media being changed with fresh complete DMEM 
24 hrs post-transfection. At the end of the three-day period, cell supernatants were collected 
and FBS was added to a final concentration of 20%. Supernatants were centrifuged for 5 
min at 1,500 ×g and then filtered using a 2-µm filter. Filtered supernatant containing 
lentivirus was aliquoted and stored at -80 °C until needed.  
THP-1 monocytes were transduced using prepared lentivirus using a Spinfection protocol. 
Approximately 1 × 106 cells were re-suspended in 500 µL of lentivirus-containing 
supernatant prepared previously. Polybrene Infection Reagent (Sigma-Aldrich) was added 
to a final concentration of 8 µg/mL and the mix was centrifuged for 45 min at 800 ×g. Cell 
pellet was washed 1× with PBS to remove excess virus and Polybrene reagent and 
transferred into complete RPMI media. Transduced cells were incubate for a minimum of 
48 hrs at 37 °C and 5% CO2 prior to use in downstream applications. 
 
2.4 RNA preparation and RT-qPCR 
2.4.1 RNA preparation 
Total RNA was isolated from cells or patient tissues through acid guanidinium thiocyanate-
phenol-chloroform extraction uysing PureZOL RNA isolation reagent (Bio-Rad). Cells or 
tissues were suspended in an appropriate volume of PureZOL reagent (1 mL of reagent per 
50-100 mg of tissue or 107 cells), vortexed briefly and allowed to incubate for 5 min at 
room temperature. Chloroform was added 1:5 v/v and the mix was allowed to incubate for 
another 5 min at room temperature with intermittent agitation. Samples were centrifuged 
for 15 min at 12,000 ×g and 4 °C, and subsequently the upper aqueous layer containing 
RNA was transferred to a fresh tube. An equal volume of isopropanol and 0.5 µL of 20 
mg/mL glycogen were added to the RNA and the mixture was incubated at -80 °C for at 
least 30 min. Samples were again centrifuged for 15min at 12,000 ×g and 4 °C to pellet 
precipitated RNA. The RNA pellet was washed 2× with 75% ethanol, air dried for 
approximately 5 min at room temperature and reconstituted in a minimal amount of RNase-
free ddH2O. RNA concentration and quality were measured using a NanoDrop 1000 
Spectrophotometer (Thermo Fisher) prior to use in downstream applications.  
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2.4.2 RT-qPCR 
cDNA was generated from total RNA using the iScript Select cDNA Synthesis Kit (Bio-
Rad) according to the manufacturer’s instructions, with an equal amount of starting RNA 
an equal mix of the random and oligo(dT)20 primer mixes. cDNA concentration and quality 
were checked using a NanoDrop 1000 Spectrophotometer prior to use in qPCR reactions. 
qPCR was performed using the Fast SYBR Green Master Mix (Thermo Fisher) an equal 
amount of starting cDNA. All qPCR primers used in this thesis can be found in Appendix 
A. PCR reactions were run on a QuantStudio 5 Real-Time PCR System (Thermo Fisher) 
for 40 cycles. Relative expression of genes of interest was calculated using the ΔΔCt 
method with either GAPDH or 18S serving as the reference gene.  
 
2.5 Western blotting 
Western blotting was employed to detect proteins of interest in cultured cells. A sufficient 
number of cells (at least 5 × 105) was cultured and was 1× with PBS immediately prior to 
lysis. Lysis was performed using either Triton X-100 (for cytoplasmic or membrane 
proteins; 150 mM NaCl, 1% Triton X-100, 50 mM pH 8.0 Tris-HCl) or RIPA (for nuclear 
proteins; 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS and 50 
mM pH 8.0 Tris-HCl). Appropriate lysis buffer containing 1:100 v/v mammalian protease 
inhibitor was added to the cells and cells were scraped into suspension. The lysate was 
transferred to a clean tube and incubated for 40 min at 4 °C on a rotator. The lysate was 
subsequently centrifuged for 15 min at 12,000 ×g and 4 °C. Following centrifugation, 
supernatants were transferred to a clean tube and 1:4 v/v 4× Laemmli’s buffer (1:5 v/v 1M 
pH 6.8 Tris-HCl, 0.08 g/mL SDS, 2:5 v/v glycerol and 0.02% bromophenol blue in ddH2O) 
and 1:10 v/v β-mercaptoethanol were added. Supernatants were subsequently incubated for 
5 min at 95 °C to fully denature proteins. 
Denatured cell lysates were run on a 10% SDS-PAGE gel for 60 min at 120 V or until the 
leading edge of the lysates have nearly reached the bottom of the gel. Proteins were 
transferred to a nitrocellulose membrane for 1 hr at 100 V or overnight at 40 V on ice or at 
4 °C. Following transfer, membranes were washed 1× with TBST prior to processing.  
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Membranes were blocked with 5% BSA in TBST for a minimum of 1 hr at room 
temperature with gentle agitation. The primary antibody was added to blocking buffer at 
an appropriate concentration and allowed to incubate for at least 1 hr at room temperature. 
Membranes were washed 3× with TBST and incubated in blocking buffer with an 
appropriate concentration of infrared dye-conjugated secondary antibody added. 
Membranes were allowed to incubate for at least 30 min at room temperature with gentle 
agitation. Subsequently, membranes were again washed 3× with TBST and imaged on an 
Odysey CLx Imaging System (LI-COR). If necessary, band densitometry was carried out 
using the Analyze Gels tools on ImageJ.1 
 
2.6 Phagocytosis and efferocytosis assays 
2.6.1 Preparation of synthetic phagocytic and efferocytic targets 
IgG-coated beads were used as synthetic phagocytic targets. An equal mixture of 10 µL of 
10% 5-µm polystyrene beads (vortexed and washed 1× with PBS prior to use) and 10 µL 
of 10 µg/mL human IgG were combined in PBS. Mixture was incubated for 90 min at room 
temperature or overnight at 4 °C rotating. Following incubation, beads were washed 3× 
with PBS (3,000 ×g, 1 min per wash) and re-suspended in 100 µL of PBS and stored for 
up to two weeks at 4 °C prior to use. If desired, beads may be labelled with 1 µg/mL of a 
fluorescently-conjugated secondary anti-human IgG antibody prior to use.  
PS-coated beads were used as synthetic efferocytic targets. A lipid mixture consisting of 
80% PC and 20% PS was prepared in a glass vial. If desired, a portion of the PS can be 
replaced with 0.1% rhodamine-conjugated PE and/or 0.1% biotin-conjugated PE to allow 
for fluorescent labelling of the beads. A 10 µL volume of 10% 3-µm silica beads was 
washed 1× with PBS (3,000 ×g, 1 min per wash) and then 1× with methanol. Beads were 
dried completely by incubating them for 5 min at 60 °C. Dried beads were re-suspended in 
100 µL of chloroform and added to the lipid mixture. The lipid/bead mixture was vortexed 
well and dried under a stream of nitrogen gas for approximately 10 min or until the 
chloroform had completely evaporated. Beads were subsequently washed 3× with PBS 
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(3,000 ×g, 20 sec per wash) to completely remove any liposomes. Beads were then re-
suspended in 100 µL of PBS and stored for up to two weeks at 4 °C prior to use. 
2.6.2 Preparation of physiologic phagocytic and efferocytic targets 
2.6.2.1 Heat killed bacteria 
An overnight culture of E. coli ML35 prepared to provide a sufficient number of bacteria 
for the phagocytosis assay. Typically, a ratio between 10:1 to 100:1 bacteria-to-phagocyte 
was used. The desired number of bacteria was pelleted for 1 min at 6,000 ×g. Pellet was 
re-suspended in 500 µL of PBS. At this stage, if necessary, bacteria were heat-killed by 
incubating for 10 min at 70 °C. Bacteria were washed 2× with PBS. 
When required, bacteria were surface biotinylated and/or labelled with a covalent 
fluorescent dye for downstream applications. Surface biotinylation was performed using 
NHS-LC-biotin. Bacteria were re-suspended in 500 µL of pH 8.0 PBS, to which 0.2 mg of 
NHS-LC-biotin re-suspended in 10 µL of DMSO was added. The mixture was incubated 
for 30 min at room temperature with gentle agitation. Excess NHS-biotin was quenched 
using an equal volume of PBS containing 100 mM glycine for 10 min at room temperature 
with gentle agitation. Biotinylated bacteria were washed 2× with PBS and re-suspended in 
PBS at the desired concentration. Fluorescent labelling was performed using either a 
CellTrace dye or an eFluor cell proliferation dye. Bacteria were re-suspended in 500 µL of 
PBS and 0.5 µL of the dye was added to the suspension. The mixture was incubated for 20 
min at room temperature with gentle agitation away from light. Excess dye was quenched 
with an equal volume of PBS containing 100 mM glycine for 10 min at room temperature 
with gentle agitation away from light. Labelled bacteria were washed 2× with PBS and re-
suspended in PBS at the desired concentration. Heat-killed bacteria were stored 4 °C up to 
five days whereas live bacteria were used immediately following preparation. 
In some experiments, bacteria were opsonized with human serum prior to use. A solution 
of 20% human serum was prepared in serum-free DMEM or RPMI media. Equal volumes 
of bacteria and opsonin solution were mixed and incubated for 20 min at room temperature 
or overnight at 4 °C rotating. Opsonized bacteria were washed 1× with serum-free DMEM 
or RPMI prior to use. 
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2.6.2.2 Apoptotic cells 
Apoptotic Jurkat cells were used as physiologic efferocytotic targets. Jurkat cells were 
grown in culture to provide a sufficient number of apoptotic cells. Typically a ratio of 10:1 
apoptotic cells-to-phagocytes was used. 1 × 106 Jurkat cells were re-suspended in 1 mL of 
serum-free RPMI media, to which staurosporine was added to a final concentration of 1 
µM. Cells were incubated for 3-16 hrs (ideally closer to 16 hrs) at 37 °C and 5% CO2. 
Apoptotic cells were washed 3× with PBS to remove excess staurosporine and re-
suspended in complete RPMI media prior to use. 
When required, apoptotic cells were surface biotinylated and/or labelled with a covalent 
fluorescent dye for downstream applications. Apoptotic cells were re-suspended in 500 µL 
of PBS. For surface biotinylation, 0.2 mg of NHS-LC-biotin was re-suspended in 10 µL of 
DMSO and added to the apoptotic cells. For direct fluorescent labelling, a CellTracker dye 
was added to a final concentration of 2 µg/mL to apoptotic cells. The mixture was 
incubated for 20 min at room temperature with gentle agitation away from light. Excess 
biotin and/or dye was quenched with RPMI media containing 10% FBS for 5 min at room 
temperature with gentle agitation away from light. Labelled apoptotic cells were 
centrifuged for 5 min at 500 ×g and cells were re-suspended in an appropriate volume of 
complete RPMI or PBS. 
In some experiments, apoptotic cells were opsonized with human serum prior to use. A 
solution of 20% human serum was prepared in serum-free DMEM or RPMI media. Equal 
volumes of bacteria and opsonin solution were mixed and incubated for 20 min at room 
temperature or overnight at 4 °C rotating. Opsonized apoptotic cells were washed 1× with 
serum-free RPMI prior to use. 
2.6.3 Phagocytosis/efferocytosis assay 
Phagocytosis and efferocytosis assays were carried out according to our labs previously 
published methods (Evans et al. and Taruc et al.).2,3 A desired number of 
phagocytes/efferocytes along with the appropriate phagocytic/efferocytic targets were 
prepared as specified above. Phagocytes/efferocytes were allowed to equilibrate to room 
temperature in order to prevent premature target uptake. The desired number of phagocytic 
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and/or efferocytic targets were added and the mixture was centrifuged for 1 min at 500 ×g 
to force contact between phagocytes/efferocytes and targets. Assays were incubated for 30 
min (IgG-coated beads), 60 min (PS-coated beads or bacteria) or 90 min (apoptotic cells). 
Following incubation, assays were allowed to equilibrate to room temperature to prevent 
any further target internalization and washed at least 2× with PBS to remove any unbound 
targets.  
 
2.7 Immunofluorescence staining 
2.7.1 Staining of tissue sections 
Immunofluorescence staining was performed on 10-µm thick tissue sections adhered to 
glass slides. Sections were immersed in cold 4% PFA for 15 min at -20 °C. Sections were 
subsequently washed 3× 5 min with PBS and excess liquid was carefully removed from 
slide surface. Tissue sections were demarcated with a PAP pen to facilitate further staining. 
Sections were blocked using 200 µL blocking buffer (10% serum from species used for 
generation of secondary antibody, 0.3 M glycine, 0.1% Tween-20 and 1% BSA in PBS) 
for at least 1 hr at room temperature. For intracellular staining, cells were permeabilized 
by supplementing blocking buffer with 0.1% Triton X-100. Following blocking, the 
blocking buffer was removed and 200 µL of primary antibody at an appropriate 
concentration in blocking buffer was added to the sections. Sections were incubated with 
primary antibody for at least 1 hr at room temperature or overnight at 4 °C and subsequently 
washed 3× 15 min using 0.1% BSA and 0.1% Tween-20 in PBS. Sections were then 
incubated with 200 µL of 1 µg/mL secondary antibody for at least 30 min at room 
temperature and subsequently washed 3× 15 min using 0.1% BSA and 0.1% Tween-20 in 
PBS. Coverslips were glued to sections using Permafluor mounting reagent and stained 
sections were kept at 4 °C until imaging.  
2.7.2 Staining of cells 
Cells to be stained were grown on 18 mm, #1.5 thickness round coverslips placed into the 
wells of a 12-well tissue culture plate. Prior to staining, cells were equilibrated to room 
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temperature to prevent membrane turnover and washed 1× with PBS. Cells were fixed with 
4% PFA for 20 min at room temperature and subsequently washed 3× 5 min with PBS to 
remove excess PFA. Fixed cells were blocked with 5% PBS (supplemented with 10% 
serum if the cells to be stained were FcγR-expressing phagocytes) for at least 20 min at 
room temperature. For intracellular staining, cells were permeabilized by supplementing 
the blocking buffer with 0.1% Triton X-100, and the length of the blocking period 
increased to at least 1 hr. Blocking buffer was removed and primary antibody in blocking 
buffer was added to the cells and allowed to incubate for 30 min (without permeabilization) 
or 60 min (with permeabilization) at room temperature. Cells were washed 3× 5 min 
(without permeabilization) or 3× 15 min (with permeabilization). Secondary antibodies in 
blocking buffer was added and allowed to incubate for 30 min at room temperature. Cells 
were again washed 3× 5 min (without permeabilization) or 3× 15 min (with 
permeabilization). Coverslips were mounted onto glass slides using Permafluor mounting 
reagent and stored at 4 °C until imaging. 
 
2.8 Patient tissue samples 
2.8.1 Human research ethics 
Patient tissues used in this study were obtained under a discarded tissue protocol from 
patients undergoing elective coronary artery bypass graft (CABG) surgery at London 
Health Sciences Centre. This study was reviewed and approved by the Office of Human 
Research Ethics at Western University Health Sciences Research Ethics Board (HSREB 
Reference Number: 107566). Since this is a discarded tissue study, we did not collect any 
personal health information, personal identifying information or clinical data nor were we 
required to obtain informed consent from patients’ whose tissues were used in this study. 
2.8.2 Surgical specimen preparation 
Aortic punch tissue specimens were obtained intra-operatively by a cardiac surgeon using 
a 4.0-mm diameter CleanCut RCL Aortic Punch (QUEST Medical) and placed into cold 
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saline. Specimens were then bisected evenly using clean surgical scissors, with one half of 
the tissue used to prepare frozen sections and the other for preparing paraffin sections.  
2.8.3 Tissue sectioning 
2.8.3.1 Frozen sections 
For laser capture microdissection, tissue specimens used for frozen sections were 
immediately embedded in OCT freezing compound and frozen on dry ice over a period of 
5-10 min and placed into -80 °C for storage. No more than 30 min was allowed to elapse 
between the time at which aortic punch tissue specimens were excised and placement of 
the frozen, OCT-embedded tissue into -80 °C for storage. Frozen sections were 
subsequently obtained from OCT-embedded tissue on a cryostat at a 10-µm thickness onto 
clean, RNase-free glass microscope slides. 
For immunofluorescence, Oil Red O staining and all other downstream applications, tissue 
specimens were fixed in fresh (< 1 week old) 4% paraformaldehyde for 24 hr at 4 °C. Fixed 
specimens were placed into PBS with 15% sucrose for  approximately 4 hr (or until the 
tissue sinks) and then into PBS with 30% sucrose overnight at 4 °C. Fixed, cryopreserved 
tissue specimens were then embedded in OCT freezing compound and frozen on dry ice 
over a period of 5-10 min and placed into -80 °C for storage. Frozen sections were 
subsequently obtained from OCT-embedded tissue on a Leica CM1900 Cryostat at a 10-
µm thickness onto clean Superfrost Plus microscope slides (Fisherbrand). 
2.8.3.2 Formalin sections 
Tissue specimens used for formalin-fixed, paraffin-embedded (FFPE) sections were fixed 
in fresh (< 1 week old) 4% paraformaldehyde for 24 hr at 4 °C. Fixed specimens were 
stored in 70% ethanol until ready for further processing. For paraffin infiltration, specimens 
were dehydrated through immersion in changes of ethanol of increasing concentration 
(70% ethanol for 1 hr, 95% ethanol for 1 hr, and four changes of 100% ethanol for 
1/1.5/1.5/2 hr), cleared with two changes of xylene for 1 hr each and immersed in two 
changes of paraffin wax at 58 °C for 1 hr. Processed tissues were embedded into paraffin 
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blocks. FFPE tissues were subsequently sectioned on a microtome at a 5-µm thickness onto 
clean glass microscope slides. 
 
2.9 Mouse work 
Use of animals for this study was obtained from the Western University Animal Care 
Committee under Animal Use Protocol (AUP) 2018-131:1. LDL receptor-deficient (Ldlr-
/-)  C57BL/6J mice were put on either a high-fat, high-cholesterol (15% fat, 1% cholesterol) 
diet or a chow control for a period of 12 weeks. Animals were subsequently sacrificed, 
with thoracic aortas being subsequently surgically isolated for further processing. 
 
2.10 Microscopy 
Microscopy was used to visualize tissue histology and perform quantification of 
fluorescence intensity. In all cases, at least three biological replicates were analyzed. For 
measurement of fluorescence within individual cells, a minimum of 30 cells were 
quantified. To minimize observer bias, random fields of view were captured whenever 
possible. 
2.10.1 White light 
Tissue section immunohistochemistry, TUNEL assay and Oil Red O-stained cells were 
imaged using an inverted-stage white light microscope equipped with a digital camera 
running Northern Eclipse image analysis software (EMPIX Imaging) using a 5× or 10× 
objective lens.  
2.10.2 Epifluorescence 
Imaging of immunofluorescently-stained frozen sections and immunofluorescently-stained 
cells was performed using a Leica DMI6000B epifluorescence microscope equipped with 
a Sedat Quad filter set (Chroma) and operated by Leica LAX software. 
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For imaging of Rab protein recruitment to phagosomes and efferosomes or for co-
localization experiments, samples were imaged using a 100×/1.40NA objective lens and 
an Evolve-512 delta EM-CCD camera (Teledyne Photometrics). 
For imaging of phagocytosis and efferocytosis assays, peptide citrullination assays, dextran 
fusion assays, nitro blue tetrazolium assays or for confirming the expression of a 
fluorescently-tagged protein, samples were imaged using a 63×/1.40 NA objective lens and 
the Evolve EM-CCD camera. If needed, z-sections were captured for apoptotic cell 
efferocytosis assays across the entire depth of the efferocyte separated by 0.5 µm between 
stacks.  
For imaging of whole immunofluorescently-stained tissue sections, samples were imaged 
using a 40×/1.00NA objective lens and the ORCA-Flash4.0 V3 Digital CMOS camera 
(Hamamatsu Photonics) with the Leica LAX Tile Scan Merge function to capture the 
entirety of the aortic wall intima. 
2.10.3 Live cell 
Cells to be imaged were grown on No. 1.5 thickness 8-mm round glass coverslips and 
transferred to a Leiden chamber and placed into a heated and CO2-perfused chamber 
attached to the piezoelectric stage of a Leica DMI6000B epifluorescence microscope. 
Between 5-10 cells of interest were marked using the Mark and Find feature of the Leica 
LAX software and live cell acquisitions of each cell were obtained at 0.5-1 frames/min 
over a period of 1-8 hrs.  
 
2.11 Image analysis 
All image analysis was performed using the FIJI distribution of ImageJ unless otherwise 
stated.1,4 Specific methods are described in detail in individual methods sections for each 
following chapter. 
In general, measurement of fluorescence intensity was performed by forming a selection 
around the region of interest (ROI) and using the Measure feature to obtain the area and 
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integrated density of the ROI. Background fluorescence was measured by drawing a ROI 
around a region free of any cells or other features and measuring the mean. Background 
subtraction was performed on fluorescence intensity measurements by subtracting from 
integrated density the product of background mean and the measurement ROI area. 
Unless otherwise specified, co-localization analysis was performed using the JACoP 
plugin on ImageJ to determine Pearson’s coefficient.5 
 
2.12 Statistical analysis 
All statistical analysis was performed on GraphPad Prism 6 software. Comparison between 
two means made use of an unpaired, two-tailed Student’s t test or Mann-Whitney U test 
when the sample distribution was noted to be non-normal. For comparison of multiple 
means, we employed 1-way or 2-way ANOVA as appropriate with the Holm-Sidak 
multiple comparisons test when comparing multiple means with a single mean or the 
Tukey’s range test when comparison multiple means with every single other mean. 
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Chapter 3  
3 The Small GTPase Rab17 is a Key Regulator of 
Efferosome Maturation Under Homeostatic Conditions 
3.1 Introduction 
3.1.1 Regulation of efferosome maturation under homeostatic 
conditions 
Appropriate regulation of efferocytic clearance of apoptotic cells and subsequent 
maturation of the resultant efferosome are crucial for the proper maintenance of tissue 
homeostasis.1–3 Much of what is currently known about the regulation of efferosome 
maturation is derived from studies in a Caenorhabditis elegans model, where the early 
stages of efferosome maturation appears to proceed similarly to canonical phagosome 
maturation.4 Efferosome and phagosome maturation is described in detail in Chapter 
1.1.5, but briefly, the small GTPase Rab5 is recruited to the surface of the nascent 
efferosome, followed by a rapid exchange of Rab5 for Rab7 mediated by the Mon1-Ccz1 
complex.5,6 Rab7 subsequently mediates the recruitment of effector molecules such as 
RILP and ORPL1, which are required for efferosomal-lysosomal fusion, and VTPases that 
drive efferosomal acidification.7–10 The result of this process is the formation of an 
efferolysosome where, akin to a phagolysosome, the apoptotic cell cargo is degraded.11 
3.1.2 Differential regulation of phagosome and efferosome maturation 
Although the mechanisms that govern phagosome and efferosome maturation are similar, 
there are drastic differences in the immunological outcomes of phagocytosis versus 
efferocytosis.11,12 Whereas phagocytosis is a pro-inflammatory process that results in 
inflammation and antigen presentation, efferocytosis is immunologically silent and instead 
drives resolution of inflammation.12 The ultimate fate of efferocytic and phagocytic 
cargoes must therefore also differ.13,14 Phagocytic cargoes are degraded and subsequently 
loaded onto MHC class II molecules for antigen presentation, whereas efferocytosis does 
not result in antigen presentation.13 
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3.1.3 The Rab family of GTPases 
The Rab (“Ras-related in brain”) family is a part of the Ras superfamily of small GTPases 
and function as master regulators of intracellular vesicular trafficking.15 Rab GTPases are 
found ubiquitously across all eukaryotes studied to date, with more than 60 family 
members identified in the human genome alone.16,17 Members of the Rab family all possess 
a distinctive set of five α helices surrounding a six-stranded β sheet. This structure is 
common to all members of the Ras superfamily and contain structures responsible for 
guanine nucleotide binding activity.18 Additionally, Rab GTPases contain two regions 
termed switch I and switch II, which contain distinctive RabF regions that can be used to 
identify Rab GTPases and undergo conformational changes depending on whether the Rab 
is in an active GTP-bound or an inactive GDP-bound state. Finally, individual Rab family 
members contain RabSF regions, which are thought to be responsible for binding with 
specific effector molecules.15,16 An illustration of the common structural features of the 
Rab GTPases is provided in Figure 3.1. 
 
 
 
Figure 3.1 Common structural features of the Rab family of small GTPases. (on 
opposite page) 
Ribbon diagram of the crystal structure of Rab3A complexed with the GTP analog 
GppNHp. Purple – bound nucleotide; orange sphere – Mg2+ ion; blue – switch I and II 
regions; green – α helices and β sheets; yellow – loops. (a) A consensus amino acid 
sequence of the Rab GTPase family. Red – Rab-specific residues (RabF1-5); dark blue – 
subfamily-specific motifs (RabSF1-4); cyan – highly conserved nucleotide-binding motifs; 
G – guanine base-binding motif; PM – phosphate/magnesium-binding motif. (b) The 
secondary structure units (α helices, β strands, and loops, λ) are indicated above the 
sequence. Figure modified from Stenmark and Olkkonen.15 
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Newly-synthesized Rab GTPases are bound by a Rab escort protein (REP), which first 
recruits a geranylgeranyl transferase enzyme that mediates transfer of a hydrophobic 
geranylgeranyl group to the carboxyl terminus of the protein.19,20 This post-translational 
modification allows the Rab to anchor itself to cellular membranes.20 Specific targeting of 
Rab GTPases to the appropriate membrane surface is thought to result from an interaction 
between the Rab-REP complex and receptors on the target membrane.21 At this stage, the 
Rab is in an inactive, GDP-bound conformation. Inactive Rab’s can become activated via 
GTP-GDP exchange mediated by a GEF. The activate Rab is then able to recruit specific 
downstream effector molecules. Active Rab’s can be inactivated by a GAP, which cleaves 
the bound GTP to GDP.22,23 
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Table 3.1 Rab-family GTPases implicated in phagosome maturation. Modified from 
Kinchen and Ravichandran.11  
 
Rab GTPases play many key functions in the regulation of almost every component of 
intracellular vesicular trafficking.11,22,24 Rab5 and Rab7 are key markers of the early and 
late phagosome/efferosome respectively and play crucial functions in the regulation of 
proper phagosome and efferosome maturation.6,25 Rab4 and Rab11 are members of this 
family that have been implicated in membrane and receptor recycling. Rab4 is required for 
the recycling of receptors from the early endosome to the cell membrane while Rab11 is a 
marker of the recycling endosome and required for trafficking of receptors from the RE to 
the cell surface.26–28 A final example is Rab27, which plays an important role in regulated 
secretion across multiple cell types and appears to play a key role in mediating granule 
release from secretory cells such as melanocytes, neurons and neutrophils.29–31 
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Unsurprisingly, there are a multitude of Rab GTPases involved in the regulation of 
phagosome/efferosome maturation (Table 3.1). These include the classical Rab5 and Rab7 
but also a number of Rab family members involved in transport between the endoplasmic 
reticulum and Golgi and the Golgi and other vesicles. 
3.1.3.1 Rab17 
One member of the Rab GTPase family of particular interest to us is Rab17 as it appears 
as a protein that is uniquely recruited to the efferosomal surface in the mass spectrometry 
experiments described below. Rab17 was initially identified in the 1990’s in epithelial cells 
and enterocytes as a key regulator of transcytosis and membrane recycling in polarized 
cells.32–34  
Since then, the presence and function of Rab17 has been described in a number of polarized 
and secretory cells, including hepatocytes35,36, neurons37 and melanocytes38. In the liver, 
Rab17 appears to play a key role in regulating the basolateral-to-apical transcytosis in 
hepatocytes and that sumoylation was required in addition to GTP-binding for Rab17 
activity.35,36 In the brain, Rab17 is expressed in neurons of the hippocampus and regulates 
formation and post-synaptic growth of dendrites.37 It is also found in brain epithelial cells, 
where it again appears to regulate the formation of “sorting tubules” that mediate the 
transcytosis of cargoes across the blood-brain barrier.39 In melanocytes, Rab17 is found to 
be associated with the RE and Rab17 knockdown resulted in impaired filopodia formation 
and melanosome release.38 A detailed mechanistic study of Rab17 involvement in 
transcytosis by Striz et al.36 revealed that it is able to associate with transcytotic vesicle-
specific VAMP’s and interact with syntaxin 2 at the apical membrane to initiate vesicle 
fusion.  
Importantly, a dominant-negative (DN) mutant of Rab17 has been previously described 
and characterized.32 This mutant contains a single asparagine to isoleucine mutation in the 
NKXD motif, which is highly conserved within GTPase proteins and is required for 
binding to GTP and conversion to the protein’s active form.40,41 DN-Rab17 does not appear 
to interact with syntaxin 2 and cells expressing DN-Rab17 displayed impair trafficking of 
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apical proteins via transcytosis, suggesting that expression of DN-Rab17 impairs proper 
cargo trafficking.35 
3.1.4 Rationale and importance 
Despite being a crucial mechanism for the maintenance of tissue homeostasis, efferocytosis 
and the mechanisms that regulate efferosome maturation remain poorly understood. Much 
of what is known about efferosome maturation is derived from either knowledge of 
phagosome maturation or from studies in model organisms such as C. elegans.6 As 
phagocytosis and efferocytosis have radically different immunological outcomes, it is 
reasonable to expect that phagosomes and efferosomes undergo different maturation 
programs.12 To date, we still lack a clear understanding of how phagosome and efferosome 
maturation are differentially regulated. 
In the present chapter, we use a mass spectrometric approach towards identifying proteins 
that are uniquely recruited to phagosomes vs. efferosomes as potential regulators of 
differential maturation. We then utilize fluorescence microscopy to track differential 
recruitment of regulators to the phagosome and efferosome surfaces and examine the 
effects of the knockdown of regulators on phagosomal and efferosomal cargo fate. 
Efferocytosis plays an important role in limiting inflammation and promoting 
resolution.3,42 Failure of efferocytosis has been implicated in the pathophysiology of a 
number of inflammatory and autoimmune diseases, including atherosclerosis,43–45 systemic 
lupus erythematosus46,47 and multiple sclerosis.48 Despite this, factors that regulate 
efferosome maturation under homeostatic conditions remain poorly understood. A clearer 
picture of how efferosome maturation is regulated will allow us to gain a better 
understanding of how efferosomal cargo is degraded without antigen presentation and will 
form the basis of investigating how this process begins to break down in autoimmune 
disease. 
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3.2 Methods 
3.2.1 Rab17 cloning  
Human Rab17 was cloned into pEGFP-C1 and pmCherry-C1 backbones using the method 
described in Chapter 2.3.1. A dominant-negative (N132I) Rab17 construct35 was prepared 
by amplifying the above construct with DN Rab17-specific 5′ phosphorylated primers 
using the standard PCR cycle with a 7 min elongation time. Parental plasmid was removed 
by the addition of 1:50 (vol/vol) DpnI to the reaction and incubating for 1 h at 37 °C. The 
resulting PCR product was then gel purified, re-circularized by incubating overnight at 16 
°C with T4 ligase and subsequently transformed into E. coli as described in Chapter 2.5.1. 
See Appendix A for primer sequences. 
3.2.2 Phagocytosis/efferocytosis assays 
Synthetic IgG- and PS-coated beads were prepared using the methods described in 
Chapter 2.6.1 while heat-killed E. coli and apoptotic Jurkat cells were prepared as 
described in Chapter 2.6.2. Phagocytosis and efferocytosis assays were performed 
following the methods described in Chapter 2.6.3 with proteins of interest labelled 
following blocking/permeabilization by addition of primary antibodies (1:1000 anti-MHC 
class II, 1:500 anti-LAMP1, 1:200 anti-Rab17) followed by fluorescently tagged Fab’s 
(1:1000 to 1:2500). 
3.2.3 Quantification of Rab17 recruitment to phagosomes/efferosomes 
Quantification of Rab17 recruitment was performed in MATLAB using modified forms of 
previously published vesicle-tracking and intensity quantification algorithms.49–51 Briefly, 
90-120 min time-lapse videos were captured of macrophages ectopically expressing the 
plasmalamellar marker PM-RFP, GFP-tagged Rab17 and far-red-labeled 
phagocytic/efferocytic targets. TIFF stacks of individual cells were then exported, and a 
local threshold applied to the target channel using a local neighborhood 2× the size of the 
targets. Targets were then identified using the 'bwlabel' command in MATLAB and the 
targets tracked using a robust tracking algorithm.50,52 Image channels corresponding to PM-
RFP and Rab17 were subjected to a global background subtraction, with no other 
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processing applied, to maintain linearity of intensity data. Internalized targets were defined 
as targets that colocalized with a distinct PM-RFP structure that was no more than 1.4× 
(beads) or 2× (E. coli or apoptotic cells) the diameter of the phagocytic/efferocytic target, 
and the first frame in which the target colocalized with a distinct PM-RFP structure was 
set as the 0 min timepoint of phagocytosis/efferocytosis. All tracks were manually curated 
to ensure accuracy, with any tracks lasting less than 15 min rejected from subsequent 
analyses. Recruitment of Rab17 to the PM-RFP/target structure was then measured at all 
subsequent timepoints and normalized to the maximum intensity Rab17 structure in the 
cell. 
3.2.4 Colocalization analysis 
Colocalization of signaling molecules with phagosomes and efferosomes in fixed cells was 
also quantified using MATLAB. Z-stack images of cells were captured and deconvolved 
using an iterative deconvolution approach. A ROI was manually drawn around each cell 
and the mean ± SEM of the fluorescence intensity of each channel within the ROI 
determined. Phagocytic/efferocytic targets were then identified using the local background 
subtraction and thresholding approach described in the previous subsection but using the 
'bwlabeln' MATLAB command to identify targets in the 3D images. Each target was 
converted into a 3D ROI by identifying the bounding pixels of each target using the 
'convhull' command. These ROIs were then expanded by a factor of 1.4× to ensure that the 
bounding PM-RFP and any recruited signaling molecules would be captured without 
significant inclusion of cytosolic staining. Targets were scored as associated with a 
molecule of interest if the mean intensity of the molecule of interest in each ROI was two 
SD higher than the mean intensity of the molecule throughout the entire cell. As with the 
Rab17 recruitment analysis described above, no intensity adjustments other than a global 
background subtraction were applied to the images of the signaling molecules to preserve 
linearity of the image intensity data. 
3.2.5 Efferosome mimics quantification 
Quantification of mimic-containing efferosomes was performed to measure the formation 
of efferosome-derived vesicles (EDVs). Time-to-fragmentation was measured from the 
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timepoint of complete efferosome closure to timepoint when fission of the first Rab17+ 
EDV was observed. The number of EDVs formed from each efferosome was recorded and 
the diameter of each EDV was quantified using the line measurement tool. 
3.2.6 Efferosome fission, fusion and movement 
Efferosomes were tracked in fluorescent images. At the timepoint of complete efferosome 
closure an ROI was drawn around the cell using the freehand selection tool, and the x/y 
coordinates of the cell barycentre determined with the measure tool. The MTrack2 plugin 
was used to track the efferosome, EDVs, and any EDV-interacting Rab17+ vesicles. Track 
positions were imported into MATLAB, the timing and location of all fission and fusion 
events annotated, and the track divided into pre- vs. post-initial fission segments. Pre-
fission tracks were translated such that all measurements were made relative to a vector 
linking efferosome closure site to the cell barycentre, and post-fission tracks translated 
such that all measurements were made relative to a vector linking the fission site to the cell 
barycentre. The directionality of movement of each track was then quantified as the ratio 
between the Euclidian distance covered by the vesicle from its start- to end-point vs. the 
total distance traveled.53,54 
3.2.7 Efferosome positioning 
Efferosome positioning was quantified using the method of Johnson et al.55 Images were 
imported into FIJI56,57 and the cell boundary, as defined by the Rab17 staining, traced using 
the freehand tool. This ROI was then degraded inwards in 1 mm increments to create 3 
shells of 1 mm thickness. The number of EDVs in each shell, EDV diameter (sub-
resolution EDVs were recorded as 0.2 mm in diameter), and colocalization with LAMP or 
TfR was quantified in each image using the methods described above. 
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3.3 Results 
3.3.1 Efferosomes and phagosomes share a common early maturation 
pathway 
Phagocytic cargos are degraded by a well-characterized maturation pathway in which the 
sequential acquisition of Rab5 and Rab7 mediates the sequential fusion of early 
endosomes, late endosomes and lysosomes with the phagosome.8 Evidence from C. 
elegans and mammalian cell lines indicate that this same maturation pathway degrades 
efferocytosed apoptotic cells.4 However, these studies did not use professional antigen 
presenting cells (pAPCs), which may use an alternative pathway to avoid antigen 
presentation following uptake of apoptotic cells.  
To test whether apoptotic cells were trafficked through a novel maturation pathway in 
pAPCs, we tracked the recruitment of ectopically expressed Rab5-GFP and Rab7-RFP in 
J774.2 macrophages engaged in phagocytosis (Figures 3.2a and 3.2c) or efferocytosis 
(Figures 3.2b and 3.2d) of 5 μm diameter synthetic phagocytic or efferocytic targets. Both 
efferosomes and phagosomes sequentially recruited Rab5 and Rab7, with efferosomes 
transitioning from a Rab5-positive to Rab7-positive compartment with slightly slower 
temporal dynamics than phagosomes (Figures 3.2c and 3.2d). To confirm that both 
phagosomes and efferosomes were completing maturation, we immunostained human 
PBMC-derived M0 macrophages for the lysosomal marker LAMP1 40 min after 
engulfment of synthetic phagocytic or efferocytic targets (Figure 3.2e). Significant 
LAMP1 accumulation was observed on phagosomes and efferosomes, confirming that 
vacuoles containing both types of cargo fuse with lysosomes. Finally, we assessed the 
possibility that macrophage polarization may result in the selective uptake of phagocytic 
versus efferocytic targets (Figure 3.2f).  
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Figure 3.2 Efferosomes and phagosomes share a common early maturation pathway. 
(on opposite page) 
Fixed and live cell microscopy was used to assess the localization of Rab5, Rab7 and the 
lysosomal marker LAMP1 to efferosomes and phagosomes containing 5 μm diameter 
bead-based mimics of apoptotic cells and bead-based mimics of pathogens. (a and b) 
Recruitment of Rab5 and Rab7 to phagosomes (a) and efferosomes (b) 10, 20 and 30 min 
following engulfment by J774.2 macrophages. Ex. Beads indicates noninternalized (i.e. 
extracellular) beads. (c and d) Dynamics of Rab5 and Rab7 recruitment to phagosomes (c) 
and efferosomes (d). T = 0 is set as the video frame when complete sealing of the 
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phagosome/efferosome was observed; data are normalized to maximum Rab5 or Rab7 
intensity on each individual phagosome. (e) Immunostaining of LAMP1 accumulation in 
phagosomes or efferosomes in human PBMC-derived M0 macrophages. (f) Uptake of 
apoptotic cell mimics (Efferosomes) and IgG-opsonized pathogen mimics (Phagosomes) 
by human PBMC-derived M0-, M1- and M2-polarized macrophages and DCs, expressed 
as the number of beads engulfed per cell. Data are representative of (a, b and e) or 
quantifies (c, d and f) at least 30 cells imaged across five independent experiments. Data 
are presented as mean or mean ± S.E.M. *p < 0.05 compared with uptake of the same type 
of target by M0 macrophages. Scale bars are 5 μm. 
M0 and M2 macrophages were highly efferocytic, while M1 macrophages and primary 
human dendritic cells were poorly efferocytic. Furthermore, no selectivity was observed 
for phagocytic targets, indicating that any capacity to differentially present efferosomal 
versus phagosomal antigens must occur following both target engulfment and the canonical 
Rab5/Rab7-mediated maturation pathway. 
3.3.2 Mass spectrometric identification of late regulators of efferosome 
and phagosome maturation 
Given that efferosomes and phagosomes shared the same early maturation pathway, any 
selective processing of these targets likely occurs at a later timepoint. As such, we 
recovered efferosomes and phagosomes using 3 μm diameter magnetic bead mimics of 
efferocytic and phagocytic targets from M0-polarized human macrophages, 40 min after 
initiation of efferocytosis or phagocytosis. Proteins from the recovered efferosomes and 
phagosomes were resolved using SDS-PAGE, revealing several proteins selectively 
recruited to efferosomes versus phagosomes (Figure 3.3). 
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Figure 3.3 Efferosomes and phagosomes interact with unique subsets of proteins. 
Coomassie staining of SDS-PAGE gels of proteins recovered from phagosomes (phago) 
and efferosomes (effero) 40 min following phagocytosis or efferocytosis of 3 µm IgG- or 
PS-coated magnetic beads. Phagosomes and efferosomes were recovered by magnet from 
human PBMC-derived M0-polarized macrophages following cell lysis.  
These unique proteins were subsequently excised and identified by liquid-
chromatography/mass spectrometry. Phagosomes (Table 3.2) contained many of the 
proteins expected of a vesicle maturing into an MHC class II loading compartment, notably 
MHC class II and indicators of Golgi-to-lysosome trafficking (Rab6b, PIK4). In addition, 
phagosomes were enriched in several proteins involved in GTPase and kinase signaling. In 
marked contrast, efferosomes (Table 3.3) lacked MHC class II and the markers of Golgi-
to-lysosome trafficking observed on phagosomes. Efferosomes instead recruited proteins 
that mediate vesicular trafficking, cytoskeletal organization and ubiquitination/ 
ISG15ylation. Of particular interest to us were the Rab family GTPases Rab17 and RASEF 
(Rab45), both of which have been implicated in trafficking to recycling endosomes and 
exocytosis.34,38,58,59 Combined, these results suggest that efferocytic cargos are intercepted 
before formation of the MHC class II loading compartment and are redirected to a recycling 
or exocytic cellular compartment. 
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Table 3.2 Unique proteins recruited to phagosomes 40 min post-phagocytosis. 
 
 
Table 3.3 Unique proteins recruited to efferosomes 40 min post-efferocytosis. 
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3.3.3 Rab17 is persistently recruited to efferosomes but not 
phagosomes 
To assess the role of Rab17 in phagocytosis and efferocytosis, we performed live cell 
microscopy of J774.2 macrophages ectopically expressing the plasma membrane marker 
PM-RFP and Rab17-GFP as they engulfed beads mimicking efferocytic or phagocytic 
targets. As expected, both phagocytic and efferocytic targets were internalized into plasma 
membrane-derived vacuoles demarcated by PM-RFP (Figures 3.4a and 3.4b). Rab17 
transiently localized to phagosomes, with dynamics similar to that of Rab5 (Figures 3.4a 
and 3.4c). In marked contrast, Rab17 was persistently recruited to efferosomes, displaying 
only a modest decrease in recruitment over the hour following engulfment of the 
efferocytic target (Figures 3.4b and 3.4c). Close inspection of individual efferosomes 
revealed that this recruitment was not constant, and rather that Rab17 is repeatedly 
recruited in a series of waves, suggestive of repeat sampling of efferosomes by Rab17 
(Figure 3.4d). 
 
 
Figure 3.4 Rab17 is selectively retained on efferosomes. (on opposite page) 
Live cell microscopy was performed on J774.2 macrophages expressing PM-RFP and 
Rab17-GFP engulfing apoptotic cell (Efferosomes) or IgG-opsonized pathogen 
(Phagosomes) mimics. (a and b) Representative images of Rab17-GFP recruitment to 
phagosomes (a) or efferosomes (b). Star/arrowhead tracks the same 
phagosome/efferosome through successive time points. (c) Dynamics of Rab17 
recruitment to phagosomes and efferosomes. (d) Recruitment dynamics of Rab17-GFP to 
three representative efferosomes. (c and d) T = 0 is set as the video frame when complete 
sealing of the phagosome/efferosome was observed and data are normalized to maximum 
Rab17 intensity on each individual phagosome. Data are presented as mean ± SEM (c) or 
mean (d). Data are representative of (a, b and d) or quantifies (c) a minimum of 22 cells 
imaged over four independent experiments. Scale bars are 5 μm. 
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Rab17 expression was observed in primary human PBMC-derived M0-, M1- and M2-
polarized macrophages as well as primary human PBMC-derived DCs, with late 
recruitment of Rab17 observed to efferosomes in M0- and M2-polarized macrophages and 
DCs (Figure 3.5). RASEF and Rab6b, the other Rab-family GTPases identified in our mass 
spectrometry screen, did not significantly associate with either phagosomes or efferosomes 
(Figures 3.6a and 3.6b). 
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Figure 3.5 Rab17 is expressed in human phagocytes and is recruited to efferosomes 
late in maturation. 
Macrophages and dendritic cells were derived by ex vivo differentiation of human PBMC’s 
into the respective cell types. Rab17 immunoblot of M0-, M1- and M2-polarized 
macrophages and dendritic cells (DCs). (a) Immunostaining of Rab17 30 min following 
efferosome closure. (b) Plots indicate the intensity of Rab17 staining along the dashed 
yellow line (DC) or horizontally across the center of the insert (M0/M2). Data from M1-
polarized macrophages are not presented as no efferosomes were observed in these cells. 
Images are representative of 3 independent experiments. Scale bars are 5 µm. 
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Figure 3.6 Rab6b and Rab45 are not recruited to the maturing phagosome and 
efferosome. 
Live cell microscopy was performed on J774.2 macrophages expressing PM-RFP and 
either Rab6b-GFP engulfing IgG-opsonized pathogen mimics (a) or Rab45-GFP engulfing 
apoptotic cell mimics (b) Representative images demonstrating lack of Rab6b and Rab45 
recruitment are shown. The arrowhead tracks the same phagosome/efferosome through 
successive time points. T = 0 is set as the video frame when complete sealing of the 
phagosome/efferosome was observed. Data are representative of a minimum of 10 cells 
imaged over three independent experiments. Scale bars are 5 μm. 
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Since our model system used non-digestible mimics of bacterial and apoptotic cells, we 
could not assess whether Rab17 altered the trafficking of degraded materials derived from 
efferosomes or phagosomes. As such, we performed live cell imaging of Rab17-GFP- and 
PM-RFP-expressing macrophages as they engulfed E. coli or apoptotic cells covalently 
labeled with a degradation-resistant, pH-stable, far-red fluorophore. Bacterial phagocytosis 
did not differ from the mimics, with E. coli internalized into a compartment that transiently 
colocalized with Rab17 and retained PM-RFP for at least 90 min (Figures 3.7a, 3.7c and 
3.7d). In marked contrast, macrophages efferocytosed small fragments (apoptotic bodies) 
from apoptotic cells into PM-RFP-demarcated efferosomes, on which Rab17 was retained 
for prolonged periods of time (Figures 3.7b, 3.7c and 3.7e). Interestingly, at later time 
points, degraded apoptotic cell materials were observed to move into a compartment 
negative for PM-RFP (Figure 3.7d), a phenomenon not observed with non-degradable 
targets (Figure 3.4b), suggesting that degraded efferocytosed materials were being 
directed out of the canonical maturation pathway—a process not observed with E. coli 
(Figure 3.7e), indicating that the degraded apoptotic cells and E. coli had been trafficked 
into different cellular compartments. 
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Figure 3.7 Rab17 is selectively retained on apoptotic cell containing efferosomes. 
Live cell microscopy was performed on J774.2 macrophages expressing PM-RFP and 
Rab17-GFP engulfing fluorescently tagged apoptotic cells (AC) or E. coli (E. coli or EC). 
(a) Representative slice from a z-stack of Rab17-GFP and PM-RFP recruitment to E. coli 
containing phagosomes 60 min following phagocytosis. Arrow indicates the phagosome 
magnified in the insert. (b) Representative slice of a z-stack of Rab17-GFP and PM-RFP 
recruitment to an apoptotic cell containing efferosome 5 min following efferocytosis. 
Arrow indicates the same Rab17+/PM-RFP+ efferosome, and arrowhead indicates the same 
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Rab17-/PM-RFP+ efferosome, in all panels. (c) Recruitment dynamics of Rab17-GFP to 
phagosomes and efferosomes, normalized to the brightest Rab17+ cell structure. (d and e) 
Portion of E. coli containing phagosomes (d) or apoptotic cell containing efferosomes (e), 
which are positive for PM-RFP only (PM+), positive for PM-RFP and Rab17 
(PM+/Rab17+) or positive for Rab17 alone (Rab17+). Scale bars are 5 μm. Small lines 
indicate the position of the cross-section shown in the corresponding xy and z images. (c–
e) T = 0 is set as the video frame when complete sealing of the phagosome/efferosome was 
observed, and data are normalized to maximum Rab17 intensity observed in each cell and 
is presented as mean ± SEM. Data are representative of (a and b) or quantifies (c–e) a 
minimum of 52 cells imaged over four independent experiments. *p < 0.05 compared with 
the 5 min timepoint for the same group. 
3.3.4 Rab17 mediates the trafficking of degraded apoptotic cell 
materials to the recycling endosome 
The previous data are consistent with a model in which phagocytosed materials traffic 
through the canonical maturation pathway, whereas efferocytosed materials are redirected 
into another cellular compartment by Rab17. Given that Rab17 has previously been found 
to regulate recycling and exocytosis, it was likely that efferocytosed materials were being 
trafficked from the efferosome to the recycling endosome.38,58 We therefore assessed the 
recruitment of Rab17, a recycling endosome marker (transferrin receptor, TfR) and MHC 
class II to phagosomes and efferosomes. Consistent with the canonical maturation process, 
90 min following engulfment most phagosomes had recruited MHC class II but not Rab17 
or TfR (Figures 3.8a and 3.8b). In contrast, efferocytosed materials did not colocalize with 
MHC class II, which remained diffusively distributed throughout the cell (Figure 3.8c). 
Instead, efferosomes strongly colocalized with TfR, with a portion colocalizing with both 
Rab17 and TfR (Figure 3.8d). We next attempted to knockdown Rab17, but transfection 
with siRNA concentrations that reliably knocked down Rab17 expression also inhibited 
phagocytosis and efferocytosis (Figure 3.8e). Instead, we transfected J774.2 cells with a 
mCherry-tagged dominant negative (DN)-Rab17 at a dose that inhibited ~ 50% of 
efferocytosis and phagocytosis (0.5 μg per well; Figure 3.8e). DN-Rab17 was not recruited 
to phagosomes and was recruited to a significantly lower fraction of efferosomes compared 
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with wild-type Rab17 (Figure 3.8f). Importantly, expression of DN-Rab17 significantly 
increased the association of MHC class II, and decreased the association of TfR, with 
efferosomes (Figure 3.8f). Combined, these results indicate that Rab17 is selectively 
recruited to efferosomes, where it mediates the transfer of degraded apoptotic cell material 
into the recycling endosome and away from the MHC class II loading compartment. 
 
 
 
 
 
Figure 3.8 Rab17 mediates trafficking of degraded apoptotic cell materials. (on 
opposite page) 
Z-stacks were captured of fixed J774.2 macrophages expressing Rab17-mCherry and either 
co-expressing TfR-GFP (TfR) or immunostained for MHC class II (MHCII) 90 min 
following engulfment of E. coli (EC) or apoptotic cells (AC). (a-d) Localization of Rab17 
and MHC class II (a and c) or TfR (b and d), relative to phagocytosed E. coli (c and d) or 
efferocytosed apoptotic cells (a and b). Uptake of E. coli and apoptotic cells by J774.2 
macrophages that were untreated/non-transfected (UT), treated with scrambled (Scm) or 
Rab17 siRNA (Rab17), or transfected with 0.1–1.0 μg per well of a construct expressing 
DN-Rab17, expressed as the number of E. coli or apoptotic cells engulfed per cell. (e) 
Quantification of the fraction of phagocytosed E. coli or efferocytosed apoptotic cells that 
recruited Rab17, MHC class II and TfR in cells expressing mCherry-tagged wild-type or 
dominant-negative (DN) Rab17. (f)  Images are representative of (a-d), and graphs 
quantify (e and f), a minimum of 15 images captured in three independent experiments. 
Scale bars are 5 μm. Small lines indicate the position of the cross-section shown in the 
corresponding xy and z images. *p < 0.05 compared with the same group in untreated cells 
(e) or cells expressing wild-type Rab17 (f). 
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3.3.5 Rab17 sorts materials on maturing efferosomes 
Having demonstrated that Rab17 mediates the transfer of degraded apoptotic cell materials 
from the efferosome to recycling endosomes, we next sought to elucidate the mechanism 
by which Rab17 mediates the transfer of materials from efferosomes to recycling 
endosomes. Firstly, the distribution of Rab17 relative to recycling endosomes (demarcated 
by transferrin receptor, TfR) and plasma-membrane derived vesicles (demarcated by PM-
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RFP) was assessed in resting macrophages. PM-RFP was found to be largely excluded 
from Rab17+ vesicles (Figure 3.9a and 3.9c). More interestingly, while all but a minute 
portion of Rab17+ vesicles were positive for TfR, there was a significant portion of TfR+ 
vesicles which lacked Rab17 (Figures 3.9b and 3.9c). Therefore, in resting macrophages, 
Rab17 demarcates a subset of the recycling endosome system and is not significantly 
recruited to plasma membraned-derived vesicles such as endosomes.  
 
 
 
 
 
 
 
 
 
Figure 3.9 Rab17 dynamics on efferosome mimics. (on opposite page) 
Colocalization of Rab17-GFP and Rab17-mCherry with PM-RFP-derived vesicles or with 
TfR-GFP-positive vesicles in resting J774.2 cells. (a and b) Percent of Rab17+ vesicles co-
staining with TfR (Rab17:TfR), TfR+ vesicles co-staining with Rab17 (TfR:Rab17) and 
PM-derived vesicles co-staining with Rab17 (PM:Rab17). (c) Dynamics of Rab17-GFP 
and PM-RFP on efferosomes containing non-digestible apoptotic cell mimics. (d) Arrows 
indicate Rab17+ vesicles fissioning from the efferosome. Images are representative of (a 
and b) or quantifies (c) 47 images captured over 4 independent experiments or is 
representative of 12 time-lapse videos captured over 5 independent experiments (d). Data 
are presented as mean ± SEM. Scale bars are 5 µm (a and b) or 10 µm (d). 
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Next, live cell microscopy was used to quantify Rab17 dynamics during efferocytosis, 
using large (5 µm) apoptotic cell mimics to provide higher spatial resolution (Figure 3.9d). 
These mimics were internalized into a PM-RFP-demarcated compartment which was 
positive for Rab17-GFP. A few minutes following closure, the efferosome vesiculated 
through the fission of Rab17+ vesicles, depleting approximately 60% of the Rab17 initially 
recruited to the efferosome (Figure 3.9d, Table 3.4). Interestingly, the fissioning vesicles 
were devoid of PM-RFP, suggesting that materials were being selectively sorted by 
vesiculation of the efferosome. The efferosome remained weakly positive for Rab17 
following vesiculation, with the occasional Rab17+ vesicle interacting with the efferosome 
during this stage. 
Table 3.4 Efferosome fission and fusion characteristics. 
 
3.3.6 Fission and fusion of efferosome-derived vesicles 
Our results from the previous section used indigestible apoptotic cell mimics, thus 
preventing us from relating Rab17 dynamics to the processing of the efferosomal cargo. 
To address this limitation, Rab17 dynamics were quantified on efferosomes containing 
labeled apoptotic Jurkat cells in macrophages expressing Rab17-mCherry and PM-GFP. 
Macrophages engulfed apoptotic bodies, not intact cells (Table 3.4, Figure 3.10a), with 
the level of Rab17 retained on efferosomes and the size of the efferosomes remaining 
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constant during the early stages of maturation (Table 3.4, Figure 3.10b). Despite some 
photobleaching, it was apparent that newly formed efferosomes migrated toward the cell 
center where they then vesiculated into multiple EDV’s (Figures 3.10b and 3.10c). 
Interestingly, the intensity of PM-GFP staining on EDV’s was variable, consistent with the 
sorting observed during the vesiculation of non-digestible efferosome mimics (Figure 
3.10b). 
 
Figure 3.10 Fission, fusion and movement of Rab17-positive efferosomes. 
Efferosome and Rab17 dynamics were quantified using live cell microscopy of 
efferocytosed fluorescently-labeled apoptotic bodies by macrophages expressing Rab17-
mCherry and PM-GFP. (a) Fluorescent image of a macrophage immediately following 
engulfment of an apoptotic body (arrow/AC). Scale bar is 5 µm. Time-lapse micrograph of 
the insert from panel a. (b) The intact efferosome is tracked by the white arrow, colored 
arrows track individual EDVs. The staining of the apoptotic body is shown only for the 
first and final frames, to emphasize the differential sorting of Rab17 and PM-GFP into 
EDV’s. Track of efferosome and EDV’s from panel b. ‘X’ indicates the efferosome starting 
position, asterisk indicates fusion between two EDV’s, and diamonds indicate sites of 
fusion with Rab17+ recycling endosomes. (c) Number of fusion events 
between EDV’s, and between EDV and recycling endosomes (RE). (d) Representative 
motion tracks of 10 pre-fission efferosomes, measured relative to a vector between the cell 
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barycentre and the site of efferosome formation. (e) Representative motion tracks of a 
single post-fission vesicle derived from each efferosome in panel e, measured relative to a 
vector between the cell barycentre and the efferosome fission point. (f) Directionality of 
efferosome movement pre-fission (Pre), Post-fission (Post), and once the EDV’s reach the 
periphery (Periph). (g) Data are representative of (a-c, e and f), or quantifies (d and g) 124 
efferosomes imaged over 3 independent experiments.  *p < 0.05 comparted to Pre, ┼p < 
0.05 compared with Post, n.s. p > 0.05 by Students t-test (d) or one-way ANOVA with 
Tukey post-hoc (g). 
By tracking the fluorescent signal of the apoptotic bodies, we were able to track EDV’s for 
prolonged periods of time, revealing that newly vesiculated EDV’s migrated toward the 
cell periphery, and once at the cell periphery, ceased moving (Figures 3.10b and 3.10c). 
During this migration most EDV’s underwent further vesiculation, as well as fusion with 
other EDV’s and with Rab17+ recycling endosomes that were otherwise devoid of 
apoptotic bodies (Figures 3.10c-d, Table 3.4), consistent with our previous findings 
demonstrating cargo transfer from efferosomes to TfR+ recycling endosomes. Both the 
inward movement of the nascent efferosome, and the subsequent outward movement of the 
EDV’s were highly linear but became non-directional once EDV’s reached the cell 
periphery (Figures 3.10e-g). 
3.3.7 Rab17 is required for efferosome-derived vesicle migration 
The inward migration of the newly formed efferosome is required for efficient fusion with 
lysosomes and cargo degradation,10,60 and indeed, we have demonstrated here that 
efferosome-lysosome fusion is concordant with Rab17 recruitment to the efferosome. In 
contrast, the subsequent peripheral migration of phagocytosed cargo is, to our knowledge, 
previously unreported. To determine if Rab17 was required for peripheral efferosome 
migration, we expressed DN- or WT-Rab17-GFP in macrophages and quantified the 
intracellular localization of efferosomes, using DN-Rab17 at a modest expression level to 
prevent the inhibition of efferocytosis observed when Rab17 siRNA is used (Figure 3.8e). 
As expected, a significant fraction of efferosomes were located in the periphery of cells 
expressing WT-Rab17, whereas efferosomes remained in the perinuclear region of cells 
expressing DN-Rab17 (Figures 3.11a and 3.11b). Efferosomes in DN-Rab17 expressing 
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cells underwent limited fission (Figures 3.11c and 3.11d, Table 3.4), but fused normally 
with LAMP1-demarkated lysosomes (Figures 3.11e and 3.11g). Consistent with our 
findings above, expression of DN-Rab17 significantly impaired the transfer of efferosome 
cargos from EDV’s to TfR+ recycling endosomes (Figures 3.11f and 3.11g) 
 
Figure 3.11 Peripheral migration of EDV’s and cargo transfer to recycling endosomes 
requires Rab17. 
Localization of fluorescently-labeled, apoptotic Jurkat cell-derived EDV’s in macrophages 
expressing WT- or DN-Rab17-GFP, and either the lysosomal marker LAMP1-mCherry or 
the recycling endosome marker TfR-mCherry, was quantified 90 min post-efferocytosis. 
Representative images of EDV location in cells expressing WT- or DN-Rab17. (a) Large 
dashed line indicates the cell periphery; fine dotted lines indicate “shells” positioned at 1 
µm increments inwards from the cell periphery. Quantification of the fraction of EDV’s 
observed in each “shell” of cells expressing WT- or DN-Rab17. (b) Quantification of 
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diameter (c) and number (d) of EDV’s in macrophages expressing WT- and DN-Rab17. 
Effect of WT- vs. DN-Rab17 on the distribution of EDV’s colocalizing with (LAMP1+) or 
lacking (LAMP1-) the lysosomal marker LAMP1. (e) Effect of WT- vs. DN-Rab17 on the 
distribution of EDV’s colocalizing with (TfR+) or lacking (TfR-) the recycling endosome 
marker TfR. (f) Comparison of the colocalization of efferosomes with LAMP1 and TfR in 
cells expressing WT- or DN-Rab17. Data are representative of (a) or quantifies (b-g) at 
least 28 cells over 3 independent experiments. *p < 0.05 compared with WT (b, g), LAMP+ 
in the same group (e) or TfR+ in the same group (f), 2-way ANOVA with Tukey post-hoc 
(b, e and f), or Students t-test (d and g). Scale bars are 5 µm. 
 
3.4 Discussion 
Proper efferosome maturation is essential for avoidance of self-antigen presentation and 
the induction of inflammation and autoimmunity.3 To date, our understanding of the 
mechanisms that regulate efferosome maturation has been limited and it has been thought 
that efferosome maturation proceeds similarly to phagosome maturation.11 However, it is 
apparent that efferosome and phagosome maturation must be differentially regulated 
processes since the immunological outcomes of these two processes are diametrically 
opposed, with phagocytosis resulting in the initiation of an inflammatory response and 
efferocytosis resulting instead in resolution of inflammation.1,3 The ultimate fate of 
phagocytic cargo is to be trafficked to the MHC class II loading compartment, where 
antigenic peptides from pathogens are loaded onto cognate MHC class II molecules and 
trafficked to the cell surface for antigen presentation.61  
Some investigators have suggested that the differences observed with efferocytosis in 
contrast to phagocytosis is driven by differences in the kinetics of efferosome vs. 
phagosome maturation.11,62 Efferosome maturation in macrophages appears to be delayed 
in comparison with phagosomes.13,62 It has been suggested that TLR signaling within 
phagosomes drive accelerated maturation and subsequent loading of antigenic peptides 
derived from phagosomal cargo onto MHC class II molecules.13,62 Indeed, murine 
macrophages deficient in either TLR2, TLR4 or MyD88 exhibited a decreased capacity to 
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phagocytose either E. coli or Salmonella typhimurium, and phagosome maturation in these 
macrophages was significantly delayed.62 However, other studies that have examined the 
rate of phagosome maturation in the presence and absence of TLR ligands showed no 
difference in the rate of acquisition of late phagosomal and lysosomal markers.63 We 
therefore set out to determine whether, in professional phagocytes such as macrophages, 
there is an intrinsic mechanism that differentially regulates efferosome maturation and 
allows efferocytic cargo to bypass the MHC class II loading compartment. 
Our data agree with existing literature that suggest efferosome and phagosome maturation 
share a common regulatory pathway.4,6,11 Indeed, we recapitulate the key finding that the 
small GTPases Rab5 and Rab7 are recruited sequentially to the maturing efferosome and 
phagosome.6 We further demonstrate that the kinetics of Rab5 and Rab7 recruit does not 
differ between efferocytosis and phagocytosis. This is perhaps unsurprising as it is well 
established that Rab7 is responsible for the recruitment of key downstream effector 
molecules that: 1) guide the assembly of a dynein-dynactin complex that drives migration 
of the efferosome/phagosome along microtubules towards the cell centre,10,64 and 2) 
mediates the fusion of lysosomes to the maturing phagosome, which delivers the vATPses 
that mediate efferosome/phagosome acidification.9,65 
However, through our mass spectrometry analysis, we identified Rab GTPases that were 
differentially recruited to efferosomes vs. phagosomes. Of these, we were particularly 
interested in the recruitment of Rab17 to efferosomes, given its established role in the 
literature as a key regulator of receptor and cargo recycling34,58. This led to the hypothesis 
that Rab17 may mediate trafficking through the recycling endosome as a mechanism by 
which efferocytic cargo can bypass the MHC class II loading compartment.34,36 Indeed, we 
observe that while Rab17 is transiently recruited to the surface of phagosome, it is 
persistently recruited to efferosomes. Consistent with others who have shown that Rab17 
regulates trafficking through the recycling endosome,58 we demonstrate here that Rab17+ 
vesicles containing efferocytic cargo colocalize with TfR, which is a marker of the 
recycling endosome system.66 Importantly, we also demonstrate that Rab17+ vesicles 
containing apoptotic cell-derived materials do not colocalize with MHC II, suggesting that 
Rab17 mediates re-direction of this cargo away from the MHC class II loading 
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compartment and to the recycling endosome. Strikingly, when we interfere with Rab17 
activity through ectopic expression of a DN-Rab17, efferocytic cargo is then observed to 
colocalize with MHC class II. Taken together, these data suggest that Rab17 is an essential 
regulator of efferosome maturation and allows antigens derived from efferocytic cargo to 
avoid being presented on MHC class II. 
Furthermore, we go on to show that the dynamics of efferosome trafficking in macrophages 
following internalization of efferocytic cargo differs significantly from that of a 
phagosome.  Phagosomes undergo migration towards the cell center during their 
maturation process in a dynamin-dependent process.7 This brings phagosomes into close 
proximity to lysosomes, which are localized around the nucleus of the cell, and facilitate 
phagolysosomal fusion and degradation of phagocytic cargo.55,60 Following 
phagolysosome formation, these bodies remain localized perinuclearly to facilitate MHC 
class II loading compartment formation.67 While the role of phagosomelysosome position 
within the cell is not entirely clear, studies have shown that lysosomes closer to the 
perinuclear area have lower pH and greater degradative capabilities.55 We find that in 
efferosome maturation, while the efferosome initially migrates towards the cell centre and 
undergoes fusion with lysosomes, the efferosome undergoes fission events and generates 
multiple EDVs, which then migrate back towards the cell periphery. This is presumably to 
facilitate trafficking of degraded efferocytic cargo to the recycling endosomes, which are 
located peripherally within the cell.68 Moreover, as the Golgi is a perinuclear organelle, 
this may act to decrease the efficiency of Golgi-to-efferosome trafficking, thus limiting the 
delivery of newly synthesized MHC II to the efferosome. Remarkably, Rab17 again 
appears to be required to facilitate EDV formation and the migration of EDVs back towards 
the cell periphery. In macrophages expressing DN-Rab17, initial migration of the 
efferosome towards the cell centre and subsequent lysosomal fusion remain unaffected. 
However, EDV formation and migration of EDVs towards the cell periphery are abrogated 
in DN-Rab17-expressing macrophages, and trafficking of cargo to the recycling endosome 
does not occur. Therefore, Rab17 appears to be required for driving efferosomal fission 
and subsequent migration of EDVs towards the cell periphery.  
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Peripheral migration of EDVs is likely a kinesin-driven process69 and it is tempting to 
imagine that Rab17 either directly recruits kinesin or recruits an effector that then recruits 
kinesin to mediate peripheral migration of EDVs along the microtubule system. Although 
this remains to be demonstrated experimentally, the role of Rab proteins in regulation of 
vesicular traffic through recruitment of kinesin has been well documented. Several Rab 
proteins, including Rab3, Rab6, Rab9, Rab11 and Rab27, have been shown to be capable 
of recruiting kinesin, either director or through adaptor proteins.70 The fate of efferocytic 
cargo following trafficking to the recycling endosome also remains unclear. Degraded 
efferocytic cargo may be expelled from the phagocyte through exocytosis or it may be 
recycled by the cell through nutrient recovery.49,71 Rab17 has been associated with both 
transcytosis and exocytosis of melanosomes, which are lysosome-derived organelles, while 
the recycling endosome is well established as a nutrient absorption site.38,68 The ultimate 
fate of efferocytosed materials remains an open question at this point. Despite these 
remaining questions, we propose a model of efferosome maturation whereby Rab17 is 
selectively recruited to the efferosome and mediates efferosome fission and trafficking 
towards the cell periphery to facilitate escape from the MHC class II loading compartment 
and instead mediate trafficking of cargo to the recycling endosome (Figure 3.12). 
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Figure 3.12 A model of differential regulation of phagosome and efferosome 
maturation. 
Phagocytic uptake of pathogen results in the formation of a phagosome that subsequently 
undergoes multiple fusions with early endosomes. Rab17 is transiently recruited to the 
early phagosome but rapidly lost. Rab5 is a key marker of the early phagosome and is 
swapped for Rab7 as part of the process of transition from early to late phagosomes. Rab7 
drives migration of the late phagosome towards the cell centre along microtubules, fusion 
of the phagosome with late endosomes and phagosomal acidification. At the cell centre, 
the late phagosome undergoes fusion with lysosomes to form the phagolysosome where 
the phagocytic cargo is degraded by lysosome proteases. MHC class II molecules are 
recruited to the phagolysosome from the Golgi and drives formation of the MHC class II 
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loading compartment. Antigenic peptides derived from degraded phagocytic cargo are 
loaded onto cognate MHC class II molecules and trafficked to the cell surface for antigen 
presentation. Efferosome maturation follows a similar pathway, with the additional 
recruitment of Rab17 to the efferosome surface. The efferosome undergoes lysosomal 
fusion but Rab17 then drives efferosomal fission and trafficking of efferosome-derived 
vesicles along microtubules towards the cell periphery where efferocytic cargo is trafficked 
to the recycling endosome and subsequently undergoes exocytosis and/or nutrient 
recovery. EE = early endosome, LE = late endosome, LY = lysosome.  
Our findings in this chapter represent a concrete advancement in our understanding of the 
regulation of efferosome maturation under homeostatic conditions. Our data suggest that 
in professional phagocytes such as macrophages, there is an intrinsic Rab17-mediated 
pathway that acts to prevent improper antigen presentation following efferocytosis. This 
supports the idea that the differential regulation of efferosome vs. phagosome maturation 
is at least partially independent of Toll-like receptor signaling. These findings may also 
have important implications in future studies that examine defects in efferocytosis in the 
context of inflammatory and autoimmune diseases. Dysregulation of Rab GTPase function 
has previously been implicated in several pathologies. For example, Rab7 function is 
impaired in the presence of hypercholesterolemia and results in defects in phagosome 
maturation.72 Further studies that examine the role of Rab17 in inflammatory and 
autoimmune diseases where efferocytosis has been implicated in disease pathogenesis are 
warranted and may indeed demonstrate that Rab17 is a viable therapeutic target in the 
treatment of these diseases.  
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Chapter 4  
4 Macrophages in Early Human Atherosclerosis Exhibit 
Dysregulated Expression of Genes Involved in 
Cholesterol Metabolism and Efferocytosis 
4.1 Introduction 
4.1.1 Challenge of studying human atherosclerotic macrophages 
The role of macrophages in atherosclerotic disease has been studied intensively for many 
years, yet our understanding of macrophage phenotype and function in human 
atherosclerosis remains limited.1 This lack of progress can be at least partially attributed to 
the inherent challenges of studying atherosclerosis in humans, and the limitations in 
available animal models of atherosclerosis (discussed in further detail in Chapters 1.4.1 
and 1.4.2).2,3 
Much of our understanding of the mechanisms driving macrophage dysfunction in 
atherosclerosis has come from animal studies in Apoe-/- or Ldlr-/- knockout mice.3,4 These 
mouse models, while widely utilized, have some significant drawbacks and features that 
diverge from human disease. Mice are naturally HDL-predominant and are thus resistant 
to atherosclerosis.3 Indeed, mice do not naturally develop atherosclerosis when fed a high 
fat diet and mouse models of atherosclerosis rely on genetically perturbing LDL 
homeostasis to generate disease.4 The anatomical distribution of atherosclerotic lesions is 
also dramatically different in mouse models when compared to human disease.5,6 Mice 
rarely develop atherosclerotic plaques within the coronary arteries, and differences in 
mouse hemodynamics means that they have greatest atherosclerotic burden in the aortic 
root and ascending aorta.5 
On the other hand, studying atherosclerosis in humans is challenging for several reasons. 
First, atherosclerosis in humans takes decades to develop into clinically significant 
disease,7 making it challenging to study the underlying disease pathogenesis.2 
Atherosclerosis is also ubiquitous amongst people living in developed, post-industrial 
nations.8,9 The PDAY study, which examined the burden of atherosclerotic disease from 
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young people who died between the ages of 15 and 34 at 15 centres in the United States, 
found that atherosclerotic lesions at the early stages of disease were present starting in the 
15-20 age group, and that lesions that occupied > 5% of intimal surface area were present 
in the aorta at rates in excess of 95% across all subjects.9,10 This makes it difficult to identify 
subjects who can be considered “disease-free” when studying atherosclerosis in humans. 
Finally, the site of disease—the atherosclerotic plaque—is difficult to access. The most 
common source of atherosclerotic plaque used to study macrophage phenotype and gene 
expression has been carotid plaque.11,12 While carotid plaque can be obtained following 
carotid endarterectomy procedures and carotid plaque is involved in ischemic stroke, 
findings from carotid plaque may not be entirely translatable to coronary and aortic 
plaques. Transcriptomics studies that have examined plaque-resident macrophage gene 
expression in lesions from different anatomical sites have shown site-specific changes in 
gene expression patterns.13 It is difficult to access coronary and aortic plaque material 
outside of autopsy studies, and as a result atherosclerosis in these vessels remain poorly 
studied. More creative approaches to studying atherosclerosis at these anatomical sites are 
needed. A recent study by Sulkava et al. was able to make use of left internal thoracic 
arteries obtained in the course of CABG surgery,13 highlighting the need to leverage 
collaboration with surgical colleagues to advance our understanding of human 
atherosclerotic disease. 
4.1.2 Cholesterol metabolism in macrophages 
Macrophage cholesterol metabolism is well established as being dysregulated in 
atherosclerosis.14,15 Formation of cholesterol-laden macrophages, known as foam cells, is 
perhaps the most well-established feature of atherosclerosis—having first been described 
by the Russian pathologist Nikolai Anitchkov in 1914.16 
A summary of cholesterol metabolism in macrophages is provided in Figure 4.1. 
Macrophages recognize and take up modified lipoproteins through the scavenger receptors 
SR-A, CD36 and the lectin-like low-density lipoprotein receptor 1 (LOX-1).17 Following 
uptake, these modified lipoproteins are trafficked into the lysosome, where lysosomal acid 
lipase (LAL) releases free cholesterol from the lipoprotein.18 Free cholesterol within the 
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lysosome is transported out of the lysosome and into the ER through the concerted activity 
of the membrane-bound cholesterol transport proteins Niemann-Pick disease, type C1 
(NPC1) and Niemann-Pick disease, type C2 (NPC2).19 In the ER, acyl coenzyme 
A:cholesterol acyltransferase 1 (ACAT1) catalyzes the conversion of free cholesterol into 
cholesterol esters, which are stored as lipid droplets within the ER and cytoplasm of the 
macrophage.18,20 Neutral cholesterol ester hydrolase (NCEH) catalyzes the hydrolysis of 
these cholesterol esters back into free cholesterol.19 This free cholesterol can subsequently 
be removed from the cell through the efflux activity of the transporters ABCA1 and 
ABCG1, upon which they are shuttled onto the cholesterol acceptors HDL and ApoA1 for 
transport to the liver for further processing and removal.20 
 
Figure 4.1 Cholesterol uptake, metabolism and efflux by macrophages. 
Overview of cholesterol metabolism in macrophages. SR-A1 = scavenger receptor-A1, 
LOX-1 = lectin-like low-density lipropotein receptor-1, LAL = lysosomal acid lipase, 
NPC1/2 = Niemann-Pick disease, type C1/2, ACAT1 = acyl coenzyme A: cholesterol 
acyltransferase-1, NCEH = neural cholesterol ester hydrolase, ER = endoplasmic 
reticulum, HDL = high-density lipoprotein. Figure modified from Chistiakov et al.20 
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In atherosclerosis, pro-inflammatory stimuli and hypercholesterolemic stress induce 
increased expression of scavenger receptors and ACAT1, along with downregulation of 
cholesterol transporters required for cholesterol efflux.21 This results in accumulation of 
lipid droplets and intracellular free cholesterol, giving the macrophage it’s characteristic 
“foamy” appearance.1,21 Additionally, accumulation of free cholesterol within the 
cytoplasm of these macrophages induces a pro-inflammatory response that results in 
production of TNF-α, IL-1β and IL-6, thus contributing to the maintenance of the 
inflammatory plaque microenvironment.22,23 
4.1.3 Efferocytosis and efferosome maturation 
Efferocytic removal of apoptotic cells (primarily apoptotic macrophages) within the 
atherosclerotic plaque is a crucial mechanism for limiting plaque progression and 
vulnerability.24,25 In early atherosclerotic disease, it is thought that macrophage 
efferocytosis of apoptotic cells contributes to the generation of anti-inflammatory 
cytokines such as TGF-β and IL-10, which function to induce generation of a protective 
fibrotic cap and restraint of inflammation within the plaque microenvironment.24 In the late 
stages of atherosclerosis, macrophage efferocytosis becomes defective, contributing 
secondary necrosis of uncleared apoptotic cells that contributes to generation of large 
necrotic cores that increase the likelihood of plaque rupture and thrombosis.24 
Mechanisms leading to defective efferocytosis remain poorly defined, especially in human 
disease. Macrophages recognize apoptotic cells through efferocytic receptors that 
recognize specific signals on the cell surface of apoptotic cells (such as 
phosphatidylserine), usually through an intermediary opsonin.25,26 These efferocytic 
receptors are thought to then function in cooperation with cell surface integrins (including 
the integrin αx and β2)27  to mediate internalization of the apoptotic cell.26 Activation of 
integrins results in the induction of several cell signaling pathways, including signaling 
through the Src family kinases and integrin-linked kinases to drive actin remodeling, 
efferocytic cup formation and efficient efferocytosis.26,28 Following internalization, the 
nascent efferosome undergoes a series of maturation steps that result in efficient 
degradation of apoptotic cell contents without generation of inflammation or antigen 
presentation (discussed in detail in Chapter 3). 
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Available evidence supports the notion that both efferocytic uptake and efferosome 
maturation may be dysregulated in the setting of atherosclerosis. Cardiac and vascular 
macrophages utilize the TAM family of receptors in binding to apoptotic cells through their 
opsonin Gas6. Linkage studies in humans have demonstrated that SNPs in MERTK and 
TYRO3, but not AXL or GAS6, are associated with carotid atherosclerosis.29,30 In 
particular MerTK appears to play a critical role in mediating efferocytic clearance of 
apoptotic cells within the atherosclerotic plaque.31 Mutations in MerTK reduce efferocytic 
efficiency and increases necrotic core size in mouse models of atherosclerosis,32 and 
ADAM17-mediated cleavage of MerTK also reduced atherosclerotic burden in Ldlr-/- 
mice.33 Dysregulation in efferosome maturation in atherosclerosis has been studied to a far 
lesser extent. However, there is some evidence that Rab GTPase activity and antigen 
presentation are altered in atherosclerotic macrophages.34,35 
4.1.4 Rationale and importance 
Several decades of intensive study into the mechanisms of atherogenesis have yielded a 
wealth of knowledge on potential mechanisms that drive atherosclerosis initiation, 
progression and reversal. However, translation of these findings into clinical interventions 
that better diagnose, monitor and treat atherosclerotic disease has remained limited.2 One 
reason for this lack of clinical translation is that the vast majority of these mechanistic 
studies have been done either in vitro or in animal models of atherosclerosis. These model 
systems, while extremely useful, fail to capture the whole complexity of human disease 
and, as a result, mechanisms that drive human atherosclerotic disease remain poorly 
understood.2,3 Evidence from both animal and human studies implicate macrophages as 
key players in the pathogenesis of atherosclerosis.24 However, macrophage dysfunction in 
atherosclerosis is challenging to study due to the inaccessibility of human plaque tissue and 
the inherent challenges of separating out a pure macrophage cell population from the 
plaque for analysis.  
In this chapter, we describe a novel approach towards studying macrophage dysfunction in 
the setting of human aortic atherosclerosis. In collaboration with cardiac surgeons, we were 
able to collect small punch biopsies of the wall of the ascending aorta that are routinely 
obtained by the surgeon during CAGB operations. We proceed to obtain macrophages from 
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the atherosclerotic lesions present on these aortic punch samples by laser capture 
microdissection (LCM) and use these macrophages in a gene expression study to examine 
dysfunction in macrophage cholesterol metabolism and efferocytosis in the setting of 
human atherosclerotic disease. 
A clearer picture of macrophage dysfunction in human atherosclerosis will provide us with 
a better understanding of which pathological mechanisms established from in vitro and 
animal work may be of importance in human atherosclerotic disease. Furthermore, 
uncovering changes in gene expression patterns in pathways related to efferocytosis and 
efferosome maturation will provide new insight into how critical function of macrophage 
efferocytosis becomes defective in the setting in atherosclerotic disease.  
 
4.2 Methods 
4.2.1 Histology 
All histology was performed by Caroline O’Neil at the Robarts Research Institute 
Molecular Pathology Core Facility. Prior to staining, all frozen sections were fixed in 10% 
buffered formalin for 20 min and washed in ddH2O. FFPE sections were deparaffinized by 
immersion in two changes of xylene for 10 min each and subsequently rehydrated by 
immersion in three changes of 100% ethanol, two changes of 95% ethanol and one change 
of 70% ethanol. Slides were then immersed in ddH2O for 5 min. 
4.2.1.1 Hematoxylin and eosin 
Hematoxylin and eosin (H&E) staining was performed on both frozen and FFPE sections. 
Slides were first immersed in Mayer’s hematoxylin solution for 3 min, followed by a brief 
wash in ddH2O. Slides were the immersed in 0.2% ammonia water solution for 30 sec to 
allow for bluing and washed in ddH2O. Slides were dipped briefly into 95% ethanol and 
stained in eosin Y solution for 3 min, followed by a brief wash in ddH2O. Slides were then 
dehydrated by immersing in 95% ethanol for 1 min, and then in three changes of 100% 
ethanol for 10 dips each. Slides were mounted onto glass coverslips. 
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4.2.2 Oil Red O 
Oil Red O staining was performed only on frozen sections. Slides were allowed to air dry 
at room temperature for 30 min prior to fixing in 10% buffered formalin. Slides were air 
dried again for 30 min at room temperature and washed in three changes of ddH2O. Slides 
were transferred into 100% isopropanol for 5 min and then stained in per-warmed Oil Red 
O solution (3 parts 1:200 w/v Oil Red O powder 100% isopropanol to 2 parts ddH2O) for 
10 min at 60 °C. Following Oil Red O staining, slides were immersed in 85% isopropanol 
for 5 min and then washed in two changes of ddH2O. Slides were then immersed in Mayer’s 
hematoxylin solution for 30 sec and washed with ddH2O for 5 min. Slides were mounted 
onto glass coverslips. 
4.2.3 Movat’s stain 
Modified Russell-Movat pentachrome staining was performed on both frozen and FFPE 
sections. Slides were immersed in Verhoeff’s elastic stain (2:1:1 5% hematoxylin in 100% 
ethanol, 10% ferric chloride, Verhoeff’s iodine solution – 2% w/v iodine and 4% w/v 
potassium iodide in ddH2O) for 30 min and subsequently washed with ddH2O for 5 min. 
Slides were immersed in three changes of 2% ferric chloride solution for 10 sec each, 
immersed in 5% sodium thiosulfate solution for 1 min and washed with ddH2O for 5 min. 
Slides were then immersed in 3% glacial acetic acid for 3  min, then 1% Alcian blue 
solution for 15 min, and finally washed with running ddH2O for 10 min. Slides were then 
immersed in Crocein scarlet-acid fuchsin solution (0.08% w/v Crocein scarlett, 0.02% w/v 
acid fuchsin and 0.5% v/v acetic acid in ddH2O) for 2 min, washed in two changes of 
ddH2O for five dips each and then in one change of 1% acetic acid for five dips. Next, 
slides are immersed in 5% phosphotungstic acid for 1 min, and washed in one change of 
1% acetic acid, one change of ddH2O and one change of 100% ethanol for five dips each. 
Slides are dehydrated in two changes of 100% ethanol for 3 min each and then immersed 
in alcoholic saffron solution (6% w/v Saffron du Gatinais in ethanol) for 15 min. Finally, 
slides are dried in two changes of xylene for 3 min each and mounted onto glass coverslips. 
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4.2.3.1 TUNEL stain 
TUNEL staining was performed on FFPE sections only to assess the number of uncleared 
apoptotic cells present.36,37 Following deparaffinization, sections were digested with 20 
µg/mL proteinase K for 15 min at room temperature to permeabilize tissue. Slides were 
rinsed with two changes of PBST for 2 min each. Slides were then immersed in 3% H2O2 
in PBS for 10 min and washed again with two changes of PBST for 2 min each. Slides 
were then immersed in TdT reaction mixture (1:9 terminal transferase enzyme, biotin-16-
UTP prepared according to the manufacturer’s instructions) for 2 hr at 37 °C in a humidity 
chamber. The labelling reaction was stopped by incubation in a buffer containing 300 mM 
NaCl and 30 mM sodium citrate for 10 min. Following washing with PBST, slides were 
immersed in streptavidin-HRP for 20 min at room temperature and then DAB chromogen 
with a PBST wash in between. Slides were rinsed in running tap water for 30 sec and 
counterstained with Mayer’s hematoxylin solution for 30 sec. Slides were washed in 
running ddH2O for 5 min and then dehydrated through subsequent immerse in one change 
of 95% ethanol and two changes of 100% ethanol for 3 min each. Sections were cleared by 
immerse in two changes of xylene for 5 min each and mounted onto a glass coverslip. 
4.2.4 Laser capture microdissection 
Patient aortic punch frozen sections as described in Chapter 2.2 on Superfrost Plus 
Microscope Slides (Fisher Scientific) and stored at -80 °C prior to use. Immediately prior 
to beginning tissue staining and dehydration, slides were removed from -80 °C storage and 
allowed to thaw briefly (~ 30 sec) at room temperature to completely remove condensation. 
Slides were fixed in ice-cold acetone for 2 mins, followed by air drying for 30 sec to remove 
excess acetone. A PAP pen was used to circumscribe each tissue section adhering to the 
slide. In a humidity chamber, sections were washed with 200 µL of PBS and 100 µL of 30-
60 µg/mL anti-CD163 antibody (Abcam, polyclonal Ab ab87099) was applied for 3 min 
at room temperature. Sections were washed 2× with PBS and 100 µL of 1:100 diluted 
secondary antibody was applied for 3 min at room temperature. Sections were again 
washed 2× with PBS and then sequentially dehydrated with application of 200 µL of 75%, 
95% and 100% ethanol for durations of 30 sec each. Slides were dried by immersion in 
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xylene for 5 min and excess xylene was allowed to evaporate under a fume hood. Processed 
slides were used immediately for LCM. 
LCM was performed on an ArcturusXT Laser Capture Microdissection System (Applied 
Biosystems) running ArcturusXT Operating Software (Applied Biosystems). Due to the 
small size of the sections in question, CapSure HS LCM Caps (Applied Biosystems) were 
used to capture dissected samples. Samples were captured using IR capture laser of 15 µm 
diameter at 70 mW, 1,500 µsec and 1 hit per capture. A minimum of 200 captures per 
section across four consecutive sections was performed to obtain sufficient cell numbers 
for downstream analysis. Following laser capture microdissection, dissected samples were 
immediately processed in TRIzol reagent to stabilize RNA. Total RNA was extracted from 
dissected samples using the protocol described in Chapter 2.6.1. 
4.2.5 Microarray 
RNA quality checks, cDNA preparation, array hybridization and microarray data analysis 
(in part) were all performed by David Carter and Jen Biltcliffe at the London Regional 
Genomics Centre.  
Total RNA for microarray was prepared from patient aortic punch macrophages prepared 
according to Chapter 4.2.4 and control peripheral blood monocyte-derived macrophages 
prepared according to Chapter 2.4.2. Prior to the microarray, RNA quality was checked 
using a 2100 Bioanalyzer Instrument (Agilent) and a minimum A260/280 of 1.5 and 
minimum RIN of 7 was required before the RNA could be used in the microarray. A 
minimum of 2.0 µg of total RNA was from each sample was used in the microarray. 
RNA samples were prepared for array hybridization using the GeneChip WT Pico Reagent 
Kit (Applied Biosystems) according to the manufacturer’s instructions with 12 cycles of 
pre-in vitro transcription amplification. Poly-A RNA standards provided by the 
manufacturer were used as exogenous positive controls. Samples were analyzed on the 
GeneChip Human Gene 2.0 ST Array chip (Applied Biosystems) hybridized on the 
GeneChip Scanner 3000 7G System (Applied Biosystems) according to the manufacturer’s 
recommended instructions.  
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4.2.6 Identification of differentially expressed genes 
Raw microarray data were analyzed using the Partek Genomics Suite platform (Partek). 
Reads were normalized using the Robust Multi-array Average (RMA) procedure with 
quantile normalization. Subsequently, a mixed-model ANOVA was used to identify 
differentially expressed genes with a foldchange cutoff of 2.0 and p-value cutoff of p<0.05. 
Unsupervised hierarchical clustering of all differentially expressed genes was performed 
to generate a heat map of differential gene expression. 
Results were verified using open-access tools in R Statistical Software (R Project for 
Statistical Computing) available through the Bioconductor project.38 The oligo package 
was used to read in raw microarray data files and perform RMA normalization.39 The 
limma package was used to identify differentially expressed genes using a linear models 
approach along with an empirical Bayes method to better estimate errors in log-fold 
change.40,41 
4.2.7 GO term enrichment analysis 
Gene ontology (GO) term enrichment analysis was performed on the Partek Genomics 
Suite (Partek) using the GO ANOVA feature, with analysis restricted to functional groups 
with more than two and fewer than 150 genes. The top 100 GO biological function terms 
were used for GO term visualization using the REVIGO online software platform (Rudjer 
Boskovic Institute), where terms were visualized by both uniqueness and connectivity.42 
4.2.8 Gene set enrichment analysis 
Gene set enrichment analysis (GSEA) was performed using the Gene Set Enrichment 
Analysis software platform (Broad Institute) with publicly-available annotated gene sets 
(cholesterol_homeostasis, antigen_processing_presentation, fcr_mediated_phagocytosis, 
phagosome_maturation) obtained from the Molecular Signatures Database (MSigDB).43,44  
Analysis run at 10,000 permutations using default settings with FDR < 0.25.  
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4.2.9 KEGG pathway analysis 
Pathway enrichment analysis was performed using the Partek Pathway software platform 
(Partek) using public-available Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathways (Phagosome, Oxidative Phosphorylation, Antigen Processing and Presentation). 
 
4.3 Results 
4.3.1 Quantification of mean wall and intimal thickness in patient aortic 
punch samples 
In order to study human aortic atherosclerosis, we utilized aortic punch tissue that is 
routinely obtained and discarded by cardiac surgeons during procedures that involve 
cannulation of the ascending aorta. The surgeon creates a full-thickness, circular punch 
through the aortic wall. The resulting tissue sample contains all the features of a typical 
artery, including the tunica intima, tunica media and tunica adventitia. An example of a 
patient aortic punch cross-section is shown in Figure 4.2.  
 
Figure 4.2 Cross-section of a typical patient aortic punch sample. 
H&E staining of a sectioned patient aortic punch tissue sample demonstrating the intact 
layers of the aortic wall. Following excision during surgery, aortic punch tissue was 
embedded and frozen in OCT. 10 µm-thick frozen sections were obtained and stained using 
hematoxylin and eosin and imaged under white light. The section shown is representative 
of the appearance of a typical patient aortic punch sample. Scale bar is 500 µm.  
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As there are relatively few studies that have examined atherosclerotic plaques in the human 
aorta, we sought to assess the average wall and tunica intima thicknesses of our patient 
aortic punch samples. To differentiate between intima and media on histology, we utilized 
the Movat pentachrome stain, which allows visualization of the elastin layer that separates 
the intimal and medial layers as a thin black line immediately below the intimal layer 
(example shown in Figure 4.3a). Average wall thickness of our patient aortic punch 
samples was approximately 3.7 mm (Figure 4.3b) while average intimal thickness was 
approximately 0.2 mm (Figure 4.3c).  
 
Figure 4.3 Quantification of wall and intimal thickness in patient aortic punch 
samples. 
Following excision during surgery, patient aortic punch tissue samples were formalin-fixed 
and embedded in paraffin. (a) 10 µm-thick sections were obtained, stained using a modified 
Russell-Movat pentachrome stain and imaged under white light. From images, (b) wall 
thickness and (c) intimal thickness were directly measured. Image is representative (a), and 
graphs quantify (b,c) four punches from four separate patients. Data are shown are mean ± 
SEM. White arrows indicate the elastin layer. Scale bars are 100 µm. 
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The literature reports varying mean ascending aortic wall thickness in healthy individuals. 
Biancari et al. report that an ascending aorta wall thickness of greater than 1.8 mm 
increases the risk of post-operative mortality following CABG,45 while Erbel and 
Eggebrecht state that a wall thickness of less than 4 mm should be considered to be normal 
in healthy adults.46 Our finding of 3.7 mm in older individuals with significant 
atherosclerotic burden therefore lies between these two reported values. Discrepancies in 
reported measurements may be a result of the methodology used to assess wall thickness, 
with both ultrasound and direct measurement on histology being utilized.47,48 In general, 
aortic wall thickness varies according to anatomical location, with the ascending aorta 
having the greatest thickness.48 The size of the aorta also increases with age, with the 
diameter increasing by 1-2 mm/year on average.46  
4.3.2 Patient aortic punch samples exhibit early stage atherosclerotic 
disease 
Upon examination of H&E staining of patient aortic punch tissue sections, we observed 
minimal evidence of advanced atherosclerotic disease (e.g. significant accumulation of 
lipids, large necrotic cores, etc.). As a result, we sought to better characterize the degree of 
atherosclerotic disease present in our aortic punch samples by examining: 1) sub-intimal 
lipid accumulation, 2) intimal thickening and fibrosis, and 3) sub-intimal macrophage 
accumulation. Serial frozen sections of aortic punch tissue were stained with H&E to assess 
tissue morphology, Oil Red O to assess lipid accumulation, Movat’s stain to assess intimal 
thickening and fibrosis, and αCD163 antibody to assess macrophage accumulation. 
CD163 was used as a marker of macrophages within the atherosclerotic plaque because the 
most commonly used human macrophage marker, CD68, is problematic in atherosclerosis 
because smooth muscle cells exposed to the atheroma microenvironment can also express 
this marker.48–50 Indeed, Allahverdian et al. demonstrated that up to 40% of CD68+ cells in 
advanced coronary atheromas are of smooth muscle cell origin.50 The hemoglobin-
haptoglobin scavenger receptor CD163 is uniquely expressed in cells of the monocyte/ 
macrophage lineage and was therefore selected as a highly specific marker of macrophages 
within the human atherosclerotic plaque.51 It is well-established that CD163 is highly 
expressed in macrophages that have been exposed to intraplaque hemorrhage, which adopt 
139 
 
an unique phenotype termed MHem (or HA-mac) that is characterized by ATF-1-driven 
up-regulation of CD163 and the HO-1 enzyme.52,53 Originally believed to be 
atheroprotective, a recently seminal study from Guo et al. has demonstrated that MHem 
macrophages actually increase inflammation in human atherosclerotic plaques via 
induction of intraplaque angiogenesis, vascular permeability and inflammatory cell 
recruitment.54 In our hands, CD163 expression can be reliably detected on human M0-, 
M1- and M2-polarized macrophages differentiated in vitro from peripheral blood 
monocytes (Figure 4.4a). We were able to further demonstrate that in our patient aortic 
punch tissue sections, CD163 and CD68 expression are highly correlated (Figure 4.4b and 
4.4c). 
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A representative example of serial sections of patient aortic punch tissue stained using the 
strategy described previously is provided in Figure 4.5a. We observed while there was a 
lack of extracellular lipid pools or necrotic core formation, our patient aortic punch tissues 
were characterized by lipid droplet accumulation beneath the intima, along with some 
intimal thickening and fibrosis. Furthermore, we could detect the presence of discrete 
macrophage populations within the intimal layer. Upon quantification of the degree of lipid 
accumulation, intimal thickening and macrophage accumulation, we could demonstrate 
that there was a significant positive correlation between the degree of lipid accumulation 
and number of macrophage cells (Figure 4.5b). Positive correlations were also observed 
between intimal thickness and number of macrophage cells (Figure 4.5c) and between 
intimal thickness and lipid accumulation (Figure 4.5d). Referencing the classic 
classification system for atherosclerotic plaque progression developed by Stary and  
colleagues in 1994, these features are characteristic of Types I-III lesions .55 
 
 
 
Figure 4.4 CD163 is a reliable marker of macrophage cells. (on opposite page) 
Immunofluorescence staining of cultured macrophages and aortic punch sections was used 
to determine whether CD163 expression can be reliably detected on macrophage cells. (a) 
Macrophages differentiated in vitro from peripheral blood monocytes from healthy human 
donors and polarized to M0, M1 and M2 phenotypes were immunostained for CD163. 
Images are representative of three independent replicates. Scale bars are 20 µm. (b) Aortic 
punch sections were co-immunostained for CD163 and CD68 and (c) Pearson’s correlation 
coefficient between CD163 and CD68 was calculated for both clearly identifiable 
macrophage cells (MAC) and random regions of the intima (INT). Images show two 
representative fields of view (FOV#1 and FOV#2) (b) or quantifies five fields of view as 
mean ± SEM (c). **p < 0.01 by unpaired two-tailed Student’s t test. Scale bar is 10 µm. 
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Figure 4.5 Patient aortic punch tissue samples exhibit features of early atherosclerotic 
disease. 
Serial sections of patient aortic punch tissues were obtained and treated with a number of 
histological stains to characterize the degree of atherosclerotic disease present in the 
samples. (a) 10 µm-thick frozen sections were stained with hematoxylin and eosin (H&E), 
Oil Red O (ORO), modified Russell-Movat’s pentachrome stain (Movat) and 
immunostained for CD163 (CD163). (b-d) The degree correlation was assessed between 
lipid accumulation and number of macrophages per high-power field (b), intimal thickness 
and number of macrophages per high-power field (c) or intimal thickness and lipid 
accumulation (d). Linear regression was calculated, with line of best fit and r2 values being 
provided in each graph. Pearson’s correlation coefficient was also calculated (p < 0.01 for 
b, n.s. for c and d). Images are representative of (a) and graphs quantify (b-d) seven 
separate aortic punch samples. Dotted line indicates the normal intimal thickness in healthy 
adults. Scale bar is 50 µm. 
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Finally, we aimed to assess the extent of necrotic cell accumulation within the intima in 
our aortic punch tissues. Uncleared apoptotic cells that have undergone secondary necrosis 
is a hallmark feature of advanced atherosclerotic disease. In accordance with our previous 
results, we found only a few necrotic cells could be observed (Figure 4.6a and 4.6b), again 
indicating an earlier stage of disease progression.  
 
Figure 4.6 Minimal necrotic cell accumulation in patient aortic punch tissue. 
TUNEL staining was used to measure the degree of necrotic cell accumulation within 
patient aortic punch tissues. (a) TUNEL staining of a 10 µm-thick frozen section of aortic 
punch tissue, and (b) quantification of the number of TUNEL stain-positive necrotic cells 
per low power field. Image is representative of (a) and graph quantifies (b) eight random 
fields of view from three separate aortic punch samples. Data are shown are mean ± SEM. 
4.3.3 Isolation of a pure macrophage cell population from patient tissue 
After establishing that CD163 immunostaining as a reliable means of identifying 
macrophage cell populations in the intima of our patient aortic punch samples (example 
shown in Figure 4.7a), we proceeded to isolate a pure macrophage cell population using 
LCM. Aortic punch frozen sections were rapidly immunostained for CD163 and used 
immediately for LCM, with CD163 staining guiding the capture of at least 800 cells per 
sample from four successive serial sections. 
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RNA was immediately isolated from captured macrophage cells and expression of the 
monocyte/macrophage-specific marker CD14 and the smooth muscle cell-specific ACTA2 
in captured cells compared to whole sections to assess the purity of captured cell 
populations. Captured cell samples were significantly enriched in CD14 expression 
(Figure 4.7b) whereas they expressed ACTA2 at significantly lower levels than whole 
section controls (Figure 4.7c), suggesting that a relatively pure macrophage cell population 
was successfully isolated by LCM.  
 
Figure 4.7 Isolation of a pure macrophage cell population from aortic punch tissue by 
LCM. 
LCM was used to selectively isolate macrophage cell populations and the purity of LCM 
dissected macrophages was confirmed by RT-qPCR. (a) Patient aortic punch tissue 
sections were immunostained for CD163 and imaged using the fluorescence microscopy 
system built into the LCM System. Borders between the intima (I), media (M) and 
adventitia (A) are denoted by dashed lines. (b, c) RT-qPCR analysis of the expression of 
CD14 (b) and ACTA2 (c) in LCM-captured macrophages and whole section controls. The 
image is representative of (a) and graphs quantify (b, c) three independent sets of captured 
macrophages and whole section controls. Data are presented as mean ± SEM. *p < 0.05 by 
unpaired two-tailed Student’s t test. Scale bar is 200 µm. 
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4.3.4 Gene expression profiling of macrophages isolated from patient 
aortic punch tissue 
To better understand the properties of macrophages within the early pre-atherosclerotic 
lesions identified in our patient aortic punch tissue, gene expression profiling by microarray 
was performed on LCM-captured patient macrophages. As a control we utilized peripheral 
blood monocytes isolated from healthy age- and sex-matched donors were differentiated 
in vitro to M0-polarized macrophages. In total, three patient macrophage samples and three 
controls were analyzed by microarray. Concentration and integrity for each sample are 
reported in Table 4.1. 
Table 4.1 Concentration and RNA integrity of samples used for microarray. 
 
Microarray analysis was performed using the GeneChip Human Gene 2.0 ST Array at 
London Regional Genomics Centre (London, Ontario). This chip provides comprehensive 
coverage of protein-coding and long intergenic non-coding RNA (lncRNA), although for 
the purposes of this study, lncRNA was not included in subsequent analyses because they 
remain poorly annotated. Gene expression profiling demonstrated significant differences 
in gene expression between patient and control macrophages. Principal component analysis 
(PCA) showed clear segregation and separation of patient and control macrophages, with 
the first two principal components accounting for 65.9% of variability between the two 
groups (Figure 4.8a). Following RMA normalization (Figure 4.8b) and differentially 
expressed gene identification using a mixed-model ANOVA, 3,374 protein-coding genes 
met the pre-specified cutoff criteria of log-foldchange > 2.0 and adjusted p value < 0.05 
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(Figure 4.8c). Compared to control macrophages, the majority of genes in patient 
macrophages were down-regulated (Figures 4.8c and 4.8d). 
 
Figure 4.8 Microarray analysis of pre-atherosclerotic macrophages demonstrates 
profound differences in gene expression. 
Microarray analysis was performed on LCM-captured patient macrophages with ex vivo 
monocyte-derived macrophages from healthy donors as controls. Three patient samples 
and three controls were used for microarray. (a) PCA of gene expression profiles from 
patient and control macrophages. (b) Average read intensities of patient and control 
macrophage samples pre- and post-RMA normalization. (c) Volcano plot demonstrating 
overall changes in gene expression in patient macrophages compared to controls. Each 
individual dot represents one gene, with red dots representing differentially expressed 
genes that met the pre-specified cut-offs of log-foldchange > 2.0 and adjusted p value < 
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0.05. In total, 3,374 protein-coding genes met cut-offs. (d) Heatmap generated through 
unsupervised hierarchical clustering of all differentially expressed genes in patient 
macrophages compared to controls, with colour scheme reflecting gene expression z-score. 
AP – patient aortic punch macrophages, CT – healthy donor control macrophages. 
From the complete list of differentially expressed protein-coding genes, we manually 
curated a list of genes of interest on the basis of either known association with 
atherosclerosis or involvement in pathways of interest. These pathways of interest 
included: 1) phagocytosis and efferocytosis, 2) cholesterol metabolism, 3) antigen 
presentation, 4) peptide citrullination, and 5) regulation of gene expression. Using this 
method, we identified 10 differentially upregulated genes of interest and 10 differentially 
downregulated gene of interest (Table 4.2). A list of the top 100 upregulated and 
downregulated genes can be found in Appendix B. 
Table 4.2 Differentially expressed genes with potential relevance to dysregulated 
macrophage function in atherosclerosis 
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The set of genes that were differentially upregulated in patient macrophages in comparison 
to controls was limited. However, this set of genes did significantly include a number of 
transcription factors (FOXF2, YAP1, GATA2, E4F1 and RARG). This was of interest to 
us because these transcription factors may drive part or all of the differences in gene 
expression observed in our patient macrophages. Of these five transcription factors, 
GATA2, E4F1 and RARG have previously been implicated in atherosclerosis. Briefly, 
SNP’s in GATA2 have been found to be associated with CAD in genome-wide association 
and linkage studies.56,57 E4F1 is an estrogen-responsive gene that is up-regulated in the 
aortas of postmenopausal women with atherosclerotic disease.58 Finally, activation of 
RARG in vitro has been shown to induce up-regulation of ABCA1, which encodes a 
protein that plays a key role in transport of cholesterol out of the cell.59 Interestingly, 
another gene that is upregulated in patient macrophages is PADI3, which encodes the type 
III peptidyl arginine deiminase – an enzyme that is responsible for peptide citrullination 
and plays a role in the pathogenesis of rheumatoid arthritis.60 Peptide citrullination has 
been reported to occur in atherosclerosis and is thought to be involved in the acceleration 
of atherosclerotic disease development in patients with rheumatoid arthritis.61 
4.3.5 Confirmation of changes in gene expression by RT-qPCR 
Since microarray data is inherently noisy, we next sought to confirm that the changes in 
gene expression identified in the microarray analysis could be reproduced by RT-qPCR. 
Furthermore, to control for the possibility of bias from using a limited number of patients 
and controls, we assessed gene expression in five independent patient and control 
macrophage samples. Genes assessed included those involved in regulation of gene 
expression: GATA2, E4F1, RARG (Figure 4.9a); those involved in cholesterol 
metabolism: ABCA1, NPC1, NPC2 (Figure 4.9b); and those involved in phagocytosis/ 
efferocytosis (Figure 4.9c). 
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Figure 4.9 RT-qPCR validation of key microarray results. (on opposite page) 
RT-qPCR analysis was performed on independent patient macrophage and control 
macrophage samples to validate microarray results. Genes assessed included those 
involved in regulation of gene expression (a), cholesterol metabolism (b) and 
phagocytosis/ efferocytosis (c). Graphs quantify five independent patient and control 
macrophage samples that had not been used in the microarray. CT – control macrophages 
from healthy donors, AP –macrophages from patient aortic punch tissue. Data are 
presented mean ± SEM. *p < 0.05, **p < 0.01, ****p < 0.001 by Mann Whitney U test. ns 
= not significant, n.d. = not detected. 
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As expected, we observed upregulation of GATA2 and downregulation of ABCA1, NPC2, 
ITGAX and RAB7A in the patient macrophages in comparison to the controls. There was 
no difference in the expression of ILK between patients and controls, which may be due to 
inter-individual differences between the subjects used in the microarray study versus for 
RT-qPCR or random variability in the original microarray data. Unexpected, neither E4F1 
nor RARG was detectable in our RT-qPCR assay. Conversely, we found that GATA2 was 
upregulated in excess of 50-fold in patient macrophages.  
4.3.6 Functional analysis of gene expression data reveals potential 
defects in cholesterol metabolism and in phagocytosis/ 
efferocytosis 
To translate differences in gene expression profile determined by microarray to altered 
patient macrophage function within the pre-atherosclerotic environment, we took 
functional and pathway-based approaches to assigning biological significance to 
differences in gene expression. We first examined GO classifications that were 
significantly enriched in our gene expression dataset. Using the 100 most significantly 
over-represented biological processes in our dataset, we generated plots of GO terms on 
the basis of uniqueness (Figure 4.10a) and connectivity (Figure 4.10b).  
 
Figure 4.10 Highly over-represented GO terms from microarray data. (on opposite 
page) 
The 100 most highly significant biological processes GO terms from the microarray dataset 
were visualized on the basis of uniqueness (a) or connectivity (b) using the REVIGO online 
GO term analysis platform. Plots assign x and y coordinates to terms by semantic similarity 
such that GO terms representing processes similar in function are grouped closer together 
(a) or by connectivity between terms such that similar GO terms are connected pairwise, 
with the line width indicating the degree of similarity (b). Colours represent p values and 
the size of each circle represents the number of differentially expressed genes from the 
microarray dataset that are categorized as part of that particular GO term (a, b).  
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From this basic analysis of GO term enrichment data, a number of key biological processes 
that involve differentially expressed genes can be identified. These processes include: 
cellular metabolism, intracellular transport, antigen presentation and cellular stress 
response. We proceeded to validate these observations through gene set enrichment 
analysis looking at over-representation of differentially expressed genes in the following 
processes with defined gene sets: cholesterol homeostasis (Figure 4.11a), Fcγ-mediated 
phagocytosis (Figure 4.11b), phagosome maturation (Figure 4.11c), and antigen 
processing and presentation (Figure 4.11d). Indeed, we found that all four gene sets were 
significantly enriched in our microarray results (false discovery rate [FDR]-adjusted p-
value = 0.083664).  
 
Figure 4.11 Gene set enrichment analysis of differentially expression genes in patient 
macrophages. 
GSEA was performed to analyze genes sets enriched in patient macrophages compared to 
controls. Enrichment plots were generated for all gene sets tested. All four gene sets tested 
were found to be significantly enriched using a FDR-adjusted p-value cutoff of 0.25. (a) 
Cholesterol metabolism (adjusted p-value = 0.083664), (b) Fcγ-mediated phagocytosis 
(adjusted p-value = 0.083664), (c) Phagosome maturation (adjusted p-value = 0.083664) 
and (d) Antigen processing and presentation (adjusted p-value = 0.083664). NES = 
normalized enrichment score. 
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Finally, we mapped differentially expressed genes onto several key pathways of interest in 
order to visualize the potential impact of altered gene expression in patient macrophages 
on the function of biological pathways. Specifically, we examined pathways related to 
phagocytosis and phagosome maturation (Figure 4.12a) and antigen processing and 
presentation (Figure 4.12b). Both phagocytosis and antigen processing were pathways that 
were previously implicated by the results of our GO term enrichment and gene set 
enrichment analyses. As expected, we found that key components of both of these 
pathways were significantly downregulated in the gene expression profile of patient 
macrophages. Looking at phagosome maturation, several key components of this process 
appear to be impaired, including Rab7, the vacuolar ATPase, and several components of 
the NADPH oxidase complex. As for antigen processing and presentation, components of 
this pathway appear to be almost universally affected, with expression of the key regulators 
calreticulin  and γ-interferon-inducible lysosomal thiol reductase (GILT) being 
significantly downregulated (Figure 4.12a and 4.12b). 
 
 
 
 
 
 
Figure 4.12 Visualization of differentially expressed genes on KEGG pathways. (on 
opposite page) 
Differentially expressed genes obtained from microarray results were mapped onto KEGG 
pathways using the Partek Pathway software platform. Pathway data for phagocytosis (a) 
and antigen presentation (b) were obtained from the Kyoto Encyclopedia of Genes and 
Genomes. Red indicates downregulation of gene expression in the microarray dataset, with 
darker shades indicating greater magnitudes of downregulation. 
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4.4 Discussion 
Macrophages play a complex and multifaceted role in the development and progression of 
atherosclerosis.62,63 Studying gene expression in human atherosclerotic plaque-resident 
macrophages poses challenges in both accessing the relevant tissues in patients and in 
isolating the macrophage cell population from the rest of the plaque. To date, there have 
been a limited number of studies that have examined gene expression in human 
atherosclerotic plaques.11,13,64–70 The majority of these studies have focused carotid 
plaques, which can be obtained following carotid endarterectomy.11,65,68,70 Significantly 
fewer studies have examined coronary arteries64,67,69 and only a select number of these have 
actually taken the additional step of separating the macrophages from the rest of the plaque 
tissue prior to analysis.65,66 
To the best of my knowledge, the current study is the first to examine gene expression 
profiles in isolated macrophages from atherosclerotic plaques located in the human aorta. 
Histopathological examination of the aortic punch tissue samples demonstrated that the 
aortic wall is characterized by early pre-atherosclerotic lesions that fall under type III 
lesions or earlier in the classic Stary classification scheme of atherosclerotic plaque 
progression.55,71 At this stage of plaque development, there is moderate intimal thickening 
and fibrosis, along with accumulation of small populations of macrophages and limited 
amounts of intracellular and extracellular lipid deposits, which aligns well with our 
observations.55 This was not completely surprisingly to us because atherosclerotic burden 
in humans is predominantly focused in the coronary and carotid vessels, along with the 
abdominal aorta and common iliac arteries.6,72 The ascending aorta, where our punch 
samples originated, in comparison is relatively spared of severe atherosclerotic disease.3,5 
While the lack of advanced plaques precluded us from studying macrophage gene 
expression in late atherosclerotic disease, when efferocytosis is already impaired, it offered 
us the opportunity to instead focus on early stages of atherosclerotic plaque development 
and characterize macrophage phenotype in early pre-atherosclerotic disease. This 
represents another novel aspect of our approach, since the existing literature has focused 
almost exclusively on late-stage, established disease that is present in the majority of 
clinical specimens recovered. At these later stages of disease development, the mechanisms 
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that drive the development of efferocytic defect may be masked by changes induced by the 
complex interactions between macrophages and the late plaque microenvironment, 
including prior plaque rupture and thrombosis and intra-plaque hemorrhages – both of 
which have been previously shown to induce distinct macrophage phenotypes.11,52,73 
The isolation of a pure macrophage cell population from the pre-atherosclerotic lesion 
presents another challenge. While some previous gene expression studies have utilized 
whole plaques, a number of cell types besides macrophages exist within the plaque. This 
includes large populations of smooth muscle cells, fibroblasts and endothelial cells that 
comprise the plaque,7,63 as well as smaller numbers of infiltrating immune cell populations 
including CD4+ and CD8+ lymphocytes, NKT cells and dendritic cells.74–76 It is therefore 
difficult to attribute any observed changes in gene expression to macrophages alone when 
whole plaques are used in gene expression profiling studies. However, isolation of 
macrophages from plaques is not a trivial task. The traditional approach of enzymatic 
digestion followed by magnetic- or FACS-based cell separation presents a challenge when 
the goal is to analyze gene expression because the conditions under which macrophages 
cells are subjected to during these procedures (e.g. enzymatic digestion, separation from 
the atheroma microenvironment) may contribute to significant changes in their gene 
expression profiles due to the incredible plasticity of these cells and their ability to rapidly 
adapt to new external environments.77 Indeed, recently single-cell RNA sequencing studies 
have demonstrated that murine microglia cells removed from the brain and placed into 
culture ex vivo exhibited dramatic changes in gene expression within six hours.78 
Therefore, we opted to immediately freeze our tissue samples and isolate macrophages by 
LCM. While freezing subjects RNA to some level of degradation, it carries the important 
advantage of preserving the integrity of overall gene expression profile.79 Several previous 
studies have used LCM to isolate macrophages from within atherosclerotic plaques. 
Following labelling of macrophages by CD163, we were able to selectively isolate 
macrophage cells from pre-atherosclerotic lesions and isolate enough RNA of sufficient 
quality to perform both microarray and RT-qPCR analysis. 
We examined gene expression changes in patient macrophages by microarray using M0-
polarized macrophages differentiated in vitro from peripheral blood monocytes as a 
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control. The lack of a more comparable source of control macrophages is a significant 
drawback of this approach, yet a suitable source of control cells is difficult to identify. In 
the healthy artery, there is not a substantial population of sub-intimal macrophages that 
could act as a control. Several groups have identified a population of “arterial 
macrophages” that are associated with arteries throughout the body, these are primarily 
located within the adventitia or in close association with the smooth muscle rather than the 
intima.80,81 Ensan et al. found that in C57BL/6J mice, only 2% of all arterial macrophages 
could be found in the intima.81 Further, studies have demonstrated that these macrophages 
are entirely tissue resident cells with an embryonic origin.81 In contrast, atherosclerotic 
plaque-resident macrophages are thought to be mostly derived from circulating monocytes, 
although they do exhibit limited self-proliferative potential.63,82 Some studies that have 
examined apoptotic cell clearance in human atherosclerotic plaque have used the tonsils as 
a control tissue with a highly active efferocytic activity.36 However, it is questionable in 
our particular situation whether tonsillar macrophages would serve as a superior control to 
monocyte-derived macrophages. Nevertheless, since our control macrophages are derived 
from a different source than patient pre-atherosclerotic macrophages, that should be taken 
into account when interpreting the results of our gene expression profiling study. 
From the results of our microarray study, it is apparent that even in the early stages of 
atherosclerotic plaque development, lesion-resident macrophages have a very different 
gene expression profile. We observed that over 3,000 protein-coding genes are 
differentially expressed in patient macrophages in comparison to controls. Undoubtedly, 
some of this difference we observe can be attributed to the comparison between lesion-
resident macrophages and monocyte-derived macrophage controls. However, many of the 
features that we identify as unique in the pre-atherosclerotic lesion-resident macrophage 
population are not obviously connected to inherent differences between macrophages 
isolated from a tissue and macrophages cultured in vitro. These features include marked 
downregulation of genes involved in cholesterol homeostasis, phagocytosis and 
phagosome maturation and antigen processing and presentation but not inflammatory 
activation. Rather, we contend that these features define a novel macrophage phenotype 
associated with early, pre-atherosclerotic lesions (Figure 4.13). Within the early 
atherosclerotic lesion, the dominant microenvironmental factor that drives macrophage 
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dysfunction is probably an excess of lipids and modified lipoproteins rather than the 
chronic inflammation that characterizes advanced plaques. Hypercholesterolemia has been 
previously described by Huynh et al. to impair phagosome maturation by interfering with 
the activity of Rab7,34 which, as described in the previous chapter, is a key regulator of 
proper phagosome and efferosome maturation. Rab7 regulates phagosome acidification 
and phagolysosomal formation and its downregulation in pre-atherosclerotic lesion-
resident macrophages suggests that phagosome and efferosome maturation may be 
impaired in these cells.  
 
Figure 4.13 Novel macrophage phenotype associated with early, pre-atherosclerotic 
lesions. 
We defined a novel macrophage phenotype associated with early, pre-atherosclerotic 
lesions located in the human ascending aorta. Upon histological examination, the vessel 
intima is observed to possess diffuse thickening in combination with accumulation of lipids 
and small, discrete macrophage cell populations. These intima-infiltrating macrophages are 
characterized by dysregulated gene expression in pathways related to cellular cholesterol 
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handling, intracellular vesicular trafficking and phagocytosis/efferocytosis. Specifically, 
we observed downregulation in the expression of the cholesterol efflux genes NPC1 and 
ABCA1, downregulation of genes encoding components of the vATPase, NADPH oxidase 
(gp91, p22phox), and downregulation of Src kinases and integrins involved in pathogen 
and apoptotic cell internalization. We observed upregulation of several transcription 
factors, notably the hematopoietic transcription factor GATA2 and upregulation of the 
PADI3 enzyme.  
The phenotype we have described herein appears to be distinct from any other previously 
established macrophage phenotypes. Defining a consistent phenotype for atherosclerotic 
macrophages has been difficult and the precise phenotype varies on the basis of whether 
investigators studied human or animal plaques, the location of the plaque and the stage of 
plaque development. In general, it is thought that atherosclerotic macrophages in later 
stages of disease are predominantly M1-like and proinflammatory in nature.83 Indeed, 
immunohistochemistry studies of advanced atherosclerotic plaques show an increase in the 
proportion of pro-inflammatory macrophages and an association between these 
macrophages and sites of plaque instability.84 Additionally, in animal models of 
atherosclerosis regression, decrease plaque size is associated with an increase in the 
number of M2-like macrophages.85,86 In advanced atherosclerosis, macrophages are shaped 
by the inflammatory microenvironment of the plaque to adopt a pro-inflammatory 
phenotype and contribute to inflammation, cytokine production and plaque instability.24,87 
The M1-M2 paradigm however fails to capture the full complexity of macrophage 
behaviours within the atherosclerotic plaque. Non-classical macrophage phenotypes have 
also been described in the setting of atherosclerosis.88 For example, Boyle et al. describe a 
heme-induced macrophage polarization stated (Mhem) that is associated with intraplaque 
hemorrhage.53 These macrophages upregulate ATF-1 and heme oxygenase-1 and are able 
to efficient clear excess hemoglobin.53 Kadl et al. describe another unique macrophage 
characterized by upregulation of Nrf2 in response to oxidized phospholipids, which express 
high levels of redox-regulating genes such as Srxn1 and Txnrd1 to control the oxidative 
stress induced by oxidized phospholipids.89 In contrast, our pre-atherosclerotic 
macrophages do not appear to overexpress markers of the macrophage M1-polarization, 
nor is there a particularly strong effect in genes involved in iron metabolism or redox 
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regulation. In contrast, we observe a non-inflammatory phenotype in our pre-
atherosclerotic macrophages along with features suggestive of ER stress and regulation of 
proteasome activity.  
Macrophage efferocytosis undoubtedly plays a critical role in the pathogenesis of 
atherosclerotic disease. Work to date has indicated that defective efferocytosis is a feature 
of advanced, late-stage atherosclerotic disease. While the mechanisms that drive defective 
efferocytosis remain poorly defined, there is some evidence to suggest that the 
inflammatory microenvironment of the atheroma drives matrix metalloproteinase-
mediated cleavage of efferocytic receptors, thereby impairing efferocytic uptake of 
apoptotic cells. Our findings here challenge these paradigms in two key ways: first, we find 
that defects in phagocytosis and efferocytosis are present (at least at the level of gene 
expression) very early on in atherosclerotic disease; second, we find that in addition to 
impairments in phagocytic and efferocytic uptake, phagosome/efferosome maturation may 
also be implicated in impaired macrophage efferocytosis. Critically, these findings are 
based on analysis of isolated macrophage cell populations from human disease and are 
therefore potentially more indicative of clinically-relevant macrophage dysfunction in 
atherosclerosis than what has been previously identified in animal models of disease or 
studies that have examined whole plaques.  
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Chapter 5  
5 The Hematopoietic Transcription Factor GATA2 is a 
Master Regulator of Defective Macrophage Efferocytosis 
in Atherosclerosis  
5.1 Introduction 
5.1.1 In vitro models of atherosclerotic macrophages 
Studying atherosclerotic macrophages in vitro is a challenging task because the complexity 
of the atherosclerotic plaque microenvironment is difficult to re-capitulate in culture.1 We 
know that at a minimum, atherosclerosis involves cross talk between three cell types: 
macrophages, endothelial cells and VSMCs.2,3 Indeed, a number of investigators have 
attempted to create models of atherosclerosis through co-culture of some combination 
endothelial cells, VSMCs and monocytes in the presence of various components of the 
extracellular matrix (ECM).4–6 These models can successfully re-capitulate certain aspects 
of atherogenesis, including SMC proliferation and migration of monocytes into the sub-
endothelial cell space and their subsequent differentiation into macrophages.4 However, 
due to the presence of multiple cell types, extra care is required in order to study 
macrophage cell biology in isolation using these approaches and it is difficult to discern 
how individual pro-atherogenic stimuli (such as the presence of modified lipoproteins) act 
directly on macrophage cells.  
Another approach that has been commonly employed is the isolation and ex vivo culture of 
macrophages from patients, or more commonly, mice with atherosclerosis.1 One strategy 
is to isolate macrophages from the peritoneum of atherosclerotic mice and subsequently 
activate and study them in vitro.1 This has been key in studying the effects of various pro-
atherogenic agents, cytokines and drugs on macrophages conditioned to the 
hypercholesterolemic environment of the atherosclerotic animal.1,7,8 For example, Yu et al. 
used this approach to establish that treatment with rosuvastatin in Apoe-/- mice had the 
direct effect of inhibiting macrophage apoptosis,7 while Kanters et al. found that 
atherosclerotic macrophages isolated from Ldlr-/- mice lacking a component of the NFκB 
signaling complex exhibited decreased IL-10 production following stimulation with LPS.8 
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However, while this approach is powerful and re-capitulates the systemic effects of 
atherosclerosis on macrophage function, it become less feasible in humans given the lack 
of a source that can provide large numbers of viable macrophages. Furthermore, unlike 
with mice or immortalized cell lines, it is very difficult to perform genetic manipulations 
on human macrophages cultured ex vivo, limiting our ability to study the effects of 
perturbing the expression of specific genes on macrophage phenotype.9  
Perhaps the simplest in vitro model of atherosclerotic macrophages is to treat cultured 
macrophage with oxLDL,10 a similar modified lipoprotein,11 or LDL in the presence of an 
ACAT inhibitor.12 The literature disagrees somewhat with the precise concentration of 
oxLDL to use and the duration of treatment, with studies using a range of concentrations 
between 25-100 µg/mL and a duration between 1-3 days.13,14 While a very simple model, 
oxLDL exposure is able to re-capitulate some of the earliest pathologic features exhibited 
by macrophages within atherosclerotic lesions. Uptake of oxLDL has a number of 
consequences for macrophage. Cholesterol recovered from the lipoprotein particle 
accumulates within the macrophage, as both neutral cholesterol esters sequestered within 
lipid droplets and as free cholesterol that accumulates within the cytoplasm and lipid 
plasma membrane of the cell.11 Cholesterol ester buildup as lipid droplets creates the 
classic “foamy” appearance of macrophage-derived foam cells.15 Free cholesterol within 
the cytoplasm aggregate as cholesterol crystal, which can induce a number of biological 
responses within the macrophage, including UPR and activation of the UPR effector 
protein CHOP, which can induce apoptosis.16,17 Cholesterol crystals also contribute to 
activation of the NRLP3 inflammasome and generation of IL-1β, which plays a key role in 
driving inflammatory responses within the atherosclerotic plaque.18 Furthermore, oxLDL 
can activate endosomal Toll-like, which in addition to generating a pro-inflammatory 
response, also inhibits the macrophage’s capacity to engage in efficient efferocytosis.19  
5.1.2 GATA family of transcription factors 
The GATA family of transcription factors is comprised of six members that have master 
regulatory roles during development, specifically in progenitor differentiation and renewal, 
and in cell lineage specification.20,21 GATA transcription factors are highly-conserved and 
are evolutionarily ancient proteins, being found among animals, plants and fungi.20 They 
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are characterized by the presence of two highly-conserved zinc finger domains that 
recognize the consensus sequence (A/T)GATA(A/G).22 In vertebrates, there are six 
members of the GATA transcription factor family (GATA1-6; see Figure 5.1).20 
Classically, these six paralogs have been divided into two subfamilies on the basis of 
function. GATA1/2/3 were thought to be primarily involved in development of the 
hematopoietic system while GATA4/5/6 were thought to be involved in cardiac 
development.21 However, more recent evidence suggests that various members of the 
GATA family play important roles in the development of many other tissues, including the 
kidneys (GATA2/3), breast (GATA3) and testes (GATA1) among others.20 The role of 
GATA transcription factor during development has been discussed in detail in two recent 
reviews from Lentjes et al. and Tremblay et al.20,21 
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GATA family members are transcription factors with pleiotropic effects, capable of 
cooperative binding with a wide range of other transcription factors.20,23 In fact, multiple 
members of the GATA family have demonstrated ability to act as pioneer transcription 
factors, binding to heterochromatic DNA sequences and promote chromatin opening to 
allow for other transcription factors to bind.20 For example, GATA2 is able to regulate 
androgen receptor binding by recognizing and opening sections of chromatin containing 
androgen receptor-target genes. GATA family members typically bind cooperatively with 
other, tissue-specific transcription factors to regulate gene expression.23 They are capable 
of regulating the activity of other transcription factors through a variety of molecular 
mechanisms (see Figure 5.2).20 In particular, during lineage specification, pairs of GATA 
transcription factors tend to negatively regulate each other, where the exchange of one 
GATA family member for another drives cell fate commitment in a process called a 
“GATA switch”.20 
 
 
 
 
 
Figure 5.1 The GATA family of transcription factors. (on opposite page) 
The six members of the GATA family of transcription factors found in vertebrates 
(GATA1-6). Members of the GATA family exhibit a high degree of sequence conservation 
within the DNA binding domain, which is comprised of two zinc finger domains that allow 
binding to the (A/T)GATA(A/G) consensus DNA binding sequence. Sequence 
conservation in the N-terminal and C-terminal regions is markedly lower. The percentage 
similarity of the protein sequence is calculated using the Matrix Global Alignment Tool 
(MatGAT).24 AD = activation domains, Zn = zinc finger, NLS = nuclear localization signal. 
Figure is modified from Tremblay et al.20 
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Figure 5.2 GATA transcription factor mechanisms of action. 
Molecular mechanisms of action employed by members of the GATA family of 
transcription factors to regulate gene expression. (A) GATA transcription factors can act 
as pioneer factors and open up chromatin to allow for binding of other transcription factors. 
(B) They are able to loop chromatin to bring distant enhancer regions in closer proximity 
with the genes they regulate. (C) The replacement of one GATA factor for another is 
termed a “GATA switch” and has been implicated in regulating cell lineage specification. 
GATA transcription factors are also able to recruit mediators that affect epigenetic 
modification, either activating (D) or repressing (E) chromatin opening. (F) Finally, GATA 
transcription factors directly enhance or repress binding of other transcription factors. 
Figure is modified from Tremblay et al.20 
GATA transcription factors regulate both primitive and definitive hematopoiesis. During 
definitive hematopoiesis, GATA factors are required for both progenitor renewal and cell 
lineage specification.23 Hematopoietic stem cells require continued GATA2 expression to 
maintain their capacity for self-renewal.23 Disturbing GATA2 expression, either through 
over-expression or knockdown, perturbs the ability of these stem cells to engage in self-
renewal.23,25 GATA factors are also markers of specific lineages of hematopoietic cells. 
GATA1 is expressed in erythrocytes and megakaryocytes, GATA2 is a marker of 
monocytic and dendritic cells, while GATA3 is only expressed in cells of the lymphoid 
lineage.20   
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5.1.2.1 GATA2 
Of the GATA family of transcription factors, GATA2 is of particular interest to us. GATA2 
was one of three non-cell cycle transcription factors found to be upregulated in patient 
atherosclerotic macrophages from our gene expression profiling study (see Chapter 4). 
Available evidence in the literature suggests that GATA2 could be involved in the 
pathogenesis of atherosclerosis in humans. Mature monocytes and macrophages do not 
normally express GATA2. A previous genome-wide association study (GWAS) and a 
linkage study have found a positive association between mutations in GATA2 and early-
onset familial CAD and several risk factors associated with CAD, including obesity, low 
HDL and hypercholesterolemia.26,27 Furthermore, a study that examined miRNA-
regulation of gene expression in CAD patients found that GATA2 was involved in a miR-
92a regulatory pathway associated with CAD.28 GATA2 appears to regulate expression of 
the long non-coding RNA CDKN2B-AS, which in turns regulates miR-92a levels.28 miR-
92a has previously been identified as driving the production of inflammatory cytokines in 
endothelial cells under pro-atherogenic conditions.29 
GATA2 has also been implicated in several regulatory pathways associated with 
inflammation. In a cohort of cardiac transplant patients receiving re-transplantation as a 
result of graft rejection, SENP1-mediated deSUMOylation of GATA2 in the coronary 
arteries was associated with graft atherosclerosis and inflammation.30 SENP1-mediated 
deSUMOylation increased GATA2 stability and ability to bind DNA, thereby increasing 
its activity.30 There is also evidence that GATA2 expression is regulated by inflammatory 
PAMP’s, including LPS. Yang et al. show that LPS induces myeloid-derived suppressor 
cell formation in mice in a GATA2-dependent fashion,31 while Wu et al. demonstrate that, 
at least in vitro, LPS stimulates GATA2 migration into the nucleus and activations 
transcription of IL-1β.32 
Along with GATA1, GATA2 is absolutely required for both primitive and definitive 
hematopoiesis. GATA1/2 knockout mice die during E10-11 due to severe hematopoietic 
defects. GATA2 is required for proper development of the lymphatic system. In mice, 
complete GATA2 knockout is embryonically lethal due to lymphatic collapse, whereas 
partial knockouts result in lymphatic system mis-patterning.33 In patients with loss-of-
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function GATA2 mutations, lymphatic valves do not properly develop and these patients 
exhibit lymphedema as a result.34 Mutations in GATA2 are also associated with diseases 
of the hematopoietic system, including both chronic and acute myeloid leukemia, 
Emberger syndrome, and MonoMAC (monocytopenia and mycobacterial infection) 
syndrome (also referred to as Immunodeficiency 21).34–36 These syndromes are 
characterized by profound deficiencies of dendritic cells, monocytes, B cells and natural 
killer cells, resulting in severe immunodeficiency and increased susceptibility to infection 
by human papillomaviruses and nontuberculous mycobacteria.37 Simultaneously, patients 
with GATA2 mutations are at increased risk of AML, pulmonary alveolar proteinosis and 
lymphedema. The mutations within GATA2 that give rise to these clinical manifestations 
are heterogeneous but can be roughly divided into three groups: missense mutations, 
frameshift mutations and in-frame deletions of the C-terminal zinc finger, mutations and 
large deletions resulting in a null allele, and mutations within the regulatory region of the 
GATA2 gene.37 
GATA2 mutations have been identified in patients with chronic myeloid leukemia (CML) 
that have experienced progression into the blast crisis phase of disease.20,25 In many of 
these patients, a distinctive L359V mutation results in increased DNA binding and 
coactivator recruitment, as well as repression of the transcription factor PU.1 through 
aberrant binding and sequestration of this protein.25 PU.1 is a major regulator of myeloid 
cell proliferation and GATA2-mediated repression of PU.1 function in vitro appears to be 
sufficient to induce maturation arrest of myeloid precursor cells at the myeloblast and 
monoblast stages.38 Disruption of GATA2 expression and function can also lead to 
AML.20,35 In this case, both GATA2 overexpression and knockdown/loss-of-function can 
lead to leukemogenesis.20 In particular, high levels of GATA2 expression correlate with 
poorer outcomes in pediatric AML and activation of GATA2 through a Ras-MAPK-
GATA2 axis is sufficient to induce CXCL2-dependent AML proliferation.39,40 
5.1.3 Processes involved in efferosome maturation 
Efferocytosis is a complex process of removing apoptotic cells in order to prevent 
secondary necrosis and maintain tissue homeostasis.41,42 We discuss efferocytosis and its 
regulation in detail in Chapter 1.1 and Chapter 3. Broadly speaking, efferocytosis can be 
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divided into three distinct stages: recognition of the apoptotic cell, apoptotic cell binding 
and uptake, and processing and degradation of the internalized apoptotic cell.42 In the 
context of atherosclerosis, a great deal of effort has gone into understanding the first two 
stages of efferocytosis but the final stage of efferocytosis—proper degradation and 
processing of internalized apoptotic cargo through regulated efferosome maturation—
remains poorly understood.43,44 Although the regulation and end result of efferocytosis is 
distinct, efferosome maturation utilizes the same fundamental processes to degrade 
apoptotic cells as phagosomes utilize to degrade pathogens. These processes include: 
superoxide generation within the efferosome, efferosome acidification, and fusion between 
efferosomes and lysosomes.45 
The generation of superoxides within the phagosome is an efficient mechanism of pathogen 
killing.46,47 In macrophages, phagosomal superoxides are generated by the phagocyte 
NADPH-oxidase (NOX) complex. NOX is capable of generating superoxide anions within 
the phagosome, which in turn can form hydrogen peroxide, a potent antimicrobial agents.46 
This mechanism is so efficient that human macrophages polarized in vitro to the pro-
inflammatory M1 phenotype actually favour superoxide formation and hydrogen peroxide 
formation at the expense of consuming protons within the phagosome and delaying 
phagosome acidification.48 The NOX complex is composed of two transmembrane 
proteins:  gp91phox, p22phox; three cytosolic regulators: p40phox, p47phox and p67phox; and a 
Rho GTPase (either Rac1 or Rac2).46,49 The gp91phox and p22phox subunits together 
assemble into an inactive flavocytochrome on the membrane of nascent phagosomes. The 
regulatory subunits exist in the cytoplasm as a complex, which translocates to the 
phagosome membrane upon stimulation and, together with Rac1 or Rac2, activates the 
flavocytochrome complex. The activated flavocytochrome is able to reduce oxygen 
molecules to generate superoxide anions within the pathogen and engage in pathogen 
degradation.49 NOX activity has also been recently demonstrated to be critical in efficient 
degradation of apoptotic cargo. Bagaitkar et al. demonstrated that efferocytosis of 
apoptotic neutrophils by murine macrophages was sufficient to induce NOX activation.50 
Using macrophages from mice with one of the NOX subunits deleted, the authors further 
demonstrated that superoxide generation was essential for the rapid degradation of 
apoptotic cargo and to prevent aberrant presentation of self-antigens to T cells.50 
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A second mechanism contributing to efficient degradation of apoptotic cargo within 
efferosomes is efferosome acidification. Acidification is crucial for phagosome and 
efferosome function.45,51 Many proteases that serve to degrade pathogens or apoptotic cells 
only become active at a pH below 6.0  In the context of phagocytosis specifically, cathepsin 
D, which plays a crucial role in the loading of peptide onto MHC class II molecules for 
antigen presentation, requires a sufficiently low pH to function efficiently.45 Acidification 
of phagosomes and efferosomes is mediated by the v-ATPases, which serve as pumps to 
move protons into the efferosome.51 The v-ATPase is comprised of two subunits, V1 and 
V0. The V1 subunit performs ATP hydrolysis and provides the energy for movement of 
protons across the efferosome membrane, while the V0 subunit forms a membrane-
spanning channel to direct movement of protons inwards.51 V-ATPase-mediated 
acidification plays several important roles in efferosome maturation. The low pH 
environment is necessary for activation of certain degradative proteases, protons within the 
efferosome participate in the formation of reactive oxygen species that enhance apoptotic 
cell degradation, and the A1 subunit of the v-ATPase appears to be required for further 
fusion of efferosomes with lysosomes to complete apoptotic cargo degradation.51,52 
Recruitment of the V-ATPase to the efferosome and proper regulation ofv-ATPase activity 
appear to depend at least in part on the activity of the small GTPase Rab7 and its effector 
protein RILP.52,53 Interestingly, under hypercholesterolemic conditions, Rab7 is recruited 
to the phagosomes but remains inactive, with phagosomal acidification impaired as a 
result.54 
One final mechanism that is involved efferosome maturation is fusion between the 
efferosome and lysosomes. This delivers lysosomal enzymes to the efferosome that aid in 
the degradation of apoptotic cargo.55 As we have demonstrated in Chapter 3, following 
internalization of apoptotic bodies, efferosomes ultimately go on to acquire lysosomal 
markers such as LAMP-1, indicating that fusion with lysosomes has taken place. Active 
Rab7 is again required for efferolysosomal fusion. RILP, along with another key Rab7 
effector ORP1L, serve to recruit a dynein-dynactin complex and drive efferosomal 
migration towards the cell centre along microtubules.53,56 This serves to bring the 
efferosomes into close proximity with lysosomes, which are concentrated in the perinuclear 
region.53 The importance of Rab7 in the regulation of this process is underscored by the 
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fact that hypercholesterolemia-induced Rab7 inactivity inhibits the capacity of 
phagosomes to undergo migration towards the cell centre and fuse with lysosomes.54 There 
is also some evidence that LC3-associated phagocytosis (LAP), which involves 
translocation of some components of the cellular autophagy machinery to the efferosome, 
is also required for efficient efferolysosomal fusion.57 
5.1.4 Rationale and importance 
As described in Chapter 4, gene expression profiling of macrophages isolated from early-
stage human pre-atherosclerotic lesions located in the proximal aorta from patients 
undergoing open-heart surgery revealed profound dysregulation in both cholesterol 
metabolism and in efferocytosis and efferosome maturation. The challenge is now to 
identify potential regulatory transcription factors that could account for part of all of this 
unique macrophage phenotype. We found just three non-cell cycle transcription factors to 
be upregulated in patient macrophages, with only GATA2 being confirmed to be 
upregulated by RT-qPCR. 
GATA2 is of interest over RARG and E4F1 since of the three, only SNPs in GATA2 are 
associated with increased risk for CAD.26,27 Mutations in GATA2 are also strongly 
associated with immunological and hematological abnormalities, including 
myelodysplasia and an elevated risk of leukemia.23,35 Intriguingly, Jaiswal et al. have 
recently shown that certain mutations associated with the development of leukemia, in 
particular mutations in TET—another transcription factor involved in hematopoiesis—also 
increase the risk of developing atherosclerosis and cardiovascular disease.58 Gain-of-
function mutations in GATA2 are associated with blast crisis in CML and increased 
GATA2 expression is a marker of worse outcomes in AML.25,40 There is therefore some 
biological plausibility in GATA2 being a master regulator of the dysregulation observed 
in patient macrophages. Further connecting GATA2 and defects in efferosomal maturation, 
Lasbury et al. have shown that in the context of Pneumocysitis carnii infection of the 
airways, GATA2 upregulation suppresses the phagocytic capacity of alveolar macrophages 
in response to infection.59  
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In this chapter, we utilize an in vitro model of atherosclerotic macrophages and genetic 
manipulation of GATA2 to study the effect of perturbing GATA2 expression on 
cholesterol homeostasis, efferocytosis and efferosome maturation, and on peptide 
citrullination in these cells. GATA2 is an attractive candidate for a master regulatory factor 
that could drive some or all of the defects observed in patient macrophages. Determining 
to what extent perturbation of GATA2 expression affects macrophage cholesterol handling 
and efferocytosis would add significantly to our understanding of the mechanisms driving 
macrophage dysregulation in early atherosclerotic disease and development of defective 
efferocytosis. GATA2 and its downstream targets could also represent potential therapeutic 
targets for development of novel atherosclerosis treatments targeting the inflammatory 
component of atherosclerotic disease.  
 
5.2 Methods 
5.2.1 Generation of atherosclerotic macrophages 
J744.2 and THP-1 macrophage cell lines were cultured as described in Chapter 2.4.1. 
Primary human macrophages were prepared as described in Chapter 2.4.2. Prior to oxLDL 
treatment, THP-1 cells were differentiated into adherent macrophages by treatment with 
100 nM PMA for 72 hrs. Cells were incubate with human oxLDL at a concentration of 50 
µg/mL for 48 hrs (J744.2 cells13 and primary human macrophages14) or 100 µg/mL for 72 
hrs (THP-1 cells10). oxLDL-treated cells were washed with PBS to remove excess oxLDL 
and were placed into fresh, oxLDL-free media prior to use in downstream assays. 
5.2.2 Measurement of cholesterol accumulation 
Cholesterol accumulation in oxLDL-treated macrophages was measured by staining with 
either Oil Red O or Nile Red. For Oil Red O staining, stock Oil Red O solution (1:250 w/v 
Oil Red O power in 100% isopropanol) was diluted 3:2 in ddH2O to a working 
concentration, mixed by vortexing, allowed sit for 20 min at room temperature, and filtered 
through a 0.2 µm filter. The cells to be stained were washed 1× with PBS and then fixed 
with 4% PFA for 20 min at room temperature. Fixed cells were washed 3× 5min with PBS 
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to remove excess PFA. Cells were then washed briefly with a 3:2 v/v mixture of 
isopropanol and ddH2O and allowed to dry completely. Cells were covered with the 
minimum volume of Oil Red O working solution to ensure complete coverage and allowed 
to incubate for 5 min at room temperature. Cells were washed 3× 5 min with PBS to remove 
excess Oil Red O. If desired, Oil Red O-stained cells may be prepared for imaging under 
white light at this point by mounting coverslips on glass slides using Permafluor. 
Otherwise, Oil Red O can be extracted by treating cells with 100% isopropanol for 10 min 
at room temperature with gentle agitation. Oil Red O concentration can be quantified by 
measurement of absorbance at 460 nm using an Eppendorf BioPhotometer Plus (Thomas 
Scientific). 
For Nile Red staining, stock Nile Red solution is prepared by dissolving Nile Red power 
in acetone at a concentration of 1 mg/mL. Cells to be stained are washed 1× with PBS and 
fixed with 4% PFA for 20 min at room temperature. Fixed cells were washed 3× 5min with 
PBS to remove excess PFA. Stock Nile Red is diluted 1:100 in PBS to generate a working 
solution. Fixed cells are covered with Nile Red working solution for 5 min at room 
temperature. Cells are then washed 3× 5 min with PBS to remove excess PBS and prepared 
for imaging by mounting coverslips on a glass slide using Permafluor. For Nile Red 
staining of live cells, cells are prepared for live cell imaging in a Leiden chamber as 
described in Chapter 2.10.2 with time-lapse images captured on white light and Nile Red 
channels at 630× magnification every 15 min for 8 hrs. Nile Red fluorescence is measured 
using a solid-state white light source in conjunction with a 550/570 nm bandpass excitation 
filter and a 605/52 nm bandpass emission filter. Nile Red stock solution is added 1:100 v/v 
directly to the culture media and live cell imaging is performed as usual. If desired, cells 
can be incubated for 3-5 hrs in serum-free media prior to staining to remove background 
lipid deposition.  
5.2.3 Cholesterol efflux assay 
Cholesterol efflux was measured using a high-sensitivity assay initially described by 
Sankaranarayanan et al.60 To prepare labelling media, BODIPY-cholesterol and unlabeled 
cholesterol were mixed together at a ratio of 1:5 v/v in a glass bottle and dried under 
nitrogen away from light. The cholesterol mixture was solubilized with MEM-HEPES 
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(MEM media with 10 mM HEPES, pH 7.4) containing 20 mM methyl-β-cyclodextran 
(MβCD) at a molar ratio of 1:40 cholesterol to MβCD in MEM-HEPES. The mixture was 
agitated in a sonicating water bath at 37 °C for 30 min. The sonicated suspension was 
placed on a stirring hot plate pre-heated to 37 °C and kept stirring with a sterile stir bar for 
3 hrs. This labelling media can be used immediately or stored at 4 °C away from light until 
ready to use. Immediately prior to use, labelling media is again sonicated in a sonicating 
water bath at 37 °C for 30 min and filtered through a 0.45 µm filter.  
ApoB-depleted human serum is used as the cholesterol acceptor. To prepare ApoB-
depleted serum, 1M CaCl2 is added to whole human plasma at a ratio of 1:40 v/v. The 
plasma is allowed to incubate for 1 hr at room temperature to allow for clotting, after which 
serum is separated from the clotted plasma proteins by centrifugation for 5 min at 1,000 
×g. ApoB was precipitated from the serum through addition of PEG solution (20% PEG 
8,000 in 200 mM glycine buffer, pH 7.4) to serum at a 2:5 v/v ratio. The mixture is allowed 
to incubate for 20 min at room temperature and then centrifuged for 30 min at 10,000 ×g 
and 4 °C. The supernatant, containing apoB-depleted serum, is transferred to a fresh tube. 
To perform the cholesterol efflux assay, THP-1 cells were cultured in a 48-well plate to a 
density of 75,000 cells/well. At 24 hrs prior to starting the assay, cells are differentiated 
into adherent macrophages through addition of 100 nM PMA. Cells are washed 1× with 
PBS and incubated with 250 µL/well of labelling media for 1 hr at 37 °C and 5% CO2. 
Cells are washed 2× with MEM-HEPES to remove excess labelling media. Cells are then 
incubated with incomplete RPMI containing 0.2% BSA for 16 hrs at 37 °C and 5% CO2. 
Cells were again washed 2× with MEM-HEPES and then incubated with fresh MEM-
HEPES containing 10% apoB-depleted serum for 4 hrs at 37 °C and 5% CO2. A negative 
control where cells are incubated with MEM-HEPES lacking apoB-depleted serum should 
also be prepared at this point. Media from each well was collected, filtered through a 0.45 
µm filter and fluorescence intensity (ex. 482 nm, em. 515 nm) was recorded using a Gemini 
Fluorescence Microplate Reader running SoftMax Pro (Molecular Devices). The cells used 
in the negative control were solubilized with the addition of 4% cholic acid and incubated 
for 4 hrs at room temperature with gentle agitation. Supernatants were collected, filtered 
through a 0.45 µm filter and fluorescence intensity was recorded and used as the baseline 
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value for total cholesterol present within the cells. The percent cholesterol efflux was 
calculated as fluorescence intensity of media divided by fluorescence intensity of cholic 
acid. 
5.2.4 Nitroblue tetrazolium assay 
A microscopy-based nitroblue tetrazolium (NBT) assay protocol was used to assess 
macrophage NADPH oxidase activity.61 Apoptotic Jurkat cells were prepared according to 
Chapter 2.8.2.2 and added at a multiplicity of infection (MOI) of 10 to PMA-differentiated 
THP-1 cells and briefly centrifuged for 1 min at 400 ×g to force contact between the 
macrophages and apoptotic cells. NBT was added to a final concentration of 100 µg/mL 
and the assay was allowed to incubate for 1 hr at 37 °C and 5% CO2. Following incubation, 
cells were washed 3× 5 min to remove unbound apoptotic cells and excess NBT reagent. 
Cells were fixed with 4% PFA for 20 min at room temperature. Cells were then washed 3× 
5 min with PBS and coverslips were mounted onto glass slides using Permafluor for 
imaging. Fluorescence of diformazan deposits formed were imaged on an epifluorescence 
microscope at 630× magnification using a solid-state white light source in conjunction with 
a 650/670 nm bandpass excitation filter and a 700/50 nm bandpass emission filter.  
5.2.5 Dextran fusion assay 
Dextran fusion assay to quantify phagolysosomal fusion was performed according to the 
protocol of Flannagan et al.62 PMA-differentiated THP-1 macrophages were treated with 
100 µg/mL 10,000 MW TRITC-conjugated dextran for at least 16 hrs at 37 °C and 5% 
CO2. Dextran-loaded macrophages were washed 3× with PBS to remove excess dextran 
and then incubated in serum-free RPMI for 1.5 hrs at 37 °C and 5% CO2 to allow for 
loading of the dextran onto the lysosomal compartment. IgG-coated beads prepared 
according to Chapter 2.8.2.1 were added to macrophages at a MOI of 10 and the mixture 
was briefly centrifuged for 1 min at 400 ×g to force contact between macrophages and 
beads. The assay was allowed to incubate for 30 min at 37 °C and 5% CO2. Following 
incubation, cells were washed 1× with PBS to remove unbound beads and labelled 1:1,000 
with a Cy5-conjugated anti-human IgG secondary antibody to label bound but 
uninternalized beads. Cells were subsequently washed 3× 5 min with PBS and fixed with 
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4% PFA for 20 min at room temperature. Following fixation, cells were washed 3× 5min 
to remove excess PFA and coverslips were mounted onto glass slides using Permafluor. 
Assays were imaged under epifluorescence microscopy at 630× magnification with a 
550/570 nm bandpass excitation filter and a 605/52 nm bandpass emission filter (TRITC-
dextran) and a 650/670 nm bandpass excitation filter and a 700/50 nm bandpass emission 
filter (Cy5-conjugated anti-human IgG). 
5.2.6 Phagosome acidification assay 
Human IgG was labelled using a pHrodo Red Microscale Labeling Kit (Invitrogen) as per 
the manufacturer’s instructions. 5 µm polystyrene/DVB beads were coated with a 50:1:1 
ratio of unlabeled:pHrodo-conjugated:AF647-conjugated human IgG as per our published 
protocols.63,64 Beads were added to PMA-differentiated THP1 macrophages at a MOI of 
10 and time-lapse images on the white light, pHrodo (ex. 550/570 nm bandpass filter, em. 
605/52 nm bandpass filter) and AF647 (ex. 650/670 nm bandpass filter, em. 700/50 nm 
bandpass filter) channels were recorded at 630× magnification, 1 frame-per-minute, for 60 
min. At the end of the imaging period, the cell culture medium was replaced with 
calibration buffers of known pH (140 mM KCl, 1 mM MgCl2, 0.2 mM EGTA, 20 mM 
NaCl with either 20 mM MES (pH 4 and 5) or 20 mM HEPES (pH 6 and 7)). Images were 
captured on the pHrodo and AF647 channels after each pH change. Using FIJI,65,66 
phagocytosed beads were identified in the DIC channel, and the intensity of the pHrodo 
and AF647 signal on individual beads recorded at each time point starting immediately 
prior to phagosome closure through to the end of the time-lapse. For each phagosome, at 
each time point, the pHrodo signal was normalized using the AF647 channel, and then the 
calibration curve for the phagosome used to determine the pH of the phagosome at each 
time point. 
5.2.7 Anti-modified citrulline staining 
Anti-modified citrulline (AMC) staining was employed to detect citrullinated peptides in 
patient aortic punch tissue sections, according to the protocol developed by Vossenaar et 
al.67 From FFPE sections prepared according to Chapter 2.2.3.2. Sections were de-
paraffinized through sequential exposure to: xylene 2× 5-10 min, 100% ethanol 2× 5-10 
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min, 95% ethanol 2× 5-10 min, 75% ethanol 2× 5-10 min, ddH2O 2× 5-10 min and PBS 
1× 20 min. Follow de-paraffinization, the citrulline modification step was performed using 
the Anti-Citrulline (Modified) Detection Kit (Sigma-Aldrich) according to the 
manufacturer’s instructions for 3 hrs at 37 °C. Antigen retrieval was performed using the 
Trypsin Enzymatic Antigen Retrieval Solution (Abcam) according to the manufacturer’s 
instructions with a 30 min room temperature incubation period. Following modification, 
sections were incubated for a further 30 min with 3% H2O2 to block endogenous 
peroxidases. Sections were washed 3× 5 min with PBS and blocked with 10% goat serum 
for 30 min at room temperature. Sections were then incubated with either 1% goat serum 
(negative control), 1µg/mL normal human IgG (isotype control), or 1:1,000 anti-peptidyl-
citrulline antibody (Sigma-Aldrich, clone F95) overnight at room temperature. Excess 
antibody was removed by washing 3× 5 min with PBS and 1:2000 of 0.8mg/mL goat anti-
human HRP conjugate was applied to the sections for 1 hr at room temperature. Sections 
were then developed with Vector DAB HRP substrate (Vector Laboratories) was applied 
for 2-10 min until staining reaches an appropriate level. Sections were rinsed with PBS to 
stop the reaction and then washed a further 2× 10 min with PBS. Sections were then 
counterstained with haemotoxylin for 5 min, rehydrated with increasing concentrations of 
ethanol followed by xylene. Sections were then mounted on glass coverslips using Cytoseal 
60. 
AMC staining of cultured THP-1 macrophages was performed using a modified version of 
the procedure outlined above. To label individual cells, 1mg/mL Cy5-conjugated wheat 
germ agglutinin was added 1:200 to cells for 10 min protected from light and washed 3× 5 
min with PBS. Cells were then fixed in 2% PFA for 15 min at room temperature, washed 
3× 5min with PBS, and then permeabilized with 0.2% Triton X-100 for 10 min at room 
temperature. Citrulline modification step was performed as described above. Cells were 
washed 3× 5 min with PBS and blocked with 5% fetal bovine serum for 3 hrs at room 
temperature. Thereafter, cells were incubated with 1% goat serum (negative control), 
1µg/mL normal human IgG (isotype control), or 1:1,000 of 1mg/mL anti-peptidyl-
citrulline antibody (Sigma-Aldrich, clone F95) for 1 hr at room temperature. Cells were 
again washed 3× 15 min with PBS and then incubated with 1:1,000 of 1mg/mL Cy3-
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conjugated goat anti-human IgG for 30 min at room temperature. Cells were washed 3× 15 
min with PBS and mounted onto glass slides using Permafluor.  
 
5.3 Results 
5.3.1 Confirmation of GATA2 expression in patient aortic punch 
macrophages 
We observed a significant upregulation of GATA2 expression in patient aortic punch 
macrophages in our microarray dataset (Chapter 4.3.4) and subsequently verified this in a 
set of independent patient and control macrophage samples by RT-qPCR (Chapter 4.3.5). 
Our results from qPCR indicated that not only was GATA2 significantly upregulated in 
patient macrophages, it was expressed at much higher levels than detected by microarray. 
To confirm that GATA2 is specifically expressed in lesion-resident macrophages, we 
performed immunofluorescence imaging of sectioned patient aortic punch tissues stained 
for human GATA2 and the human pan-macrophage marker CD68 (Figure 5.3a). 
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Figure 5.3 Co-localization of GATA2 expression with patient lesion-resident CD68+ 
macrophages. 
Patient aortic punch tissue sections were stained for GATA2 and the pan-macrophage 
marker CD68. Sectioned were subsequently imaged using a fluorescence microscope to 
examine co-localization between GATA2 and CD68+ cells. The image is representative of 
(a) and the graph quantifies (b) localization of GATA2 within CD68+ across N = 3 patients 
shown as mean ± SEM. LUM = lumen, INT = intima. ***p < 0.001 by unpaired, two-tailed 
Student’s t test. Scale bar = 20 µm. 
We observed co-localization of GATA2 with approximately 50% of CD68+ cells within 
the intima (Figure 5.3b), indicating that expression of GATA2 is heterogenous across the 
population of lesion-resident macrophages. It is also possible that a number of these CD68+ 
cells are smooth muscle cells that have adopted a foam cell-like phenotype,68 however this 
experiment was not designed to be able to discriminate between these two cell populations.  
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5.3.2 Generation of an in vitro model of atherosclerotic macrophages 
To study the effects of GATA2 on macrophage function, we first generated an in vitro 
model of atherosclerotic macrophages through exposure of human monocyte-like THP-1 
cells to oxLDL following PMA-differentiation based on the method of Seo et al.14 
Characterization of Oil Red O accumulation in THP-1 macrophages incubated with 100 
µg/mL oxLDL by white light microscopy (Figure 5.4a) or quantification of Oil Red O 
content extracted from cells by measurement of absorbance at 420 nm by 
spectrophotometer (Figure 5.4b) demonstrated a linear increase in intracellular lipid 
content over a period of 24 hrs, resulting in cells that resemble cholesterol-laden foam cells 
in appearance. Due to the kinetics of GATA2 expression in THP-1 cells exposed to oxLDL, 
we also examined sustained exposure of THP-1 cells to oxLDL over a period of 72 hrs and 
again demonstrated a significant increase in intracellular lipid content in these cells as 
compared to cells cultured for 72 hrs without exogenous oxLDL (Figure 5.4c). 
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Figure 5.4 Exposure to oxLDL induces an increase in intracellular lipid content in 
THP-1 macrophages. (on opposite page) 
THP-1 monocyte-like cells were incubated with 100 µg/mL human oxLDL over a period 
of 48 (a, b) or 72 hrs (c). (a) Cells were stained with Oil Red O following 0, 12, 24 and 48 
hrs incubation with oxLDL and imaged under a white light microscope. (b) Cells were 
incubated with oxLDL for the time points specified previously and stained with Oil Red 
O. Intracellular Oil Red O was quantified at 420 nm as a proxy of total intracellular lipid 
content. (c) Cells were incubated with oxLDL for 0 or 72 hrs and intracellular Oil Red O 
content was quantified at 420 nm. Data are presented as mean ± SEM of N = 3 replicates. 
*p < 0.05 compared to Time = 0 hrs by 1-way ANOVA with Sidak multiple comparison 
test (b) or compared to oxLDL concentration = 0 µg/mL by unpaired, two-tailed Student’s 
t test. Scale bar = 10 µm. 
Accumulation of intracellular lipid droplets is perhaps the most important feature of lesion-
resident atherosclerotic macrophages and foam cells. We demonstrate here that incubation 
of THP-1 macrophages with human oxLDL for at least 48 hrs is sufficient to induce 
significant amounts of intracellular lipid accumulation in these cells, suggesting that we 
are able to re-capitulate at least part of the lesion-resident atherosclerotic phenotype in 
vitro.  
5.3.3 Exposure to oxLDL induces GATA2 expression in THP-1 and 
primary human macrophages 
After confirming that exposure to oxLDL in vitro can induce an atherosclerosis-like 
phenotype in THP-1 macrophages, we went on to determine whether oxLDL exposure is 
sufficient to induce upregulation of GATA2 expression in both THP-1 cells and primary 
human macrophages. We incubated THP-1 cells with 100 µg/mL oxLDL and primary 
human macrophages with 50 µg/mL oxLDL (100 µg/mL oxLDL resulted in toxicity in 
these cells, data not shown) over 72 hrs and quantified GATA2 expression by RT-qPCR 
over this time period (Figure 5.5).  
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Figure 5.5 Exposure to oxLDL is sufficient to induce upregulation of GATA2 
expression in macrophages. 
Quantification of relative GATA2 expression in macrophage cells following exposure to 
oxLDL. PMA-differentiated THP-1 macrophages (a) or ex vivo monocyte-derived primary 
human macrophages (b) were incubated with 100 or 50 µg/mL human oxLDL respectively 
for up to 72 hrs. GATA2 expression levels were measured by RT-qPCR at various time 
points and normalized to GATA2 expression at Time = 0 hrs. Data are shown as mean ± 
SEM from N = 3 biological replicates. *p < 0.05 compared to Time = 0 hrs by 1-way 
ANOVA with Sidak multiple comparisons test. 
Incubation with oxLDL resulted in a linear increase in the level of GATA2 expression in 
THP-1 macrophages but this increase was not significant compared to baseline until 72 hrs 
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post-oxLDL exposure (Figure 5.5a). With respect to primary human macrophages, we did 
not observe an increase in GATA2 until 72 hrs of incubation with oxLDL but we did not 
find this increase to be significantly different compared to baseline (Figure 5.5b). This 
may be a result of the lower concentration of oxLDL used in the primary human 
macrophage experiments or it could be that a longer incubation period is required. 
However, on the basis of this data and the previous section, incubation with oxLDL for a 
period of 72 hrs is sufficient to induce cholesterol accumulation within THP-1 
macrophages accompanied by a significant increase in GATA2 expression. 
5.3.4 Generation of GATA2 overexpression and knockdown cell lines 
To study the effect of perturbing GATA2 expression both in the presence and absence of 
oxLDL, we generated stable GATA2 overexpression and knockdown THP-1 cell lines. To 
generate a GATA2 overexpression vector, the human GATA2 consensus coding sequence 
was cloned into a pLVX-IRES-ZsGreen1 backbone, a lentiviral expression vector that 
allows simultaneous expression of GATA2 along with the ZsGreen1 fluorophore under a 
CMV promoter (see Figure 5.6a for cloning strategy and Appendix A for sequences of ). 
To generate a GATA2 knockdown vector, shRNA sequences targeting human GATA2 
were generated using the siRNA Wizard Software 3.1 (InvivoGen). Each shRNA generated 
was cloned into a pGFP-C-shLenti backbone, a lentiviral shRNA expression vector that 
allows simultaneous expression of a GATA2 shRNA and the TurboGFP fluorophore under 
a SV40 promoter (see Figure 5.6b for cloning strategy for most effective shRNA 
sequence). See Appendix A for the sequence of the most effective shRNA sequence. 
 
 
Figure 5.6 Cloning strategy for GATA2 overexpression and knockdown vectors. (on 
opposite page) 
Cloning strategy employed to create the (a) GATA2 overexpression (pLVX-IRES-
ZsGreen1 GATA2) and (b) knockdown (pGFP-C-shLenti GATA2 shRNA1) vectors. 
Diagrams were created using SnapGene Version 4.3 (GSL Biotech). 
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The GATA2 overexpression vector was packaged into a lentivirus and stably transduced 
into THP-1 cells. Transduced cells were sorted to contain only successfully-transfected cell 
populations by a fluorescence-activated cell sorting strategy using a FACSAria III Flow 
Cytometric Cell Sorter (BD Biosciences) and gating on the 10% of live cells expressing 
the highest levels of green fluorescence (data not shown). Immunofluorescence imaging 
demonstrated that in ZsGreen1+ cells that were successfully transduced with the 
overexpression vector, GATA2 is significantly overexpressed (Figure 5.7a). As expected, 
controls transduced with an empty pLVX-IRES-ZsGreen1 vector did not show any 
GATA2 expression (Figure 5.7a). We examined this at the protein level, measuring 
GATA2 protein expression by Western blot in stably-transduced THP-1 cells. GATA2 
protein levels were increased in the transduced THP-1 cells as compared to a untransduced 
control, as demonstrated by the Western blot (Figure 5.7b) and densitometry quantification 
thereof (Figure 5.7c). Finally, we confirmed upregulation of GATA2 expression in 
transduced THP-1 cells by RT-qPCR (Figure 5.7d). 
 
Figure 5.7 Generation of a stably-transduced THP-1 GATA2 overexpression cell line. 
(on opposite page) 
A stably-transduced THP-1 GATA2 overexpression cell line was generated through 
lentiviral transduction of the pLVX-IRES-ZsGreen1 GATA2 vector into THP-1 cells and 
a pure GATA2-overexpression THP-1 population was obtained through FACS sorting of 
ZsGreenbright cells. (a) Stably-transduced THP-1 were immunostained for human GATA2, 
using THP-1 cells transduced with an empty pLVX-IRES-ZsGreen1 vector as a negative 
control. (b) Demonstration of GATA2 protein production in stably-transduced THP-1 as 
compared to a negative control transduced with the empty vector by Western blotting, and 
(c) quantification thereof by band densitometry analysis. (d) Measurement of GATA2 
overexpression in stably-transduced cells by RT-qPCR compared to cells transduced with 
an empty vector control. Images and graph are representative of (a-c) or quantifies (d) N 
=3 biological replicates. Data are shown as mean (c) or mean ± SEM (d). **p < 0.01 by 
unpaired, two-tailed Student’s t test. Scale bar = 10 µm.  
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Since THP-1 cells do not produce appreciable levels of endogenous GATA2, it was not 
possible to test the efficiency of shRNA constructs on knocking down GATA2 expression 
in these cells directly. Instead, we adopted a strategy of co-transfecting the GATA2 
overexpression and the shRNA vectors into HEK cells. This allowed us to determine the 
degree to which each shRNA construct created could inhibit GATA2 overexpression. We 
demonstrated that the most effective shRNA construct (hereafter referred to as shRNA1) 
could reduce GATA2 protein expression by approximately 50% (Figure 5.8a, 5.8b). The 
shRNA1 sequence was used to generate the GATA2 knockdown vector, which was stably-
transduced into THP-1 cells and sorted by FACS to generate a pure GATA2 knockdown 
THP-1 cell population (data not shown). Analysis of GATA2 mRNA levels in stably-
transduced THP-1 cells following oxLDL exposure showed a significant reduction in 
GATA2 levels in the cells expressing the GATA2 shRNA compared to cells transduced 
with a scrambled shRNA control (Figure 5.8c).  
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Figure 5.8 Generation of a stably-transduced THP-1 GATA2 knockdown cell line. 
A stably-transduced THP-1 GATA2 knockdown cell line was generated through lentiviral 
transduction of the pGFP-C-shLenti GATA2 shRNA1 vector into THP-1 cells and a pure 
GATA2-knockdown THP-1 population was obtained through FACS sorting of 
TurboGFPbright cells. (a) Demonstrating that co-transfection of HEK cells with the GATA2 
overexpression and knockdown vectors results in a decrease in GATA2 protein levels 
compared to co-transfection of HEK cells with the overexpression vector and a scrambled 
shRNA control by Western blotting, and (b) quantification thereof by band densitometry. 
Empty = empty pLVX-IRES-ZsGreen1 vector, scr = scrambled shRNA vector. THP-1 
GATA2 knockdown cell line was generated through lentiviral transduction of the pGFP-
C-shLenti GATA2 shRNA1 vector into THP-1 cells and a pure GATA2-knockdown THP-
1 population was obtained through FACS sorting of TurboGFPbright cells. (c) Quantification 
of GATA2 knockdown in stably-transduced GATA2-knockdown THP-1 cells incubated 
with human oxLDL for 72 hrs compared to cells transduced with a scrambled shRNA 
control by RT-qPCR. Image and graph are representative of (a, b) or quantifies (c) N = 3 
biological replicates. Data are shown as mean (b) or mean ± SEM (c). *p < 0.05 by 
unpaired, two-tailed Student’s t test. 
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5.3.5 Perturbation of GATA2 expression does not alter macrophage 
cholesterol metabolism 
Following the generation of stably-transduced GATA2 overexpression and knockdown 
THP-1 cell lines, we used these cells to examine the effect of perturbing GATA2 
expression on macrophage cholesterol handling. Cholesterol loading in macrophages with 
exposure to oxLDL was measured by observing accumulation of the lipophilic dye Nile 
Red in THP-1 macrophages over a period of 8-12 hrs (Figure 5.9a). THP-1 macrophages 
continually accumulate cholesterol over a period of 12 hrs, with the most rapid rate of 
accumulation occurring between 4-8 hrs of oxLDL exposure and slowing down after 8 hrs 
(Figure 5.9b).  
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Figure 5.9 Perturbation of GATA2 expression does not have a consistent effect on 
macrophage cholesterol handling. (on opposite page) 
Cholesterol handling was assessed in THP-1 cell lines with differing levels of GATA2 
expression. (a) Accumulation of cholesterol in THP-1 macrophages imaged with live cell 
Nile Red staining over a period of 12 hrs, and (b) quantification of these images 
demonstrating intracellular cholesterol accumulation. (c) Accumulation of cholesterol over 
8 hrs in THP-1 cells with differing levels of GATA2 expression. (d and e) Cholesterol 
efflux from THP-1 macrophages grown under normal (Control) or hyperlipidemic 
(oxLDL) conditions quantified using fluorescent BODIPY-labelled cholesterol shown as 
percent efflux from baseline (d) or relative to the degree of cholesterol efflux in cells grown 
in normal conditions (e). WT = wild type THP-1 cells, GATA = GATA2 overexpressing 
THP-1 cells, shRNA = GATA2 knockdown THP-1 cells. Colours in (a) are representative 
of Nile Red fluorescence intensity. Data are representative of (a) or quantifies (b - e) a 
minimum of N = 3 biological replicates. Data are shown as mean ± SEM. (b) ***p < 0.001 
and ****p < 0.0001 compared to Time = 0 hrs by 1-way ANOVA with Sidak multiple 
comparisons test, (d, e) #p < 0.05 compared to the WT + Control condition and *p < 0.05 
compared to Control condition in the same cell line by 2-way ANOVA with Tukey’s post-
hoc test. Scale bar = 10 µm. 
We examined cholesterol accumulation by Nile Red staining of live wild type, GATA2 
overexpressing and GATA2 knockdown THP-1 macrophages, and we did not find any 
difference in the rate or degree of cholesterol accumulation between these cells over a 
period of 8 hrs (Figure 5.9c), suggesting that perturbation of GATA2 expression does not 
significantly affect the rate of cholesterol accumulation in macrophages. We also measured 
the rate of cholesterol efflux in wild type, GATA2 overexpressing and GATA2 knockdown 
THP-1 macrophages cultured normally or in the presence of human oxLDL. GATA2 
overexpression significantly increased the rate of cholesterol efflux, suggesting that 
GATA2 expression may be an adaptive response to elevated cholesterol stress. However, 
this enhanced efflux was not retained in the presence of oxLDL, and unexpectedly, GATA2 
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knockdown had no effect on the efflux rate (Figures 5.9d and 5.9e). Regardless of the level 
of GATA2 expression, neither enhanced or impaired cholesterol efflux was observed under 
hyperlipidemic conditions, suggesting that the enhanced efflux of cholesterol observed in 
GATA2-overexpressing cells is suppressed by the presence of oxLDL via a non-GATA2 
pathway (Figure 5.9e).  
5.3.6 oxLDL exposure and perturbation of GATA2 expression alters 
macrophage phagocytic/efferocytic capacity and phagosome/ 
efferosome maturation 
We went on to determine the effect of perturbing GATA2 expression on macrophage 
efferocytic capacity and efferosome maturation. We first examined the impact of GATA2 
overexpression and knockdown on the capacity of macrophages to internalize IgG-coated 
beads (Figure 5.10a). GATA2 has previously been shown to regulate phagocytic activity 
in rat macrophages in the context of Pneumocystis carinii infection, where GATA2 
downregulation resulted in decreased macrophage phagocytic capacity.59 In contrast, in our 
hands human macrophages overexpressing GATA2 demonstrated significant impairment 
in their capacity to internalize the IgG-coated beads. This impairment was even more 
pronounced if the GATA2 overexpressing macrophages were cultured in the presence of 
oxLDL. Conversely, downregulation of GATA2 expression did not result in any significant 
impairment of phagocytic capacity and was actually sufficient to rescue the impairment in 
phagocytosis seen when wild type macrophages were cultured in the presence of oxLDL. 
The same trend was observed when we examined the capacity of our macrophages to 
efferocytose PS-coated beads (Figure 5.10b). Culturing wild type macrophages in the 
presence of oxLDL resulted in a decrease in efferocytic capacity, which is consistent with 
previously published literature.69,70 GATA2 overexpressing macrophages showed impaired 
efferocytotic capacity, regardless of whether they were cultured in the presence of oxLDL. 
While GATA2 overexpressing macrophages cultured with oxLDL showed slightly 
decreased efferocytic capacity compared to those cultured under normal conditions, this 
was not statistically significant. Interestingly, as with phagocytosis, GATA2 knockdown 
did not impair efferocytosis in macrophages cultured under normal conditions and restored 
efferocytic capacity in macrophages cultured in the presence of oxLDL. The same 
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observations held true when we used apoptotic Jurkat cells in place of PS-coated beads and 
quantified the fraction of individual apoptotic cells internalized by macrophages (Figure 
5.10c). Efferocytosis of apoptotic cells was markedly reduced both when wild type 
macrophages were cultured in the presence of oxLDL and by GATA2 overexpression 
independently of oxLDL levels. Again, no impairment in efferocytosis was observed in 
GATA2 knockdown macrophages and critically, GATA2 knockdown protected 
macrophages against the oxLDL-induced loss of apoptotic cell efferocytosis. 
 
Figure 5.10 GATA2 overexpression impairs macrophage phagocytic and efferocytic 
capacity. 
Phagocytic and efferocytic capacity in THP-1 macrophages with perturbed GATA2 
expression grown under normal (Control) or in the presence of human oxLDL (oxLDL) 
was assessed by phagocytosis and efferocytosis assays using a variety of bead-based 
phagocytic/efferocytic mimics and apoptotic cells. (a) Phagocytic index of THP-1 
macrophages incubated for 30 min with IgG-coated 5-µm polystyrene beads was assessed 
by fluorescence microscopy. (b) Efferocytic index of THP-1 macrophages incubated for 
60 min with PS-coated 3-µm silica beads was assessed by fluorescence microscopy. (c) 
THP-1 macrophages were co-incubated with fluorescently-labelled apoptotic Jurkat cells 
for 90 min and the fraction of apoptotic materials internalized by macrophages was 
assessed by microscopy. WT = wild type THP-1 cells, GATA = GATA2 overexpressing 
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THP-1 cells, shRNA = GATA2 knockdown THP-1 cells. Data quantifies a minimum of N 
= 3 biological replicates. Data are shown as mean ± SEM. #p < 0.05 compared to the WT 
+ Control condition and *p < 0.05 compared to Control condition in the same cell line by 
2-way ANOVA with Tukey’s post-hoc test. 
In addition to efferocytic uptake, proper maturation of the efferosome is equally important 
for proper processing of apoptotic cells, the avoidance of self-antigen presentation, and the 
generation of autoimmunity.71 Therefore, beyond simply assessing efferocytic capacity, we 
also sought to assess efferosome maturation in THP-1 macrophages with perturbed 
GATA2 expression. There are multiple mechanisms involved in proper efferosome 
maturation, including generation of superoxides within the efferosome through the action 
of NADPH oxidase, efferosome acidification driving by vacuolar ATPases and fusion 
between efferosomes and lysosomes (reviewed in detail in Chapter 5.1.3). 
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Figure 5.11 GATA2 overexpression impairs macrophage efferosome maturation. 
Efferosome maturation in THP-1 macrophages with perturbed GATA2 expression grown 
under normal (Control) or in the presence of human oxLDL (oxLDL) was assessed using 
a number of functional assays. (a, b) Nitro blue tetrazolium assay was used to measure 
NADPH oxidase activity in THP-1 macrophages. Fluorescence intensity of diformazan 
deposits was quantified as a measure of superoxide production. (c, d) Macrophages were 
pulsed with tetramethylrhodamine-conjugated dextran to label cellular lysosomal 
compartments and then allowed to internalize IgG-coated beads. Phagolysosomal fusion 
was monitored by fluorescence microscopy as internalized beads that have accumulated 
dextran. (e, f) Phagocytosis assays with pHrodo- and IgG-coated beads were imaged using 
live cell fluorescence microscopy over a period of 60 min at 1 frame/min to determine 
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terminal phagosome pH and phagosomal acidification rate for the first five minutes post-
complete phagosomal closure respectively. WT = wild type THP-1 cells, GATA = GATA2 
overexpressing THP-1 cells, shRNA = GATA2 knockdown THP-1 cells. Images are 
representative of (a, c) N =3 biological replicates. Graphs quantify N = 3 biological 
replicates (d-f) or 30 individual cells across N = 3 biological replicates (b). White arrows 
indicate beads that have been internalized (c). Data are shown as mean ± SEM. #p < 0.05 
compared to the WT + Control condition and *p < 0.05 compared to Control condition in 
the same cell line by 2-way ANOVA with Tukey’s post-hoc test. Scale bar = 10 µm. 
To assess NADPH oxidase activity, we allowed macrophages to efferocytose apoptotic 
Jurkat cells in the presence of nitro blue tetrazolium, which reacts with superoxide radicals 
to form a fluorescent diformazan precipitate (Figure 5.11a and 5.11b). Macrophages 
cultured in the presence of oxLDL show reduced NADPH activity, as do GATA2 
overexpressing macrophages, even in the absence of oxLDL. GATA2 knockdown does not 
significantly alter NADPH activity, however, in contrast to what was observed with 
phagocytic and efferocytic capacity, GATA2 knockdown does not completely rescue the 
defect in superoxide production in macrophages cultured with oxLDL. 
To assess whether phagolysosomal fusion would also be impaired in our model system, we 
performed a pulse-chase experiment with fluorescently-labelled dextran to assess fusion 
between lysosomes and phagosomes containing IgG-coated beads (Figures 5.11c and 
5.11d). Consistent with the previous observations, we noted a slight but statistically 
significant decrease in phagolysosomal fusion in macrophages cultured with oxLDL and 
in GATA2 overexpressing macrophages. In contrast, GATA2 knockdown macrophages 
did not display any impairment in phagolysosomal fusion and indeed, GATA2 knockdown 
was sufficient to prevent impaired phagolysosomal fusion in macrophages cultured with 
oxLDL. 
We assessed vacuolar ATPase activity by first assessing the terminal pH of maturing IgG 
phagosomes (Figure 5.11e) following internalization of IgG- and pHrodo-coated beads (as 
efferosome and phagosome acidification are thought to be driven by the same 
mechanisms). We observed both a failure to reach an appropriate terminal phagosome pH 
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in macrophages cultured with oxLDL. The same held true for GATA2 overexpressing 
macrophages, regardless of whether or not they were cultured in the presence or absence 
of oxLDL, and again, these impairments were rescued in GATA2 knockdown 
macrophages. 
Since lysosome fusion was impaired (Figure 5.11d), it is possible this lack of phagosome 
acidification was due to poor lysosome fusion rather than decreased vATPase expression. 
To assess this possibility, we quantified the rate of acidification in the first five minutes 
following phagosome closure, which is prior to the time of phagosome-lysosome fusion.72 
The same trends were observed in the early acidification rate as were observed with 
phagosome terminal pH, confirming that oxLDL-driven GATA2 overexpression impairs 
phagosome acidification, at least in part, through decreased expression of the vATPase 
(Figure 5.11f). 
5.3.7 oxLDL exposure but not perturbation of GATA2 expression alters 
peptide citrullination in macrophages 
Amongst the genes found to be upregulated in patient macrophages in our microarray 
dataset was PADI3, a member of the peptide arginine deaminase (PAD) family of enzymes 
that catalyze peptide citrullination and which play a central role in the pathogenesis of 
rheumatoid arthritis.67,73 There is a well-established connection between rheumatoid 
arthritis and increased cardiovascular disease risk, with aberrant presentation of self-
antigen within the atherosclerotic plaque being a potential driver of autoimmune 
disease.74,75 We therefore sought to assess whether peptide citrullination was occurring 
with the atherosclerotic lesions in our patient aortic punch tissue samples and whether 
GATA2 drives increased peptide citrullination in the context of atherosclerotic disease. 
IHC staining of sectioned patient aortic punch tissue with an AMC antibody demonstrated 
evidence of peptide citrullination specifically within the aortic intima (Figure 5.12a). 
Experimental evidence shows that macrophages (and monocytes) in patients with 
rheumatoid arthritis express increased levels of PAD enzymes.76 We therefore examined 
PADI3 gene expression levels in both patient and control macrophages and PADI3 levels 
were found to be significantly increased in patient macrophages (Figure 5.12b). As we 
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have previously demonstrated, oxLDL is a crucial environmental ligand that induces 
macrophages to become impaired in efferocytic uptake and efferosome maturation. Here, 
we show that THP-1 macrophages cultured in the presence of oxLDL also showed 
increased expression of PADI3 as compared to macrophages cultured under control 
conditions (Figure 5.12c). Indeed, we could further demonstrate the exposure of THP-1 
macrophages to oxLDL resulted in the generation of citrullinated peptides in vitro (Figure 
5.12d).  
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Figure 5.12 oxLDL exposure but not GATA2 expression drives PADI3 expression and 
peptide citrullination in atherosclerotic macrophages. (on opposite page) 
The degree of peptide citrullination and PADI3 enzyme expression was assessed in both 
patient aortic punch tissues and atherosclerotic THP-1 macrophages. (a) FFPE patient 
aortic punch tissue sections were immunostained for modified citrulline with an AMC 
antibody (AMC) or an IgG isotype (IgG) as a negative control; AMC = anti-modified 
citrulline. (b, c) Quantification of PADI3 expression by RT-qPCR in patient and control 
macrophages (b) and THP-1 macrophages cultured under normal (Control) and 
hyperlipidemic (oxLDL) conditions (c). (d) Immunofluorescence staining of THP-1 
macrophages cultured for 72 hrs in the presence (oxLDL) or absence (Control) of human 
oxLDL with an AMC antibody (AMC) or an IgG isotype (IgG) as a negative control. 
Individual cells are labelled using a AF647-conjugated wheat germ agglutinin (WGA). (e 
– g) Immunofluorescence staining of wild type THP-1 macrophages (e), GATA2 
overexpressing THP-1 macrophages (f) and GATA2 knockdown THP-1 macrophages (f) 
cultured under either normal (Control) or hyperlipidemic (oxLDL) conditions using an 
AMC antibody (AMC) or IgG isotype (IgG) as a negative control. Images are 
representative of either N = 3 individual patients (a) or N = 3 biological replicates (d). 
Graphs are representative of N = 5 individual patients (b), N = 3 biological replicates (c) 
or 30 cells across N = 3 biological replicates (e – g). Data are shown as mean ± SEM. *p < 
0.05 by unpaired, two-tailed Student’s t test (b, c), ***p < 0.001 and ****p < 0.0001 by 1-
way ANOVA with Tukey’s post-hoc test (e – g). Black arrows indicate the vessel intima. 
Scale bars = 100 µm (a) or 10 µm (d). 
We then sought to determine the role of perturbed GATA2 expression on oxLDL-induced 
peptide citrullination in THP-1 macrophages. The degree of peptide citrullination as 
quantified by immunofluorescence staining of macrophages with the AMC antibody was 
assessed in wild type THP-1 macrophages (Figure 5.12e), GATA2 overexpressing THP-1 
macrophages (Figure 5.12f) and GATA2 knockdown macrophages (Figure 5.12g). In 
each case, we found that little to no peptide citrullination occurred in the absence of oxLDL 
regardless of the GATA2 expression level, whereas for cells cultured with oxLDL peptide 
citrullination was observed at comparable levels regardless of GATA2 expression. 
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5.3.8 GATA2 overexpression is driven by signaling through ERK and 
the Src family kinases 
We next sought to determine the upstream signaling pathways that contribute to GATA2 
upregulation in response to stimulation with oxLDL. There are a number of canonical 
oxLDL receptors that are expressed on the cell surface of human macrophages, including 
members of the class A and B scavenger receptors (in particular CD36) and TLR4. CD36 
and TLR4 are able to activate a number of distinct downstream signal transduction 
pathways.13 Wu et al. have shown that stimulation of TLR4 by LPS drives GATA2 
upregulation in a MEK/ERK-dependent pathway.32 This pathway may be specifically 
inhibited using the small molecule inhibitor U0126.77 Heit et al. have demonstrated that 
CD36 internalizes ligands through engagement with Src-family kinases (SFK’s) and Syk.78 
The small molecule inhibitors protein phosphatase 1 (PP1) and Syk inhibitor (SykI) are 
small molecule inhibitors of SFK’s and Syk respectively.78,79 
Using these small molecule inhibitors, we inhibited in turn the activity of SFK’s (Figure 
5.13a), MEK/ERK (Figure 5.13b) and Syk (Figure 5.13c) in THP-1 macrophages cultured 
with human oxLDL for 72 hrs. Compared to a DMSO-treated control, macrophages treated 
with PP1 or SykI exhibited significantly impaired GATA2 upregulation in response to 
oxLDL stimulation. Treatment with U0126 had no effect on GATA2 upregulation. 
Downstream of these signaling pathways, we did not determine experimentally which 
transcription factor(s) are involved in oxLDL-driven GATA2 upregulation. However, 
previous studies have suggested that SP1 is important in driving GATA2 expression. SP1 
is phosphorylated downstream of the c-Src/Syk signaling pathway following ligand 
engagement by CD36.80,81 Therefore, SP1 is a likely candidate for activating GATA2 
transcription in response to oxLDL-driven signaling through the c-Src/Syk pathway 
downstream of CD36 (Figure 5.13e).  
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Figure 5.13 oxLDL-induced GATA2 upregulation requires signaling through the Src 
pathway. 
THP-1 macrophages were cultured in the presence of oxLDL for 72 hrs with 200 nM PP1 
(a), 2 nM U0126 (b) or 10 µM SykI (c). GATA2 expression in these cells were compared 
to THP-1 macrophages cultured for 72 hrs with oxLDL and a DMSO vehicle control (Veh). 
(d) Schematic of oxLDL-induced GATA2 upregulation in human macrophages. Data are 
shown as mean ± SEM and quantify N = 3 biological replicates. *p < 0.05 by unpaired, 
two-tailed Student’s t test.  
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5.3.9 GATA2 trends toward being elevated in Ldlr-/- mice fed a high-fat 
diet 
Finally, we examined Gata2 expression levels in the aorta of Ldlr-/- mice fed high-fat, high-
cholesterol (HFHC) or standard chow diet for 12 weeks by RT-qPCR (Figure 5.14). The 
expression of Gata2 was consistently low in the plaques of Ldlr-/- mice fed a normal diet, 
but underwent a highly heterogeneous response in response to a high-fat diet. These data 
suggest that GATA2 may be upregulated in Ldlr-/- mice in response to a high-fat diet, but 
this protocol requires further refinement before conclusive data can be generated. 
 
Figure 5.14 Gata2 expression trends towards being increased in high-fat diet 
atherosclerotic mice. 
Ldlr-/- knockout mice were maintained for 12 weeks on a chow (CHOW) or high-fat (HDF) 
diet. At 12 weeks, mice were sacrificed, and their aortas dissected for use in RT-qPCR 
studies that measured Gata2 expression. Data summarize N = 3 mice in each group and are 
presented as mean ± SEM. The difference in Gata2 expression was found to not be 
statistically significant by a two-tailed, unpaired Student’s t test. 
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5.4 Discussion 
In this Chapter, we examined the impact of perturbing GATA2 expression on macrophage 
cholesterol handling, peptide citrullination and efferocytosis/efferosome maturation using 
an in vitro model of atherosclerotic macrophages. We found that GATA2 overexpression 
was sufficient to impair macrophage efferocytotic uptake and efferosome maturation, even 
in the absence of pro-atherogenic stimuli. Importantly, knockdown of GATA2 expression 
using an shRNA normalized efferocytosis and efferosome maturation when macrophages 
were exposed to oxLDL. Taken together, these data indicate that GATA2 acts as a master 
regulatory factor that appears to be required for oxLDL-mediated impairment of 
macrophage efferocytic uptake and efferosome maturation. However, we did not find any 
effect of GATA2 perturbation on either cholesterol handling nor peptide citrullination, 
suggesting that the effect of GATA2 is specific to macrophage apoptotic uptake and 
degradation.  
Our most interesting finding is the impact of perturbing GATA2 expression on efferocytic 
uptake of apoptotic cells and on subsequent efferosome maturation and processing of 
apoptotic cargo. We are able to replicate the finding that macrophage efferocytosis is 
impaired following exposure to oxLDL, but our data show that this effect appears to be 
dependent on the upregulation of GATA2 in response to this atherogenic stimulus. Indeed, 
we find that when GATA2 expression is abrogated using a shRNA, macrophages retain 
full efferocytic capacity. To date, mechanisms underlying impaired macrophage 
efferocytic capacity in atherosclerosis remain poorly defined. Cai et al. showed that 
ADAM17-mediated cleavage of a key efferocytic receptor, MerTK, results in increased 
plaque necrotic core size in Ldlr-/- mice.82 Our finding that oxLDL-mediated GATA2 
upregulation leads to impaired efferocytic capacity may represent an alternate mechanism 
driving defective efferocytosis in atherosclerotic plaques. Importantly, we have also found 
that perturbation of GATA2 expression had profound impacts on efferosome maturation in 
addition to efferocytic capacity. Our data show that GATA2 upregulation drives 
impairment in efferosomal NADPH oxidase activity and superoxide generation, 
efferosomal acidification and potentially interferes with efficient efferosome-lysosome 
fusion. Efficient efferosomal maturation and processing of cargo is essential for 
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macrophages in maintaining a rapid rate of efferocytosis, and impaired efferosomal 
maturation may partially explain how efferocytosis becomes defective in the course of 
atherosclerotic disease. Impaired apoptotic cargo degradation may also result in the 
generation of inflammation and autoimmunity. A number of investigators have identified 
rapid cargo degradation as a key mechanism in limiting antigen presentation. For example, 
Erwig et al. found that efferosomal maturation following apoptotic cell uptake by 
macrophages proceeded much faster than following uptake of IgG-coated pathogen 
mimics, while Yates et al. observed decreased phagosome degradative capacity following 
macrophage activation.83,84 Impaired efferosomal maturation, in addition to interfering 
with efficient apoptotic cell clearance, may also be a potential mechanism driving 
autoantigen presentation and autoimmunity in atherosclerosis. 
Another fascinating observation from our microarray dataset was the upregulation of the 
PADI3 enzyme in patient macrophages. Here, we demonstrate through IHC that peptide 
citrullination is present within the early atherosclerotic plaque. This is in agreement with 
the findings of Sokolove et al., who identified the presence of citrullinated fibrinogen 
within human atherosclerotic plaques by Western blot.85 While Sokolove et al. suggested 
that intra-plaque citrullination is driven by PADI4,85 our data implicates PADI3 as another 
player in this process. We demonstrated by RT-qPCR that PADI3 expression is upregulated 
within both atherosclerotic lesion-resident macrophages and in macrophages treated in 
vitro with oxLDL. While we did not find strong evidence that GATA2 affects the 
expression of PADI3 or the degree of peptide citrullination that occurs in atherosclerotic 
macrophages, exposure of macrophages to oxLDL is sufficient to induce citrullination in 
vitro regardless of the level of GATA2 expression. Increased risk of cardiovascular disease 
in patients with rheumatoid arthritis has been well established, thought to be the result of 
elevated inflammation in these patients.75,86 However, there is some evidence that the 
relationship is a reciprocal one, with atherosclerosis driving the genesis and/or progression 
of rheumatoid arthritis and other forms of autoimmune disease.87,88 Autoantibodies against 
oxLDL, HSP60 and ApoB100 (the major lipoprotein component of LDL) have been 
identified in patients with atherosclerosis.87 Furthermore, various T cell subsets have been 
isolated from human atherosclerotic plaques, with Th1 cells being the predominant type.88 
Whether these lesion-resident T cells also recognize and respond to the presence of 
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citrullinated peptides remains to be shown, but such a mechanism would help explain the 
high degree of coincidence between rheumatoid arthritis and atherosclerosis. 
There is some evidence that GATA2 could be involved in regulation of cholesterol 
handling in macrophages. Cheng et al. showed that leptin-mediated activation of GATA2 
expression and DNA binding resulted in the downregulation of the transcription factor 
PPARγ.89 PPARγ plays a number of important roles in the context of atherosclerosis. First, 
it is a major driver of anti-inflammatory activation and PPARγ agonists have been shown 
to demonstrate some protective effects in animal models of atherosclerosis through 
restraining inflammation within the atherosclerotic plaque.90,91 Simultaneously, Lee et al. 
have demonstrated that activation of PPARγ results in upregulation of ABCA1 and 
increases the rate of cellular cholesterol efflux.92 However, our data indicate that while 
GATA2 expression does enhance cholesterol efflux, this effect is lost in the presence of 
oxLDL and therefore cannot serve a protective function in the context of atherosclerosis. 
This could be a result of the potent activation of multiple pathways related to cholesterol 
metabolism as a result of oxLDL exposure that are antagonistic to either GATA2 
expression or function. These results are interesting, however, in that they suggest that 
GATA2 may be upregulated by macrophages in order to adapt to cellular stress, and that 
the negative impacts on phagocytosis and efferocytosis are an unwanted side-effect of this 
adaptive process. However, further work remains to be done in dissecting out the specific 
role of GATA2 in cholesterol handling during atherogenesis in order to fully explore this 
possibility.  
We have begun to define the signaling pathways upstream of oxLDL-induced GATA2 
upregulation. Inhibition of either Src family kinases or Syk results in decreased levels of 
GATA2 expression in response to oxLDL. Src and Syk are recruited downstream of ligand 
engagement by CD36, a class B scavenger receptor that plays a crucial role in recognition 
and internalization of oxLDL in macrophages.78,93 CD36 is activated as a multi-unit 
complex along with β1 and β2 integrins along with CD9 and CD81. This complex 
phosphorylates the signaling adaptor FcRγ, which, via its phosphorylated ITAM motifs 
and active SFKs, is capable of recruiting and activating Syk.78 While less well understood, 
the Toll-like receptors TLR2 and TLR4 are also known to be activated by oxLDL, and to 
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activate a similar Src/Syk pathway. The downstream targets of Src and Syk in the context 
of CD36 and TLR activation are poorly understood. However, a few recent studies of novel 
therapeutic agents in leukemia have shed light on one potential regulatory pathway that can 
drive GATA2 activation.94,95 Yang et al. have shown that inhibition of GATA2 by the 
proteasome inhibitor K-7174 results in sensitization of acute myeloid leukemia cells to 
chemotherapy.94 K-7174 is known to exert its activity on GATA2 via degradation of the 
transcription factor Sp1, which functions as a transactivator of class I histone deacetylases 
and promotes transcriptional activation of GATA2.95 Sp1 may be activated by Src family 
kinases or PI3K downstream of Syk signaling.80,96 Therefore, we propose a model whereby 
activation of CD36 by oxLDL results in Src and Syk signaling, which activates Sp1 and 
drives transcriptional activation and upregulation of GATA2. Whether Sp1 is able to 
directly bind upstream of GATA2 and drive transcription or if it functions through its 
chromosomal remodeling activity to allow other transcription factors to cooperatively drive 
GATA2 expression remains to be determined.  
To study the impact of GATA2 on efferocytosis, peptide citrullination and cholesterol 
handling, we established an in vitro cell culture model of atherosclerotic macrophages by 
incubating THP-1 cells with human oxLDL. We show that after 72 hrs of culture in the 
presence of oxLDL, THP-1 macrophages adopt a distinctive foam cell-like appearance, 
which is accompanied by upregulation of GATA2 expression. Culture of macrophages 
with oxLDL or another modified LDL is a well-established method of generating foam 
cells in vitro.10 While the precise type and concentration of lipoprotein as well as the culture 
time varies between different investigators, multiple groups have shown that oxLDL-
treated macrophages accumulate cholesterol and form lipid droplets in their 
cytoplasm.14,97,98 Cholesterol loading of macrophage also induces production of 
proinflammatory cytokines, including TNFα, IL-6 and IL-1β, as well as ER stress and the 
unfolded protein response.16,99 While we did not examine generation of proinflammatory 
cytokines and our in vitro system is certainly an oversimplification of the actual 
atherosclerotic plaque microenvironment, we were able to observe significant cholesterol 
accumulation and lipid droplet formation in our THP-1 macrophages. However, we are the 
first to report upregulation of GATA2 in response to cholesterol accumulation in both THP-
1 macrophage-like cells and primary monocyte-derived human macrophages. This 
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suggests that within the atherosclerotic plaque microenvironment, endogenous modified 
lipoproteins such as oxLDL are sufficient to induce GATA2 upregulation. 
In summary, we have identified the hematopoietic transcription factor GATA2 as a master 
regulator of defective efferocytosis in atherosclerotic macrophages. GATA2 upregulation 
impairs both the efferocytic uptake of apoptotic cells and multiple stages of the subsequent 
catabolic process which degrades the efferosomal cargo. This impairment in efferosomal 
maturation represents a previously unrecognized mechanism that not only drives defective 
apoptotic cell clearance in atherosclerosis but may also contribute to autoantigen 
presentation and the generation of inflammation and autoimmunity within the 
atherosclerotic plaque. Therefore, GATA2 could prove to be an important therapeutic 
target for enhancing efferocytosis within the atherosclerotic plaque, promoting 
inflammation resolution, and limiting the development of the necrotic core of the plaque 
to reduce plaque vulnerability in the setting of advanced atherosclerotic disease. In the 
aftermath of the CANTOS trial demonstrating a role for therapies targeting the 
inflammatory component of atherosclerotic disease,100 targeting inflammation through 
improving efferocytosis within the plaque could hold the potential to address the unmet 
residual inflammatory risk of atherosclerotic disease. 
 
5.5 References 
1.  Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 
2011;145(3):341-355. doi:10.1016/j.cell.2011.04.005 
2.  Tabas I. 2016 Russell Ross Memorial Lecture in Vascular Biology. Arterioscler 
Thromb Vasc Biol. 2016:ATVBAHA.116.308036. 
doi:10.1161/ATVBAHA.116.308036 
3.  Moore KJ, Sheedy FJ, Fisher E a. Macrophages in atherosclerosis: a dynamic 
balance. Nat Rev Immunol. 2013;13(10):709-721. doi:10.1038/nri3520 
4.  Wada Y, Sugiyama A, Kohro T, et al. In vitro model of atherosclerosis using 
214 
 
coculture of arterial wall cells and macrophage. Yonsei Med J. 2000;41(6):740-
755. 
5.  Dorweiler B, Torzewski M, Dahm M, et al. A novel in vitro model for the study of 
plaque development in atherosclerosis. Thromb Haemost. 2006;95:182-189. 
doi:10.1160/TH05 
6.  Zuniga MC, White SLP, Zhou W. Design and utilization of macrophage and 
vascular smooth muscle cell co-culture systems in atherosclerotic cardiovascular 
disease investigation. Vasc Med (United Kingdom). 2014;19(5):394-406. 
doi:10.1177/1358863X14550542 
7.  Yu P, Xiong T, Tenedero CB, et al. Rosuvastatin Reduces Aortic Sinus and 
Coronary Artery Atherosclerosis in SR-B1 (Scavenger Receptor Class B Type 
1)/ApoE (Apolipoprotein E) Double Knockout Mice Independently of Plasma 
Cholesterol Lowering. Arterioscler Thromb Vasc Biol. 
2017;1:ATVBAHA.117.305140. doi:10.1161/ATVBAHA.117.305140 
8.  Kanters E, Hofker MH, De MPJ, et al. Inhibition of NF- k B activation in 
macrophages increases atherosclerosis in LDL receptor – deficient mice Find the 
latest version : Inhibition of NF- κ B activation in macrophages increases 
atherosclerosis in LDL receptor – deficient mice. J Clin Invest. 2003;112(8):1176-
1185. doi:10.1172/JCI200318580.Introduction 
9.  Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the 
biology of atherosclerosis. Nature. 2011;473(7347):317-325. 
doi:10.1038/nature10146 
10.  Lara-Guzmán OJ, Gil-Izquierdo Á, Medina S, et al. Oxidized LDL triggers 
changes in oxidative stress and inflammatory biomarkers in human macrophages. 
Redox Biol. 2018;15(September 2017):1-11. doi:10.1016/j.redox.2017.11.017 
11.  Chistiakov DA, Bobryshev Y V., Orekhov AN. Macrophage-mediated cholesterol 
handling in atherosclerosis. J Cell Mol Med. 2015;XX(X):n/a-n/a. 
215 
 
doi:10.1111/jcmm.12689 
12.  Li Y, Seitz H, Cui D, et al. Cholesterol-induced Apoptotic Macrophages Elicit an 
Inflammatory Response in Phagocytes , Which Is Partially Attenuated by the Mer 
Receptor *. J Bacteriol. 2006;281(10):6707-6717. doi:10.1074/jbc.M510579200 
13.  Miller YI, Viriyakosol S, Binder CJ, Feramisco JR, Kirkland TN, Witztum JL. 
Minimally modified LDL binds to CD14, induces macrophage spreading via 
TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem. 
2003;278(3):1561-1568. doi:10.1074/jbc.M209634200 
14.  Seo J-W, Yang E-J, Yoo K-H, Choi I-H. Macrophage Differentiation from 
Monocytes Is Influenced by the Lipid Oxidation Degree of Low Density 
Lipoprotein. Mediators Inflamm. 2015;2015:1-10. doi:10.1155/2015/235797 
15.  Kim K, Shim D, Lee JS, et al. Transcriptome Analysis Reveals Nonfoamy Rather 
Than Foamy Plaque Macrophages Are Proinflammatory in Atherosclerotic Murine 
Models. Circ Res. 2018;123(10):1127-1142. 
doi:10.1161/CIRCRESAHA.118.312804 
16.  Li Y, Schwabe RF, DeVries-Seimon T, et al. Free cholesterol-loaded macrophages 
are an abundant source of tumor necrosis factor-α and interleukin-6: Model of NF-
κB- and map kinase-dependent inflammation in advanced atherosclerosis. J Biol 
Chem. 2005;280(23):21763-21772. doi:10.1074/jbc.M501759200 
17.  Doran AC, Ozcan L, Cai B, et al. CAMKIIγ suppresses an efferocytosis pathway 
in macrophages and promotes atherosclerotic plaque necrosis. J Clin Invest. 
2017;(16):1-15. doi:10.1172/JCI94735 
18.  Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for 
atherogenesis and activated by cholesterol crystals. Nature. 2010;464(7293):1357-
1361. doi:10.1038/nature08938 
19.  Roshan M, Tambo A, Pace N. The role of TLR2, TLR4, and TLR9 in the 
pathogenesis of atherosclerosis. Int J Inflam. 2016:1-11. 
216 
 
doi:10.1056/NEJM197608192950805 
20.  Tremblay M, Sanchez-ferras O, Bouchard M. GATA transcription factors in 
development and disease. Development. 2018;145:1-20. doi:10.1242/dev.164384 
21.  Lentjes MH, Niessen HE, Akiyama Y, de Bruïne AP, Melotte V, van Engeland M. 
The emerging role of GATA transcription factors in development and disease. 
Expert Rev Mol Med. 2016;18(May):1-15. doi:10.1017/erm.2016.2 
22.  Trainor CD, Ghirlando R, Simpson MA. GATA zinc finger interactions modulate 
DNA binding and transactivation. J Biol Chem. 2000;275(36):28157-28166. 
doi:10.1074/jbc.M000020200 
23.  Bresnick EH, Katsumura KR, Lee HY, Johnson KD, Perkins AS. Master 
regulatory GATA transcription factors: Mechanistic principles and emerging links 
to hematologic malignancies. Nucleic Acids Res. 2012;40(13):5819-5831. 
doi:10.1093/nar/gks281 
24.  Campanella JJ, Bitincka L, Smalley J. MatGAT: An application that generates 
similarity/identity matrices using protein or DNA sequences. BMC Bioinformatics. 
2003;4:1-4. doi:10.1186/1471-2105-4-29 
25.  Zhang S-J, Ma L-Y, Huang Q-H, et al. Gain-of-function mutation of GATA-2 in 
acute myeloid transformation of chronic myeloid leukemia. Proc Natl Acad Sci. 
2008;105(6):2076-2081. doi:10.1073/pnas.0711824105 
26.  Connelly JJ, Wang T, Cox JE, et al. GATA2 is associated with familial early-onset 
coronary artery disease. PLoS Genet. 2006;2(8):1265-1273. 
doi:10.1371/journal.pgen.0020139 
27.  Muiya NP, Wakil S, Al-Najai M, et al. A study of the role of GATA2 gene 
polymorphism in coronary artery disease risk traits. Gene. 2014;544(2):152-158. 
doi:10.1016/j.gene.2014.04.064 
28.  Cheng M, An S, Li J. CDKN2B-AS may indirectly regulate coronary artery 
217 
 
disease-associated genes via targeting miR-92a. Gene. 2017;629(February):101-
107. doi:10.1016/j.gene.2017.07.070 
29.  Schober A, Weber C. Mechanisms of MicroRNAs in Atherosclerosis. Annu Rev 
Pathol Mech Dis. 2016;11(1):583-616. doi:10.1146/annurev-pathol-012615-
044135 
30.  Qiu C, Wang Y, Zhao H, et al. The critical role of SENP1-mediated GATA2 
deSUMOylation in promoting endothelial activation in graft arteriosclerosis. Nat 
Commun. 2017;8:1-15. doi:10.1038/ncomms15426 
31.  Yang Y, Sun D, Zhou J, et al. LPS expands MDSCs by inhibiting apoptosis 
through the regulation of the GATA2/let-7e axis. Immunol Cell Biol. 2018. 
doi:10.1111/imcb.12204 
32.  Wu T, Tai Y, Cherng Y, et al. GATA-2 Transduces LPS-Induced il-1β Gene 
Expression in Macrophages via a Toll-Like Receptor 4 / MD88 / MAPK- 
Dependent Mechanism. PLoS One. 2013;8(8):1-10. 
doi:10.1371/journal.pone.0072404 
33.  Lim KC, Hosoya T, Brandt W, et al. Conditional Gata2 inactivation results in HSC 
loss and lymphatic mispatterning. J Clin Invest. 2012;122(10):3705-3717. 
doi:10.1172/JCI61619 
34.  Kazenwadel J, Scott HS, Harvey NL, et al. GATA2 is required for lymphatic 
vessel valve development and maintenance. J Clin Invest. 2015;125(8):2979-2994. 
doi:10.1172/JCI78888.prior 
35.  Shih AH, Jiang Y, Meydan C, et al. Mutational cooperativity linked to 
combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer Cell. 
2015;27(4):502-515. doi:10.1016/j.ccell.2015.03.009 
36.  Rae W, Ward D, Mattocks CJ, et al. Autoimmunity/inflammation in a monogenic 
primary immunodeficiency cohort. Clin Transl Immunol. 2017;6(9):e155. 
doi:10.1038/cti.2017.38 
218 
 
37.  Spinner MA, Sanchez LA, Hsu AP, et al. GATA2 deficiency: A protean disorder 
of hematopoiesis, lymphatics, and immunity. Blood. 2014;123(6):809-821. 
doi:10.1182/blood-2013-07-515528 
38.  Walsh JC, DeKoter RP, Lee HJ, et al. Cooperative and antagonistic interplay 
between PU.1 and GATA-2 in the specification of myeloid cell fates. Immunity. 
2002;17(5):665-676. doi:10.1016/S1074-7613(02)00452-1 
39.  Katsumura KR, Ong IM, DeVilbiss AW, Sanalkumar R, Bresnick EH. GATA 
factor-dependent positive-feedbak circuit in acute myeloid leukemia cells. Cell 
Rep. 2016;16(9):2428-2441. doi:10.1016/j.cogdev.2010.08.003.Personal 
40.  Luesink M, Hollink IHIM, van der Velden VHJ, et al. High GATA2 expression is 
a poor prognostic marker in pediatric acute myeloid leukemia. Blood. 
2012;120(10):2064-2075. 
41.  Tabas I. Macrophage death and defective inflammation resolution in 
atherosclerosis. Nat Rev Immunol. 2009;10(1):36-46. doi:10.1038/nri2675 
42.  Henson PM. Cell Removal : Efferocytosis. Annu Rev Cell Dev Biol. 2017;33:1-18. 
43.  Cai B, Kasikara C, Doran AC, Ramakrishnan R, Birge RB, Tabas I. MerTK 
signaling in macrophages promotes the synthesis of inflammation resolution 
mediators by suppressing CaMKII activity. 2018;3721(September). 
44.  Thorp E, Cui D, Schrijvers DM, Kuriakose G, Tabas I. Mertk receptor mutation 
reduces efferocytosis efficiency and promotes apoptotic cell accumulation and 
plaque necrosis in atherosclerotic lesions of apoe-/- mice. Arterioscler Thromb 
Vasc Biol. 2008;28(8):1421-1428. doi:10.1161/ATVBAHA.108.167197 
45.  Kinchen JM, Ravichandran KS. Phagosome maturation: going through the acid 
test. Nat Rev Mol Cell Biol. 2008;9(10):781-795. doi:10.1038/nrm2515 
46.  Schlam D, Bohdanowicz M, Chatilialoglu A, et al. Diacylglycerol kinases 
terminate diacylglycerol signaling during the respiratory burst leading to 
219 
 
heterogeneous phagosomal NADPH oxidase activation. J Biol Chem. 
2013;288(32):23090-23104. doi:10.1074/jbc.M113.457606 
47.  Nunes P, Demaurex N, Dinauer MC. Regulation of the NADPH oxidase and 
associated ion fluxes during phagocytosis. Traffic. 2013;14(11):1118-1131. 
doi:10.1111/tra.12115 
48.  Canton J, Khezri R, Glogauer M, Grinstein S. Contrasting phagosome pH 
regulation and maturation in human M1 and M2 macrophages. Mol Biol Cell. 
2014;25(21):3330-3341. doi:10.1091/mbc.E14-05-0967 
49.  Panday A, Sahoo MK, Osorio D, Batra S. NADPH oxidases: An overview from 
structure to innate immunity-associated pathologies. Cell Mol Immunol. 
2015;12(1):5-23. doi:10.1038/cmi.2014.89 
50.  Bagaitkar J, Huang J, Zeng MY, et al. NADPH oxidase activation regulates 
apoptotic neutrophil clearance by murine macrophages. Blood. 2018. 
doi:10.1104/pp.111.188953 
51.  Flannagan RS, Jaumouillé V, Grinstein S. The Cell Biology of Phagocytosis. Annu 
Rev Pathol Mech Dis. 2011;7(1):61-98. doi:10.1146/annurev-pathol-011811-
132445 
52.  Rupper A, Grove B, Cardelli J. Rab7 regulates phagosome maturation in 
Dictyostelium. J Cell Sci. 2001;114(13):2449-2460. 
53.  Johnson DE, Ostrowski P, Jaumouillé V, Grinstein S. The position of lysosomes 
within the cell determines their luminal pH. J Cell Biol. 2016;212(6):677-692. 
doi:10.1083/jcb.201507112 
54.  Huynh KK, Gershenzon E, Grinstein S. Cholesterol accumulation by macrophages 
impairs phagosome maturation. J Biol Chem. 2008;283(51):35745-35755. 
doi:10.1074/jbc.M806232200 
55.  Fairn GD, Grinstein S. How nascent phagosomes mature to become 
220 
 
phagolysosomes. Trends Immunol. 2012;33(8):397-405. 
doi:10.1016/j.it.2012.03.003 
56.  Harrison RE, Bucci C, Vieira O V, Schroer T a, Grinstein S. Phagosomes fuse 
with late endosomes and/or lysosomes by extension of membrane protrusions 
along microtubules: role of Rab7 and RILP. Mol Cell Biol. 2003;23(18):6494-
6506. doi:10.1128/MCB.23.18.6494 
57.  Green DR, Oguin TH, Martinez J. The clearance of dying cells: table for two. Cell 
Death Differ. 2016;23(6):915-926. doi:10.1038/cdd.2015.172 
58.  Jaiswal S, Natarajan P, Silver AJ, et al. Clonal Hematopoiesis and Risk of 
Atherosclerotic Cardiovascular Disease. N Engl J Med. 2017;377(2):111-121. 
doi:10.1056/NEJMoa1701719 
59.  Lasbury ME, Tang X, Durant PJ, Lee C. Effect of Transcription Factor GATA-2 
on Phagocytic Activity of Alveolar Macrophages from. Infect Immun. 
2003;71(9):4943-4952. doi:10.1128/IAI.71.9.4943 
60.  Sankaranarayanan S, Kellner-Weibel G, de la Llera-Moya M, et al. A sensitive 
assay for ABCA1-mediated cholesterol efflux using BODIPY-cholesterol. J Lipid 
Res. 2011;52(12):2332-2340. doi:10.1194/jlr.D018051 
61.  Trinh LA, McCutchen MD, Bonner-Fraser M, Fraser SE, Bumm LA, McCauley 
DW. Fluorescent in situ hybridization employing the conventional NBT/BCIP 
chromogenic stain. Biotechniques. 2007;42(6):756-759. doi:10.2144/000112476 
62.  Flannagan RS, Heit B, Heinrichs DE. Intracellular replication of Staphylococcus 
aureus in mature phagolysosomes in macrophages precedes host cell death, and 
bacterial escape and dissemination. Cell Microbiol. 2016;18(4):514-535. 
doi:10.1111/cmi.12527 
63.  Taruc K, Yin C, Wootton DG, Heit B. Quantification of Efferocytosis by Single-
cell Fluorescence Microscopy. J Vis Exp. 2018;(138):1-12. doi:10.3791/58149 
221 
 
64.  Evans AL, Blackburn JWD, Yin C, Heit B. Quantitative efferocytosis assays. 
Methods Mol Biol. 2017;1519:25-41. doi:10.1007/978-1-4939-6581-6 
65.  Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of 
image analysis. Nat Methods. 2012;9(7):671-675. doi:10.1038/nmeth.2089 
66.  Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: an open-source platform for 
biological-image analysis. Nat Methods. 2012;9(7):676-682. 
doi:10.1038/nmeth.2019 
67.  Vossenaar ER, Nijenhuis S, Helsen MMA, et al. Citrullination of synovial proteins 
in murine models of rheumatoid arthritis. Arthritis Rheum. 2003;48(9):2489-2500. 
doi:10.1002/art.11229 
68.  Allahverdian S, Chehroudi AC, McManus BM, Abraham T, Francis GA. 
Contribution of intimal smooth muscle cells to cholesterol accumulation and 
macrophage-like cells in human atherosclerosis. Circulation. 2014;129(15):1551-
1559. doi:10.1161/CIRCULATIONAHA.113.005015 
69.  Yurdagul A, Doran AC, Cai B, Fredman G, Tabas IA. Mechanisms and 
Consequences of Defective Efferocytosis in Atherosclerosis. 2017;4(January):1-
10. doi:10.3389/fcvm.2017.00086 
70.  Cai B, Thorp EB, Doran AC, et al. MerTK receptor cleavage promotes plaque 
necrosis and defective resolution in atherosclerosis. J Clin Invest. 2017:1-5. 
doi:10.1172/JCI90520 
71.  Blander JM, Medzhitov R. On regulation of phagosome maturation and antigen 
presentation. Nat Immunol. 2006;7(10):1029-1035. doi:10.1038/ni1006-1029 
72.  Yin C, Kim Y, Argintaru D, Heit B. Rab17 mediates differential antigen sorting 
following efferocytosis and phagocytosis. Cell Death Dis. 2016;7(12):e2529-12. 
doi:10.1038/cddis.2016.431 
73.  Olivares-Martínez E, Hernández-Ramírez DF, Núñez-Álvarez CA, Cabral AR, 
222 
 
Llorente L. The amount of citrullinated proteins in synovial tissue is related to 
serum anti-cyclic citrullinated peptide (anti-CCP) antibody levels. Clin Rheumatol. 
2016;35(1):55-61. doi:10.1007/s10067-015-3047-2 
74.  Wade NS, Major AS. The problem of accelerated atherosclerosis in systemic lupus 
erythematosus: insights into a complex co-morbidity. Thromb Haemost. 
2011;106(5):849-857. doi:10.1016/j.biotechadv.2011.08.021.Secreted 
75.  Crowson CS, Liao KP, Davis JM, et al. Rheumatoid arthritis and cardiovascular 
risk. Am Heart J. 2013;166:622-628. doi:10.1016/j.ahj.2013.07.010 
76.  Vossenaar ER, Radstake TRD, Van Der Heijden A, et al. Expression and activity 
of citrullinating peptidylarginine deiminase enzymes in monocytes and 
macrophages. Ann Rheum Dis. 2004;63(4):373-381. doi:10.1136/ard.2003.012211 
77.  An D, Hao F, Hu C, Kong W, Xu X, Cui M-Z. JNK1 Mediates 
Lipopolysaccharide-Induced CD14 and SR-AI Expression and Macrophage Foam 
Cell Formation. Front Physiol. 2017;8(January):1075. 
doi:10.3389/fphys.2017.01075 
78.  Heit B, Kim H, Cosío G, et al. Multimolecular signaling complexes enable syk-
mediated signaling of CD36 internalization. Dev Cell. 2013;24(4):372-383. 
doi:10.1016/j.devcel.2013.01.007 
79.  Mócsai A, Ligeti E, Lowell CA, Berton G. Adhesion-dependent degranulation of 
neutrophils requires the Src family kinases Fgr and Hck. J Immunol. 
1999;162(2):1120-1126. 
80.  Liu ZM, Huang HS. As2O3-induced c-Src/EGFR/ERK signaling is via Sp1 
binding sites to stimulate p21WAF1/CIP1 expression in human epidermoid 
carcinoma A431 cells. Cell Signal. 2006;18(2):244-255. 
doi:10.1016/j.cellsig.2005.04.006 
81.  Merchant JL, Du M, Todisco A. Sp1 phosphorylation by Erk 2 stimulates DNA 
binding. Biochem Biophys Res Commun. 1999;254(2):454-461. 
223 
 
doi:10.1006/bbrc.1998.9964 
82.  Cai B, Thorp EB, Doran AC, et al. MerTK receptor cleavage promotes plaque 
necrosis and defective resolution in atherosclerosis. J Clini. 2017;127(2):564-568. 
doi:10.1172/JCI90520.We 
83.  Erwig L-P, McPhilips KA, Wynes MW, Ivetic A, Ridley AJ, Henson PM. 
Differential regulation of phagosome maturation in macrophages and dendritic 
cells mediated by Rho GTPases and ezrin–radixin–moesin (ERM) proteins. Proc 
Natl Acad Sci USA. 2006;103(34):12825-12830. doi:10.1155/2015/359153 
84.  Yates RM, Hermetter A, Taylor GA, Russell DG. Macrophage activation 
downregulates the degradative capacity of the phagosome. Traffic. 2007;8(3):241-
250. doi:10.1111/j.1600-0854.2006.00528.x 
85.  Sokolove J, Sharpe O, Brennan M, et al. Citrullination within the atherosclerotic 
plaque: A potential target for the anti-citrullinated protein antibody response in 
rheumatoid arthritis. Arthritis Rheum. 2013;65(7):1719-1724. 
doi:10.1002/art.37961 
86.  Legge A, Hanly JG. Managing premature atherosclerosis in patients with chronic 
inflammatory diseases. CMAJ. 2018;190(14):E430-E439. 
doi:10.1503/cmaj.170776 
87.  Koltsova EK, Ley K. How dendritic cells shape atherosclerosis. Trends Immunol. 
2011;32(11):540-547. doi:10.1016/j.it.2011.07.001 
88.  Tse K, Tse H, Sidney J, Sette A, Ley K. T cells in atherosclerosis. Int Immunol. 
2013;25(11):615-622. doi:10.1093/intimm/dxt043 
89.  Cheng Y, Zhu X, Cheng F, Ji L, Zhou Y. Delta-like homolog1/GATA binding 
protein 2 axis mediates leptin inhibition of PPARγ2 expression in hepatic stellate 
cells in vitro. Life Sci. 2018;192(November 2017):183-189. 
doi:10.1016/j.lfs.2017.11.050 
224 
 
90.  Croasdell A, Duffney PF, Kim N, Lacy SH, Sime PJ, Phipps RP. PPAR ?? and the 
Innate Immune System Mediate the Resolution of Inflammation. PPAR Res. 
2015;2015(Figure 1):1-20. doi:10.1155/2015/549691 
91.  Chistiakov DA, Melnichenko AA, Myasoedova VA, Grechko A V., Orekhov AN. 
Mechanisms of foam cell formation in atherosclerosis. J Mol Med. 
2017;95(11):1153-1165. doi:10.1007/s00109-017-1575-8 
92.  Lee SM, Moon J, Cho Y, Chung JH, Shin MJ. Quercetin up-regulates expressions 
of peroxisome proliferator-activated receptor γ, liver X receptor α, and ATP 
binding cassette transporter A1 genes and increases cholesterol efflux in human 
macrophage cell line. Nutr Res. 2013;33(2):136-143. 
doi:10.1016/j.nutres.2012.11.010 
93.  Freeman SA, Grinstein S. Phagocytosis: Receptors, signal integration, and the 
cytoskeleton. Immunol Rev. 2014;262(1):193-215. doi:10.1111/imr.12212 
94.  Yang L, Sun H, Cao Y, et al. GATA2 inhibition sensitizes acute myeloid leukemia 
cells to chemotherapy. PLoS One. 2017;12(1):1-12. 
doi:10.1371/journal.pone.0170630 
95.  Kikuchi J, Yamada S, Koyama D, et al. The novel orally active proteasome 
inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-
regulating the expression of class i histone deacetylases. J Biol Chem. 
2013;288(35):25593-25602. doi:10.1074/jbc.M113.480574 
96.  Liu Y, Liao R, Qiang Z, Zhang C.  Pro-inflammatory cytokine-driven 
PI3K/Akt/Sp1 signalling and H 2 S production facilitates the pathogenesis of 
severe acute pancreatitis . Biosci Rep. 2017;37(2):BSR20160483. 
doi:10.1042/bsr20160483 
97.  Chan L, Hong J, Pan J, et al. Role of Rab5 in the formation of macrophage-derived 
foam cell. Lipids Health Dis. 2017;16(1):170. doi:10.1186/s12944-017-0559-6 
98.  Pulanco MC, Cosman J, Ho M, et al. Complement Protein C1q Enhances 
225 
 
Macrophage Foam Cell Survival and Efferocytosis. J Immunol. 2016;198. 
doi:10.4049/jimmunol.1601445 
99.  Tabas I. Apoptosis and plaque destabilization in atherosclerosis: the role of 
macrophage apoptosis induced by cholesterol. Cell Death Differ. 2004;11 Suppl 
1:S12-S16. doi:10.1038/sj.cdd.4401444 
100.  Ridker PM, Dellborg M, Kastelein JJP, et al. Antiinflammatory Therapy with 
Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-
1131. doi:10.1056/nejmoa1707914 
 
 
  
226 
 
Chapter 6  
6 Summary, Discussion and Future Directions 
6.1 Summary of major findings 
The clearance of apoptotic cells by efferocytosis is an essential mechanism of limiting 
inflammation and maintaining tissue homeostasis.1 In contrast to the phagocytosis and 
clearance of pathogens, efferocytosis is immunologically silent and may promote the 
generation of anti-inflammatory and pro-tolerogenic factors by professional efferocytes 
such as macrophages.2,3 When efferocytosis becomes impaired, apoptotic cells are not 
cleared and instead undergo secondary necrosis—resulting in the release of pro-
inflammatory danger signals and self-antigens that are normally confined within the 
cytoplasm of apoptotic bodies.4 In the context of atherosclerosis, efferocytic removal of 
apoptotic cells and debris within the atherosclerotic plaque by lesion-infiltrating 
macrophages is an important mechanism of limiting plaque growth and the development 
of the necrotic core that is a pathological feature of late-stage disease.5,6 In this thesis, we 
identified a Rab17-dependant vesicular trafficking pathway responsible for the 
immunologically silent degradation of efferocytosed materials, and identified a GATA2-
driven transcriptional profile that drives efferocytic defects in early-stage atheroma 
formation. This work provides new insights into the cellular mechanisms regulating 
efferocytosis, and on how atherogenic conditions can drive defects in these processes. 
In Chapter 3 of this thesis, we made use of an unbiased mass spectrometry approach to 
identify proteins that differentially localize to the surface of efferosomes versus 
phagosomes. Through this approach, we discovered several proteins that appeared to be 
selectively recruited to the surface of the maturing efferosome. In particular, we identified 
the small GTPase Rab17 as one of these efferosome-specific proteins. Rab GTPases act as 
master regulators of intracellular trafficking, marking specific intracellular organelles and 
compartments and recruiting effector molecules that mediate vesicular docking and fusion 
in a highly-regulated fashion.7,8 We therefore examined whether Rab17 functioned as a 
regulator of differentially cargo processing between efferosomes and phagosomes. First, 
we saw that while Rab17 is transiently recruited to the surface of nascent phagosome and 
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then quickly displaced, it is maintained on the surface of efferosomes throughout 
efferosome maturation. Following fusion with lysosomes, the efferosome undergoes a 
fission process, generating several smaller EDVs. Rab17-labelled EDVs subsequently 
migrate to the cell periphery and fuse with the recycling endosome, presumably resulting 
in exocytosis or recycling of degraded efferosomal cargo. Knockdown of Rab17 activity 
using a dominant negative mutant disrupted this process. Efferosomes did not undergo 
fission to the same degree but instead remained sequestered within the perinuclear region 
of the cell, where they acquired MHC class II molecules and presumably matured into 
MHC class II loading compartments. We therefore concluded that Rab17 is a central 
regulator of immunologically silent efferosome maturation and is required to direct 
efferosomal cargo to the recycling endosome in order to avoid the loading of apoptotic cell-
derived self-antigens onto MHC class II.  
The onset of defective macrophage efferocytosis greatly accelerates plaque growth and the 
development of large necrotic cores that are characteristic of unstable plaques.9,10 In 
Chapter 4, we sought to perform gene expression profiling of lesion-resident macrophages 
isolated from human atherosclerotic plaques to better characterize the molecule 
mechanisms that drive the development of defective efferocytosis. We obtained tissue 
samples from the ascending aorta of patients undergoing coronary artery bypass graft 
surgery. Plaques identified in these tissue samples we found to have the histological 
features of pre-atherosclerotic lesions. Macrophages from these early-stage lesions were 
selectively isolated by laser capture microdissection using the scavenger receptor CD163 
as a macrophage-specific marker. Purified patient macrophages were compared to in vitro 
differentiated peripheral monocyte-derived macrophages from healthy individuals used as 
controls by microarray. This revealed dramatic dysregulation in patient macrophage gene 
expression, with approximately 3,000 protein-coding transcripts found to be differentially 
expressed in these cells. Significantly, these genes clustered in pathways involved in 
cellular lipid metabolism, cell stress responses, and intracellular trafficking. Gene set 
enrichment analysis revealed specific defects in cholesterol handling, efferocytosis and 
efferosome maturation. Of note, we identified three non-cell cycle transcription factors 
genes to be significantly upregulated in patient macrophages: RARG, GATA2 and E4F1. 
Amongst these, only GATA2 was previously associated with cardiovascular disease, is not 
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normally expressed by mature myeloid cells, and is a known regulator of myeloid cell 
development.11–13 We confirmed that GATA2 was upregulated nearly 50-fold in patient 
macrophages by RT-qPCR. Together, these results suggest that lesion-resident 
macrophages in early-stage human plaques possess a distinctive and previous 
unappreciated phenotype characterized by impaired cholesterol handling and efferosome 
maturation that may be driven by aberrant GATA2 expression.  
As we had identified the hematopoietic transcription factor GATA2 as being significantly 
upregulated in patient macrophages, we proceeded to determine in Chapter 5 whether 
GATA2 was a master regulator of the unique macrophage phenotype we had previously 
described. We confirmed that GATA2 was present in a significant proportion of CD68+ 
foam cells within patient aortic intima and that in vitro exposure of macrophages to the 
pro-atherogenic molecule oxLDL resulted in GATA2 upregulation. Using stable GATA2-
overexpressing and -knockdown THP-1 macrophage cell lines we performed a number of 
functional assays to assess the impact of perturbing GATA2 function on a variety of 
macrophage functions, including efferocytosis and efferosome maturation. As expected, 
both exposure to oxLDL and GATA2 overexpression independently resulted in markedly 
impaired macrophage efferocytosis and efferosome maturation, but neither GATA2 
overexpression or depletion had any effect on cholesterol influx or efflux. Critically, 
shRNA-mediated knockdown of GATA2 expression was sufficient to prevent impaired 
efferocytic uptake and efferosome maturation in macrophages cultured in the presence of 
oxLDL, with GATA2 upregulation by oxLDL dependent on signaling pathways known to 
be downstream of oxLDL signaling. Therefore, we concluded that GATA2 is a novel 
transcription factor induced by exposure to modified lipoproteins, that is involved in the 
pathogenesis of atherosclerosis through driving impaired apoptotic cell uptake and 
degradation. GATA2 upregulation in response to oxLDL exposure drives both impaired 
efferocytic internalization of apoptotic cells and the efficient degradation of apoptotic 
cargo through efferosome maturation.  
 
229 
 
6.2 Discussion 
6.2.1 A novel mechanism of apoptotic cargo sorting following 
efferocytosis 
Despite the critical role of efferocytosis in restraining pathologic inflammation and 
autoimmunity, there are many open questions on how professional efferocytes like 
macrophages recognize and internalize apoptotic cells, and how these efferocytes then 
process the apoptotic cargo to avoid an inflammatory response and self-antigen 
presentation.4,14 We are beginning to develop a comprehensive understanding of the first 
question, with researchers uncovering a host of apoptotic cell-derived signals and 
corresponding efferocyte receptors that mediate the localization, recognition and 
internalization of apoptotic cells by professional efferocytes.15 However, comparatively 
less is known about how efferocytes then process efferosomal cargo following 
internalization of the apoptotic cell. Much of what is currently known about the process of 
efferosomal maturation has been inferred from studies on the maturation of 
phagosome.8,16,17 Although these processes undoubtedly share many similarities, 
degradation of pathogens within the phagosome ultimately leads to antigen presentation 
and activation of an adaptive immune response.18 However, the same is not true of 
efferocytosis and the molecular mechanisms that distinguish the ultimate fate of 
phagosomal versus efferosomal cargo remain largely unknown. 
Some previous studies have suggested that signaling from pattern recognition receptors 
such as TLRs on the surface of phagosomes is responsible for discrimination between self- 
and non-self-antigens.19 Blander & Medzhitov describe a “phagosome-autonomous” 
model whereby phagosomes containing TLR ligands undergo rapid maturation in order to 
generate the hydrolytic environment necessary to successfully process the MHC class II-
associated invariant chain (Ii).20,21 Processing of Ii is required for generation of the class 
II-associated invariant chain-associated peptide (CLIP) and proper binding of antigenic 
peptides to MHC class II.22 Under this framework, efferosomes containing apoptotic cells 
undergo terminal cargo degradation without creating the conditions necessary for antigenic 
loading of MHC class II.20 However, these findings have been called into questions by 
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Yates & Russell, who found that phagosome maturation proceeds at similar rates regardless 
of whether TLR2 or TLR4 ligands were present.23 
In this thesis, we have described a novel mechanism of sorting apoptotic versus pathogen-
derived cargo following internalization. In macrophages, we found that Rab17 is recruited 
to the surface of nascent efferosomes and directs apoptotic cargo away from the MHC class 
II loading compartment and towards the recycling endosome. Rab17+ efferosomes undergo 
fission to form EDVs, which traffic to the cell periphery in process which is likely 
dependent on the activity of kinesins. Importantly, when Rab17 function is disrupted, 
apoptotic cargo is instead directed to the MHC class II loading compartment, presumably 
without any TLR signaling from the efferosome. Whether TLR signaling from phagosomes 
prevents Rab17 recruitment or actively removes Rab17 from the surface of pathogen-
containing phagosomes remains to be seen, but our findings suggest that it is the presence 
of Rab17 that prevents efferosomes from maturing into MHC class II loading 
compartments and present apoptotic cell-derived self-antigens.  
6.2.2 Defects in macrophage function develop early in atherosclerotic 
disease 
Altered macrophage function in atherosclerosis has been well-documented.24,25 Within the 
plaque microenvironment, macrophages are exposed to hypercholesterolemic conditions 
that reprogram their behaviour.26 Uptake of cholesterol by macrophages has several 
important consequences. The accumulation of free cholesterol in the cytoplasm can 
activate the unfolded protein response and drive the production of pro-inflammatory 
cytokines, including IL-1β, TNFα and IL-6.27,28 Exposure to pro-inflammatory cytokines 
polarizes lesion-resident macrophages to a M1-like phenotype, which drives the further 
production of cytokines and a decrease in efferocytic capacity.29 Excess cholesterol is also 
thought to inhibit the ability of macrophages to efficiently clear apoptotic cells, although 
the mechanisms that underlie this phenomenon remain unclear.30 
While the ontology of human aortic and cardiac macrophages are not as well understood, 
macrophages with markers of M1-polarization (iNOS, CD86), M2-polarization (MR, 
dectin-1), and TREM2+-polarization (TREM2, CD9hi) have been identified in human 
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plaque31,32. Later in disease other macrophage sub-types may emerge. For example, 
intraplaque hemorrhage gives rise to atheroprotective HA-mac and Mhem macrophages in 
mice, which scavenge hemoglobin and are resistant to oxidative stress33,34. While multiple 
macrophage polarization states have been identified in mouse models and in human 
atheroma samples, very little is known of the transcription factors or the tissue- and 
environment-specific cues which regulate their transcriptional programs. One of the best 
characterized atheroma-resident macrophage populations is the Mox sub-type, which in 
mice accounts for 30% of atheroma-resident macrophages35. Mox cells are characterized 
by a transcriptional profile mediated by the transcription factor Nrf2 which, when knocked 
out, delays atheroma formation36. Nrf2 upregulates several genes not normally expressed 
in M1 or M2 polarized cells, including genes for processing heme, angiogenic factors, and 
anti-oxidant mechanisms35. 
In general, it has previously been thought that defects in apoptotic cell clearance only 
occurs in advanced atherosclerotic plaques.4,10 Indeed, the accumulation of uncleared 
apoptotic cells is a marker of late-stage disease and forced induction of macrophage 
apoptosis during early stages of disease actually slows progression and promotes plaque 
stabilization, at least in murine models of atherosclerosis.37,38 In human studies, 
accumulation of TUNEL+ secondary necrotic cells have been documented in carotid plaque 
samples obtained from endarterectomy.37 This stands in contrast to tissues where there is a 
high rate of cell turnover but efferocytic capacity remains preserved, such as the tonsils. In 
these tissues, TUNEL+ cells are almost undetectable.37 However, the carotid samples 
commonly used in human atherosclerosis studies consist almost exclusively of late-stage 
plaques where uncleared apoptotic and secondarily necrotic cells are known to accumulate. 
To date, there have been very few studies that have studied early-stage atherosclerotic 
plaques in humans.39,40 Furthermore, to the best of our knowledge none of these studies 
have examined apoptotic cell clearance or macrophage function. Although animal studies 
of plaque progression including early-stage plaque have been more comprehensive, studies 
that have shown a benefit of macrophage apoptosis early in atherosclerosis have used 
knockout mice lacking proteins involved in the intrinsic apoptotic pathways (Bax and 
Bcl2).41 Deletion of these critical proteins may have resulted in off target effects that 
complicates the interpretation of the experimental results. 
232 
 
In our study, we studied primarily early-stage human atherosclerotic plaques as a result of 
our use of aortic punch samples, which typically are excised from regions of the aorta that 
have a comparatively lower degree of plaque burden. Although initially somewhat 
discouraging, this strategy ultimately provided us with the rare opportunity to study early-
stage human atherosclerosis lesions. Consistent with previous reports, we observed diffuse 
intimal thickening along with sub-intimal lipid accumulation along with macrophage 
accumulation in our patient samples.40 Surprisingly, we found that even in an early stage 
of disease, macrophage gene expression was severely dysregulated in lesion-resident 
macrophages. Genes involved in cellular cholesterol efflux, efferocytic uptake and 
efferosome maturation were significantly downregulated in patient macrophages compared 
to controls. However, despite the apparent downregulation of the core efferocytic 
machinery in lesion-resident macrophages, we found very few necrotic TUNEL+ cells in 
our patient tissue samples. One interpretation of these results is that the ability of 
macrophages to clear apoptotic cells begins to decline early in atherosclerosis, but this 
defect does not become severe enough for macrophage efferocytic capacity to be unable to 
keep up with apoptotic cell turnover in the plaque until later on during disease progression. 
These results could also mean that there is heterogeneity in macrophage function early in 
atherosclerosis, with some macrophages developing impaired efferocytosis while others 
remain fully functional. Unfortunately, our study was not designed to assess these 
possibilities, but our data suggest that there is greater complexity in macrophage behaviour 
in early atherosclerosis than has been previously appreciated. 
6.2.3 Impaired efferosome maturation contributes to defective 
efferocytosis in atherosclerosis 
While defective efferocytic clearance of apoptotic cell is widely recognized as an important 
driver of atherosclerotic disease progression through accelerating the growth of plaque 
necrotic cores and increasing intra-lesion inflammation, how efferocytosis becomes 
impaired in the context of atherosclerosis remains poorly understood.4 Several recent 
studies have implicated decreased expression of key efferocytic receptors or their cleavage 
from the macrophage cell surface within the inflammatory plaque microenvironment, 
while other studies have shown that alleviation of “don’t eat me” signals in the plaque can 
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delay disease progression.9,42,43 Other studies have found that excessive oxidation of 
phosphatidylserine can actually inhibit CD36-mediated apoptotic cell clearance.44 A recent 
seminal study from Cai et al. showed that ADAM17-mediated cleavage of the efferocytic 
receptor MerTK leads to increased necrotic core size and plaque progression.9 
Significantly, the authors of this study also demonstrated the presence of cleaved MerTK 
in human carotid plaques, suggesting that this is a bona fide mechanism of impaired 
efferocytosis in human atherosclerotic disease.9 
Beyond the engagement between efferocytic receptor and target required for binding and 
uptake of apoptotic cells, we now understand that efficient processing of internalized 
apoptotic cargo is required to maintain efficient efferocytosis. Wang et al. have shown that 
defects in Drp1, a protein involved in mitochondrial fission, leads to impaired apoptotic 
cargo degradation and recycling.45 This in turn drove defective apoptotic cell clearance and 
promoted the accumulation of necrotic cells in Drp1-/-/Ldlr-/- double-knockout mice.45 
In this thesis, we uncovered evidence suggesting that macrophage efferosome maturation 
and apoptotic cargo degradation are impaired in human atherosclerotic disease. We found 
that several genes involved in efferosome maturation to be downregulated in patient 
macrophages compared to controls. These included RAB7, which coordinates both 
phagosome and efferosome maturation through regulating fusion with late endosome and 
driving phagosome/efferosome fusion with lysosomes,46 and genes encoding the NADPH 
oxidase and the vacuolar ATPase, both of which function to permit efficient degradation 
of apoptotic cell cargo.8,47 We further determined that culturing macrophages in the 
presence of a pro-atherogenic stimulus results in impairment of several key mechanisms 
that are required for efficient apoptotic cargo degradation, including generation of 
superoxides, efferosome acidification and efferolysosomal fusion. Therefore, our data 
suggest that in addition to cleavage of efferocytic receptors, impaired efferosome 
maturation in macrophages is an additional mechanism that drives defective efferocytosis 
in human atherosclerotic disease. 
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6.2.4 GATA2 is involved in driving macrophage dysfunction in 
atherosclerosis 
Our previous findings collectively support the conclusion that we have identified a 
previously unappreciated macrophage phenotype that is unique to early-stage human 
atherosclerosis. These macrophages are characterized by impaired cholesterol handling and 
efferocytic capacity without demonstrating the features classically associated with M1-like 
macrophages or other known atherosclerosis-associated subsets such as increased 
production of proinflammatory cytokines.48,49 We sought to identify transcription factors 
that were responsible for the induction of this phenotype. Only a few transcription factors 
have been identified to be associated with atherosclerotic macrophages. These include the 
PPARs, liver X receptor (LXR), retinoic acid receptor (RAR) and retinoid X receptor 
(RXR).50–52 These receptors tend to be activated in respond to macrophage cholesterol 
loading and function to modulate macrophage cholesterol metabolism and drive expression 
of both proteins involved in cholesterol efflux such as ABCA1 and efferocytic receptors 
such as CD36.53 
In this thesis, we identified just three non-cell cycle transcription factors as being 
upregulated in patient macrophages in our microarray dataset. Initially, we were excited to 
see a member of the RAR family of transcription factors RARγ amongst these. However, 
we could not confirm RARγ upregulation in an independent set of patient and control 
macrophage samples. Therefore, we turned our focus to GATA2, a zinc finger transcription 
factor best studied for its role in maintenance of the hematopoietic stem cell population 
and in myeloid lineage specification during hematopoiesis.54 Interestingly, SNPs in 
GATA2 have been implicated in previous genome-wide association studies to be involved 
in coronary artery disease.11 We found that GATA2 overexpression in the absence of a pro-
atherogenic trigger was sufficient to induce defects in efferocytotic uptake and in multiple 
steps of efferosome maturation. Furthermore, knockdown of GATA2 could protect 
macrophages against oxLDL-induced impairments in efferocytic uptake and efferosome 
maturation. These data suggest that aberrant GATA2 expression drives efferocytic defects 
in macrophages during the early stages of human atherosclerotic disease. 
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Germline mutations in GATA2 in humans are exceedingly rare but when they do occur 
result in a spectrum of diseases connected by aberrant development of the myeloid cell 
lineage (macrophages and neutrophils) and a propensity for developing acute myeloid 
leukemia (AML).55,56 Indeed, de novo mutations in GATA2 within the bone marrow have 
been recognized as contributing to the development of AML.56 Recent work from Jaiswal 
et al. demonstrated that mutations in genes that pre-dispose individuals to developing AML 
also contributes to increased risk of atherosclerosis and coronary artery disease in a process 
termed “clonal hematopoiesis of indeterminant potential” (CHIP).57 AML driver mutations 
increase the rate of myeloid cell proliferation and accelerate the development of 
atherosclerosis.58,59 In particular, work from Fuster et al. on the same phenomenon found 
that in Ldlr-knockout mice lacking Tet2, an enzyme that regulates epigenetic modification 
of DNA, atherosclerotic plaques were larger and lesion-resident macrophages produced 
greater levels of IL-1β.58 Interestingly, GATA2 is recognized as another gene that is often 
found to be mutated in AML.56,60 Although to date there have been no reported cases of 
GATA2 mutations contributing to CHIP in humans, it is possible that de novo mutations 
in GATA2 may increase the risk of coronary artery disease. 
 
6.3 Limitations 
6.3.1 Alteration in Rab17 expression or function in atherosclerotic 
macrophages 
Given the importance of Rab17 as a regulator of efferosomal maturation in macrophages, 
and the broad array of maturation defects present in oxLDL-treated macrophages, we were 
surprised to find that it was not differentially expressed in our patient macrophages. 
Instead, impaired efferosome maturation in our patient atherosclerotic macrophages was 
found to be mediated primarily through a downregulation of Rab7—which mediates 
efferosome-lysosome fusion61—as well as efferosomal acidification, NADPH oxidase 
activation, and efferolysosomal fusion. We did not initially examine Rab17 expression or 
localization in our GATA2 overexpression and knockdown macrophage cell lines here 
because its expression was not significantly altered in our microarray dataset. However, 
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further investigation in this direction is warranted. Consequently, it is unclear at this point 
whether Rab17 plays a role in macrophage dysfunction in atherosclerosis. While Rab17 
expression may not be affected in atherosclerosis, its function or localization may well be. 
Unfortunately, we do not currently have a clear picture of how Rab17 is recruited to the 
surface of efferosomes, nor have we identified any potential downstream Rab17 effectors. 
This makes studying Rab17 function in atherosclerotic macrophages challenging. Further 
work is required in defining how Rab17 directs efferosomal cargo trafficking before we 
will be able to unravel whether it plays a role in defective efferocytosis in atherosclerosis.  
6.3.2 Sampling of patient atherosclerotic plaques 
The choice to utilize aortic punch tissue as our source of atherosclerotic plaque presents 
both advantages and drawbacks. Since plaque burden in the ascending aorta in humans is 
relatively low and surgeons will select a region of the aorta that is macroscopically free 
from plaque when performing the aortic punch biopsy, we were able to obtain early-stage 
atherosclerotic plaque for our studies. Early stage plaque is understudied in the human 
context because investigators to date have focused on the late-stage lesions that are readily 
available from carotid endarterectomy procedures, while mouse studies into early plaque 
are limited by the accelerated disease progression in these models.62,63 Moreover, while our 
aortic biopsy samples contain plaque that is histologically classified as early plaque, this 
material is recovered from patients with advanced disease. Consequently, while we propose 
that this thesis has explored early-stage plaque, it is possible that some of the observed 
gene expression patterns are a product of late-stage disease. Concordantly, we are in the 
process of starting a new study to perform comparative gene expression studies of 
monocytes and aortic plaque macrophages from the same patients, in order to trace the 
ontology of the defects we have observed.  Ideally, we would also liked to have accessed 
advanced lesions in our original study as well. These plaques have been better studied and 
are arguably more clinically-relevant to study because of they tend to be more vulnerable 
and have an increased risk of rupture.64  Access to both early-stage and advanced plaque 
from the same patient would have also offered us the possibility of comparing gene 
expression changes between different stages of disease progression. Unfortunately, 
limitations in current clinical practice (i.e. the same patient is unlikely to require both a 
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CABG operation and a carotid endarterectomy within a reasonable timeframe) make it 
difficult to access both early and advanced lesions from the same patient and precludes us 
from doing these studies. 
6.3.3 Utilization of CD163 as a macrophage-specific marker 
The use of CD163 as our macrophage-specific marker is an undoubtedly controversial 
choice. We selected this marker because the most commonly-utilized macrophage markers 
in human studies, CD68, is abundantly expressed within the atherosclerotic plaque by 
smooth muscle cells.66 In fact, recent studies suggest that more than half of the CD68+ cells 
in atherosclerotic plaques are derived from smooth muscle cells rather than macrophages.67 
CD163 is a hemoglobin/haptoglobin scavenger receptor that is typically thought of as a 
marker of alternatively-activated M2-like macrophages.33,68 However, there is abundant 
evidence that in humans CD163 expression is not restricted to M2 macrophages. CD163 
expression has been detected in several populations in tissue-resident macrophages, 
including Kupffer cells and splenic red pulp macrophages.68 Significantly, a study of 1,105 
pathology specimens at Stanford University Medical Center found CD163 to be restricted 
to cells of the monocyte/macrophage lineage, making it a highly specific marker of 
macrophages.69 Furthermore, our own data showed that CD163 was detectable on the 
surface of primary monocyte-derived macrophages in vitro regardless of whether these 
macrophages were polarized to M0, M1 or M2 states (Figure 4.4a). We also observed that 
CD163 was often co-expressed with CD68 expression in patient aortic intima (Figure 
4.4b), suggesting that we were able to capture a majority of macrophages by CD163 
staining. However, our approach did sacrifice sensitivity for specificity and it is unknown 
whether this led to any bias in our microarray dataset. An alternative approach that could 
be taken in future studies is to stain for CD45 along with CD68. CD45 expression is 
restricted to leukocytes and therefore we can be reasonably certain that any CD68/CD45 
double-positive cells within the plaque would be macrophages or macrophage-derived 
foam cells.70 
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6.3.4 Use of peripheral monocyte-derived macrophages as a control 
in gene expression profiling 
Finally, the most significant limitation of this thesis was the use of peripheral monocyte-
derived macrophages from age- and sex-matched healthy individuals as the control for our 
microarray study. This approach made it difficult to distinguish gene expression changes 
specific to atherosclerotic macrophages from those arising from the in vitro differentiation 
of monocytes into macrophages. Our rational for using these cells are four-fold. Firstly, 
macrophages are present at extremely low density in non-diseased vascular intima – in our 
samples, aortic biopsies lacking early-stage plaque had fewer than 1-2 intimal macrophages 
per low-power field. Assuming those numbers are typical of what would be observed in 
non-diseased individuals, the density of macrophages in healthy intima would be too low 
to allow for recovery of enough cells for microarray analysis.  Secondly, the resident 
cardiac macrophages found in the healthy heart and adventitial macrophages found in 
healthy arteries are largely of embryonic origin and therefore are of a completely different 
ontology than plaque macrophages, the majority of which are hematopoietic in origin.71–73 
Thirdly, low-level atherosclerosis is near-ubiquitous in the North American adult 
population, making it questionable whether truly non-diseased tissue is available.74 Finally, 
it is established that myeloid cells undergo significant changes in their gene expression 
profiles as individuals age.75 As such, the choice to use monocyte-derived macrophages 
recapitulates the correct ontology and age of the cells, in sufficient numbers to enable 
experimentation, while allowing us to compare our patient samples to macrophages from 
an environment free of atherogenic cues. That said, the lack of aortic intima-specific 
developmental cues will have contributed some of the differentially-expressed genes we 
observed in our microarray dataset. While we took pains to verify through functional assays 
in vitro of GATA2-mediated impairment of efferocytosis and efferosome maturation, an 
alternative source of control macrophages would have added to our confidence in the 
macrophage phenotype we have described. Unfortunately, an appropriate population of 
macrophages to serve as a control is lacking. An alternative approach would have been to 
compare gene expression in macrophages isolated from early-stage and late-stage plaques, 
or to compare the expression of genes between monocytes and lesion-resident macrophages 
from the same patient. In our case this was not possible because of a lack of late-stage 
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plaque from our aortic punch tissue samples and the inability to specifically identify the 
patients from which each aortic punch sample was obtained due to the nature of our ethics 
approval, which was limited to use discarded tissue. 
 
6.4 Future Directions 
6.4.1 Understanding the role of Rab17 in antigen presentation and 
atherosclerosis 
In this thesis, we have demonstrated that Rab17 is a crucial mediator of cargo trafficking 
in efferocytosis. However, while we have demonstrated that interfering with Rab17 
function results in mis-trafficking of apoptotic cargo to the MHC class II loading 
compartment, whether this results in presentation of apoptotic cell-derived antigens 
remains to be seen. Moving forwards, we will utilize model pathogens and apoptotic cells 
expressing a fusion protein consisting of ovalbumin and the Eα peptide to study antigen 
presentation in a Rab17 knockdown model. Ovalbumin-derived antigens are presented on 
both MHC class I (SIINFEKL; H-2Kb) and MHC class II (OVA 323-339; I-A[d]), whereas 
Eα peptide is presented exclusively on MHC class II (Eα 52-68; I-A[b]). Presentation of 
ovalbumin-derived SIINFEKL peptide on MHC class I H-2Kb is readily detectable by the 
25-D1.16 mouse monoclonal antibody whereas presentation of Eα 52-68 on MHC class II 
I-A[b] can be detected using the Y-Ae mouse monoclonal antibody. Presentation of 
ovalbumin-derived antigens on MHC class I and MHC class II may also be assessed by T 
cell proliferation assays with naïve lymphocytes from OTI and OTII transgenic mice, 
which express a limited T cell repertoire such that they are only responsive to ovalbumin-
derived antigens. Using these methods, we will be able to assess the impact on antigen 
presentation following either phagocytosis of a pathogen or efferocytosis of an apoptotic 
cell under normal conditions and with Rab17 functionally knocked down.  
It will also be interesting to determine whether Rab17 has any biological role in 
atherosclerosis. Our microarray and functional data show that efferosome maturation and 
apoptotic cargo processing are dysregulated in atherosclerotic macrophages. Whether 
Rab17 plays a role in this process remains unknown. It is well established that the 
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development of plaque-reactive antibodies and T cells accelerates atherosclerosis disease. 
This raises the interesting hypothesis that impaired or altered apoptotic cell processing in 
atherosclerosis, potentially due to altered Rab17 activity, may drive the pro-atherogenic 
presentation of atheroma-derived antigens–self-antigens which normally be restricted from 
presentation by Rab17-mediated trafficking.76 We will seek to use live-cell fluorescence 
imaging to assess the recruitment of Rab17 to efferosome under atherosclerotic conditions 
and also to determine whether functional knockdown of Rab17 gives rise to any deleterious 
effect in atherosclerotic macrophages.  
6.4.2 Further elucidation of the biological role of GATA2 in 
atherosclerosis 
We have demonstrated thus far that GATA2 is upregulated in atherosclerotic macrophages 
in early-stage lesions and that GATA2 upregulation appears to be required for oxLDL-
mediated impairment of efferocytic uptake and efferosome maturation in these 
macrophages. We further demonstrated that signaling through the Src/Syk pathway 
downstream of the oxLDL receptors CD36, TLR2 and TLR4 is required for GATA2 
upregulation in response to oxLDL stimulus. However, there are still many unanswered 
questions about the role of GATA2 in atherosclerosis. 
First, there is a need to identify the mechanism(s) driving GATA2 upregulation. This could 
be through oxLDL signaling via CD36 or other receptors, or in response to ER-stress 
pathways activated in these cells—neither of which were explored in this thesis. This may 
be achieved using receptor-specific shRNA and inhibitors of TLR and ER-stress signaling. 
Second, it is still unclear how GATA2 upregulation results in impairment of efferocytosis 
and efferosome maturation. Data from our microarray analysis suggests that this may be 
through downregulation of signal transduction molecules required for efferocytic receptor-
mediated apoptotic cell internalization (e.g. ILK, ITGAX) and downregulation of specific 
genes required for efficient efferosome maturation (e.g. RAB7A, ATP6V1B1). However, 
this remains to be demonstrated experimentally. One immediate first step is to perform a 
ChIP-Seq assay in patient aortic punch macrophages or oxLDL-treated macrophages to 
determine which genes GATA2 regulates in these cells. It may also be of interest to directly 
compare gene expression in wild type macrophages compared to GATA2 overexpressing 
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macrophages to identify the complete set of genes for which expression levels change with 
increased levels of GATA2.  
Fundamentally, it will also be necessary to directly demonstrate that GATA2 has a 
biological role in atherosclerosis by studying the effect of GATA2 deletion on 
atherosclerotic plaque development. This will require generating a monocyte/macrophage-
specific Gata2 knockout mouse and either back-crossing this mouse onto a Ldlr-/- 
background or performing bone marrow transplantation from the Gata2 knockout into Ldlr-
/- mice. It is unclear at this time whether GATA2 is regulated the same in mice as in humans, 
with preliminary experiments in Ldlr-/- mice fed a high-fat diet for 12 weeks compared to 
chow diet-fed animals showing variable upregulation of GATA2 in the plaque. A myeloid-
specific approach is necessary because whole body Gata2 knockout is embryonically lethal 
due to hematopoietic and lymphatic collapse.54 Additionally, since GATA2 is required for 
maintenance of the hematopoietic stem cell population and for myeloid-lineage 
specification, it may be necessary create a floxed mouse where target gene recombination 
is under the transcriptional control of a gene that is only expressed in terminally-
differentiated monocytes (e.g. CD11b), or where GATA2 excision is controlled by a 
mature myeloid-restricted inducible knockout.54 We would then look at plaque size and 
surface area, necrotic core size, macrophage numbers and phenotype within the plaque as 
well as characterize plasma lipid levels and levels of circulating immune cells. Studying 
myeloid-specific Gata2 knockout will be critical in establishing a biological role for this 
transcription factor in atherosclerosis. 
6.4.3 Characterizing changes in macrophage and monocyte gene 
expression with atherosclerotic disease progression 
A limitation in the present study is a lack of an appropriate population of control 
macrophages to which atherosclerotic macrophage gene expression can be compared. One 
way to circumvent this difficulty is to compare the gene expression profiles of macrophages 
isolated from the plaques and monocytes isolated from the blood of patients with differing 
atherosclerotic disease severities. There are many clinical scores that assess atherosclerotic 
disease severity, including the Gensini score and the SYNTAX score.77,78 These scores 
may be used to stratify patients into differing categories of disease severity. The gene 
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expression profiles of macrophages and monocytes from patients from different categories 
may then be compared against one another. This approach will allow us to identify genes 
involved in atherosclerosis disease progression, at least within the latter stages of disease 
in humans. 
Another approach is to compare gene expression between lesion-resident macrophages and 
circulating monocytes within the same patient. This would allow us to determine the 
changes that occur in gene expression as monocytes migrate into the atherosclerotic plaque 
and differentiate into macrophages. Such an approach has the potential to answer important 
questions on the effect of the plaque microenvironment on macrophage function following 
migration into the plaque. 
6.4.4 Utilizing macrophage and monocyte gene expression profiling 
to predict clinical outcomes in patients with coronary artery 
disease  
Understanding gene expression changes in macrophages and monocytes with progressive 
atherosclerotic disease severity has the potential to allow us to identify important genes 
and pathways involved in the underlying biology of plaque macrophages. This information 
may then serve as a basis for determining whether differences in monocyte and macrophage 
gene expression can be used to predict clinical outcomes in patients with significant 
atherosclerotic disease (i.e. those patients who have experienced at least one cardiac or 
cerebrovascular event as a result of atherosclerosis).  
From a cohort of patients undergoing coronary artery bypass graft surgery for any reason, 
the expression of a few genes of interest (e.g. GATA2), as determined on the basis of 
characterizing the genes and pathways important for disease progression as outlined in the 
previous section, will be quantified. These patients will then be followed for a period of 
two years for cases of major adverse cardiovascular and cerebrovascular events (MACCE; 
defined as a composite of myocardial infarction, ischemic stroke, need for repeat bypass 
surgery and death).79 We will then determine whether gene expression in monocytes and/or 
macrophages correlate with the incidence of MACCE. This will allow us to determine 
whether the expression of certain genes in macrophages and/or monocytes can be used as 
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a biomarker of adverse clinical outcomes in patients with high existing atherosclerotic 
disease burden. 
 
6.5 Concluding Remarks 
In conclusion, the work presented in this doctoral thesis advances our understanding of 
efferocytosis and the mechanisms by which efferocytosis becomes impaired in the setting 
of atherosclerotic disease. We present three major findings: 1) the small GTPase Rab17 
traffics degraded apoptotic cell contents from the phagolysosome to the recycling 
endosome, likely preventing the presentation of apoptotic cell-derived antigens, 2) 
macrophages isolated from early-stage plaque down-regulate many of the genes required 
for efficient uptake and processing of apoptotic cells, and 3) upregulation of the 
hematopoietic transcription factor GATA2 is required for the onset of impaired 
efferocytosis and efferosome maturation in macrophages in response to oxLDL loading. 
The findings presented here advance our fundamental knowledge of how apoptotic cells 
are processed and degraded following internalization by an efferocyte. To date, how 
macrophages discriminate between pathogens and apoptotic cells during cargo processing 
is poorly understood. Previous studies have suggested that differences in TLR signaling 
from the phagosome or in the inherent differences in kinetics between phagosome and 
efferosome maturation are responsible for the divergent outcomes observed following 
efferocytosis and phagocytosis.21,80 Our observation that Rab17 is required for efferosomal 
cargo trafficking to the recycling endosome and that impaired Rab17 activity leads to mis-
trafficking of cargo to the MHC class II loading compartment (Chapter 3) suggests that 
there is a phagocyte-intrinsic, TLR-independent pathway that plays a role in discrimination 
between pathogens and apoptotic cell cargo. 
Our findings also challenge some widely-held notions in the field about the development 
of efferocytic defects in the setting of atherosclerosis. Our observation that lesion-resident 
macrophages from early-stage human plaques already have dysregulated expression of 
genes involved in efferocytosis (Chapter 4) suggest that the onset of impaired 
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efferocytosis may be occurring much earlier than previously thought. We are also the first 
to identify a potential defect in efferosome maturation in human lesion-resident 
macrophages (Chapter 4), suggesting that defects in how macrophages process apoptotic 
cargo, in addition to defects in recognition and efferocytic uptake of apoptotic cells, plays 
a role in the development of defective efferocytosis. Finally, we are also the first to identify 
a potential role for the hematopoietic transcription factor GATA2 in driving macrophage 
dysfunction in human atherosclerotic disease. We observed that GATA2 is required for 
oxLDL-mediated impairments in both efferocytic uptake and efferosome maturation 
(Chapter 5), implicating this transcription factor as a major driver of dysregulated 
macrophage function under atherosclerotic conditions. 
Much work remains to be done in furthering our understanding of the role of macrophages, 
defective apoptotic cell clearance and inflammation in atherosclerosis. Following decades 
of clinical interest and success in treating the dyslipidemia component of atherosclerosis, 
the results of the recent CANTOS trial have brought the inflammatory component of this 
disease back into the primetime.81 The results presented in this thesis represent a just small 
step forward in unraveling our understanding of the underlying mechanisms of how 
apoptotic cell clearance becomes impaired in human atherosclerotic disease. Importantly, 
our discovery of GATA2 as a potential master regulator of defective efferocytosis in early-
stage human atherosclerotic macrophages merits further investigation. GATA2 and its 
downstream targets may represent viable therapeutic targets in the development of novel 
anti-inflammatory agents for the treatment of the residual inflammatory risk in 
atherosclerosis.  
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Appendices 
Appendix A List of all constructs used in this thesis 
Gene Sequence 
qPCR primers 
18S 
5’-GAGGGAGCCTGAGAAACGG-3’ 
5’-GTCGGGAGTGGGTAATTTGC-3’ 
CD14 
5’-AGCCAAGGCAGTTTGAGTCC-3’ 
5’-TAAAGGACTGCCAGCCAAGC-3’ 
SMA 
5’-CCGACCGAATGCAGAAGGA-3’ 
5’-ACAGAGTATTTGCGCTCCG-3’ 
GATA2 
5’-GTCACTGACGGAGAGCATGA-3’ 
5’-GGCACATAGGAGGGGTAGGT-3’ 
E4F1 
5’-ACACCACACAGGCGAGA-3’ 
5’-TCCTCAGACACCAGCAAC-3’ 
RARG 
5’-CTGCCAGTACTGCCGGCTAC-3’ 
5’-TCTGCACTGGAGTTCGTGGTATACT-3’ 
ABCA1 
5’-GCACTGAGGAAGATGCTGAAA-3’ 
5’-AGTTCCTGGAAGGTCTTGTTCAC-3’ 
NPC1 
5’-AGCCAGTAATGTCACCGAAAC-3’ 
5’-CCGAGGTTGAAGATAGTGTCG-3’ 
NPC2 
5’-TATCCCTCTATAAAACTGGTGGTG-3’ 
5’-CCAGATGCACCGAACTCAAT-3’ 
RAB7A 
5’-CATCCTGGGAGATTCTGGAGTC-3’ 
5’-TGTGTCCCATATCTGCATTGTG-3’ 
ITGAX 
5’-GCTGAAGGCACACTGTGAAA-3’ 
5’-AGGGAGGCCGTGAAGTATCT-3’ 
CD44 
5’-TGGCACCCGCTATGTCCAG-3’ 
5’-GTAGCAGGGATTCTGTCTG-3’ 
ILK 
5’-ATGTACTACATGAAGGCACCAATTTC-3’ 
5’-CCCCTTGCCATGTCCAAAG-3’ 
PADI3 
5’-GGAGACCCTCGTGGACATTT-3’ 
5’-CTCCAAAGTCGCGTCAAAGC-3’ 
mGata2 
5’-GCAGAGAAGCAAGGCTCGC-3’ 
5’-CAGTTGACACACTCCCGGC-3’ 
mGapdh 
5’-CTCCCACTCTTCCACCTTCG-3’ 
5’-GCCTCTCTTGCTCAGTGTCC-3’ 
PCR primers 
GATA2 
5’-TATTTCCGGTGAATTCATGGAGGTGGCGGCCGAGCA-3’ 
5’-CGGGATCCGCGGCCGCTAGCCCATGGCGGTCACCATGCT-3’ 
Rab17 
5’- AAAAAAAAAGAATTCGATGGCACAGGCACACAGGACCCC-3’ 
5’-TTTTTTTTTGGATCCCTAGTGGGCGCAGCATTTGGCCT-3’ 
DN-Rab17 
5’-GCCCACCAGCATCACCAGGACTTC-3’ 
5’-ATCAAGACGGACCTCAGCCAGGAGCGG-3’ 
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shRNA sequences 
GATA2 
5'-AAGGATCCAGCAAGGCTCGTTCCTGTTCATCAAG 
AGTGAACAGGAACGAGCCTTGCTTTTTTACCGGTAA-3' 
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Appendix B List of all primers and oligos used in this thesis. 
Construct Backbone 
Enzyme Cut 
Sites 
Sequencing 
Primer(s) 
PM-RFP pcDNA3 HindIII; XbaI 
CMV; 
SV40pA-R 
PM-GFP pcDNA3 HindIII; XbaI 
CMV; 
SV40pA-R 
Rab5-GFP pEGFP-C1 EcoRI; BamHI 
EGFP-C; 
SV40pA-R 
Rab7-RFP pmCherry-C1 EcoRI; BamHI SV40pA-R 
Rab17-GFP pEGFP-C1 EcoRI; BamHI 
EGFP-C; 
SV40pA-R 
Rab17-RFP pmCherry-C1 EcoRI; BamHI SV40pA-R 
DN-Rab17-RFP pmCherry-C1 EcoRI; BamHI SV40pA-R 
Rab6b-GFP pEGFP-C1 EcoRI; BamHI 
EGFP-C; 
SV40pA-R 
Rab45-GFP pEGFP-C1 EcoRI; BamHI 
EGFP-C; 
SV40pA-R 
pLVX-IRES-
ZsGreen1 GATA2 
pLVX-IRES-
ZsGreen1 
EcoRI CMV 
pGFP-C-shLenti 
GATA2 shRNA1 
pGFP-C-shLenti BamHI; AgeI CMV 
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Appendix C List of the 100 most up-regulated genes from the patient macrophage 
microarray 
Number Gene Symbol Fold Change 
1 OR2T12 9.62722 
2 LRRC3C 6.74565 
3 ZNF705E 4.42287 
4 LOC646743 3.85502 
5 CLEC18A 3.84465 
6 TCEA2 3.78658 
7 GPRC5D 3.78366 
8 OR52I1 3.7386 
9 OR2A42 3.50104 
10 KRTAP12-4 3.42346 
11 LINC01562 3.33314 
12 CHFR 3.22888 
13 OR51S1 3.20428 
14 PGM5 3.16232 
15 C10orf53 3.12336 
16 BAGE4 3.07173 
17 CAMK2N2 3.05843 
18 C7orf65 3.05369 
19 OR2T3 3.02501 
20 OR51B4 2.93111 
21 ZNF648 2.92935 
22 ZNF675 2.86593 
23 NBPF4 2.86195 
24 KRTAP4-8 2.73692 
25 TMEM200C 2.73062 
26 TPBGL 2.66528 
27 PRAMEF8 2.66506 
28 AVP 2.66329 
29 LOC101930023 2.65457 
30 RAB44 2.63632 
31 KCNK18 2.61918 
32 CNTNAP3 2.60335 
33 CHST3 2.55363 
34 C3orf18 2.54441 
35 OR10H4 2.53899 
36 FOXF2 2.53369 
37 CACNG5 2.52677 
38 OR5F1 2.50943 
39 C9orf62 2.48851 
40 FAM26E 2.48581 
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41 ZACN 2.48312 
42 HPCA 2.47082 
43 OLFM1 2.4674 
44 LGALS14 2.46699 
45 YAP1 2.45382 
46 MSX2 2.45281 
47 KRT81 2.43951 
48 CHST5 2.43565 
49 GATA2 2.42342 
50 ANKRD63 2.42284 
51 TMEM98 2.42282 
52 C5orf60 2.41695 
53 MYH7 2.40692 
54 KIR3DL2 2.37758 
55 CFAP77 2.37248 
56 LOC162137 2.37207 
57 NANOS3 2.36682 
58 S100A7A 2.36563 
59 ARID3C 2.36417 
60 GOLGA7B 2.3582 
61 LINC00355 2.34773 
62 SNORA78 2.3349 
63 TMEM74B 2.32943 
64 E4F1 2.32076 
65 SPRN 2.3178 
66 RARG 2.30969 
67 LOC101929469 2.30961 
68 PADI3 2.30731 
69 FOXD4L5 2.30638 
70 MTRNR2L10 2.2982 
71 LDB3 2.29628 
72 MAGIX 2.2868 
73 PNMA5 2.2776 
74 FKRP 2.27714 
75 LAGE3 2.27668 
76 ANKRD60 2.27227 
77 HOXA7 2.25975 
78 SBK3 2.25707 
79 MOSPD3 2.24509 
80 PSKH2 2.24342 
81 ANTXRL 2.23942 
82 LMX1B 2.23414 
83 LOC101927503 2.22992 
84 C1orf116 2.22789 
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85 CGN 2.22447 
86 HSFX1 2.21322 
87 TRPC7 2.21214 
88 HNF4A-AS1 2.2089 
89 ST6GALNAC5 2.20807 
90 KCNJ14 2.20672 
91 HCRTR1 2.20412 
92 BHLHB9 2.19662 
93 CYP2A13 2.19164 
94 TCEAL3 2.18544 
95 DRD3 2.184 
96 MMRN1 2.18251 
97 LOC100287477 2.18245 
98 KDM4D 2.18208 
99 DNAJB7 2.17999 
100 RUNX1T1 2.17761 
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Appendix D List of the 100 most down-regulated genes from the patient 
macrophage microarray 
Number Gene Symbol Fold Change 
1 TXN -411.775 
2 C15orf48 -304.907 
3 FTL -273.736 
4 SUMO2 -251.54 
5 HLA-DRA -249.226 
6 PLAUR -213.088 
7 RAB7A -181.069 
8 CTSS -175.483 
9 OAZ1 -161.761 
10 TMSB10 -155.19 
11 CYBB -142.868 
12 FCER1G -125.149 
13 POMP -117.743 
14 PRDX1 -117.17 
15 LAPTM5 -114.969 
16 CCL4 -112.871 
17 CXCL16 -111.563 
18 SLC7A11 -106.723 
19 NPC2 -103.934 
20 RPL27 -99.386 
21 MMP9 -94.4103 
22 PSAP -90.8828 
23 SQRDL -88.5736 
24 ATP6V0E1 -87.0824 
25 IGSF6 -86.649 
26 IFI30 -86.0078 
27 CD68 -85.0816 
28 COX4I1 -84.5514 
29 SRGN -84.234 
30 SLAMF7 -81.9502 
31 LYZ -81.1264 
32 RPL41 -81.035 
33 CHI3L1 -80.5382 
34 RPS2 -79.1202 
35 CBWD2 -77.2671 
36 ATP6V1F -76.9367 
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37 BCL2A1 -70.9492 
38 PLA2G7 -70.2001 
39 PSMA3 -69.3309 
40 ARPC5 -68.7327 
41 RPS2 -68.2021 
42 COX8A -67.5268 
43 AQP9 -66.065 
44 ACTG1 -65.3203 
45 RAB31 -64.7101 
46 ATP5B -61.2968 
47 GMFG -60.7423 
48 TNFAIP6 -58.9338 
49 ANXA5 -57.8008 
50 NBEAL1 -57.4835 
51 UBA52 -56.6651 
52 SEP15 -56.6403 
53 SPP1 -56.5101 
54 DAD1 -56.3629 
55 CD44 -55.613 
56 LAPTM4A -55.4191 
57 SOD1 -53.6316 
58 EIF4G2 -53.1141 
59 ADAMDEC1 -52.9579 
60 AHR -52.8631 
61 CES1P1 -51.9996 
62 ITGAX -51.7944 
63 WSB1 -51.2909 
64 ACTR3 -50.372 
65 FDX1 -50.1473 
66 NDUFA1 -49.7039 
67 UBE2K -48.7071 
68 PSMB3 -48.5966 
69 KYNU -48.1175 
70 RPS2 -47.79 
71 MSN -47.2697 
72 SERINC3 -46.8628 
73 ANXA1 -46.2265 
74 RPS28 -45.5 
75 CYB5A -45.3311 
76 GLIPR1 -44.9408 
77 CALR -44.1832 
78 TIMM23 -43.4285 
79 ITM2B -42.5918 
80 RAB1A -42.1434 
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81 RPS11 -42.0848 
82 GRN -41.6052 
83 CCL2 -41.4591 
84 VAMP8 -41.3574 
85 APLP2 -41.1694 
86 MMP7 -40.7584 
87 HIST1H2AC -38.9235 
88 IL1A -38.9067 
89 VMP1 -38.8178 
90 DRG1 -38.6188 
91 ATP6AP2 -38.5816 
92 IL1B -37.4948 
93 ATP6V1C1 -37.2856 
94 YBX1 -37.2772 
95 CSGALNACT2 -36.9458 
96 ERP44 -36.484 
97 NOP10 -36.1277 
98 CXCR4 -35.7405 
99 CCL3L3 -35.4365 
100 ELF1 -35.0605 
264 
 
Appendix E Patient aortic punch collection protocol ethics permission 
 
265 
 
Appendix F Human whole blood collection protocol ethics permission 
 
266 
 
Appendix G Animal use protocol ethics permission 
 
 
267 
 
 
 
268 
 
Appendix H Permission to use published manuscript from Springer Nature 
 
269 
 
 
 
270 
 
Appendix I Permission to use published manuscript from Taylor & Francis 
 
 
271 
 
Curriculum Vitae 
 
Name:   Charles Yin 
 
Post-secondary  McMaster University 
Education and  Hamilton, Ontario, Canada 
Degrees:   2010-2014 B.Sc. (Hons.) Integrated Science 
 
The University of Western Ontario 
London, Ontario, Canada 
2016-2019 Ph.D. Microbiology and Immunology 
 
The University of Western Ontario 
London, Ontario, Canada 
2014-2021 M.D. (expected) 
 
Honours and   The University of Western Ontario 
Awards:   Hargreaves MD Award 
   2014-2016, 2019-2021 
 
Canadian Institutes of Health Research (CIHR) 
MD/PhD Studentship 
2015-2020 
 
Canadian Institutes of Health Research (CIHR) 
Frederick Banting and Charles Best Canada Graduate Scholarship 
2016-2017 
 
The University of Western Ontario 
Western Graduate Research Scholarship 
2016-2019 
 
Department of Microbiology and Immunology 
Dr. Frederick W. Luney Graduate Travel Award 
2017 
 
Canadian Institutes of Health Research (CIHR) 
Vanier Canada Graduate Scholarship 
2017-2019 
 
The University of Western Ontario 
Inductee to School of Graduate and Postdoctoral Studies Wall of 
Fame 
2017 
272 
 
Society for Leukocyte Biology (SLB) 
Travel Award 
2017 
 
Department of Microbiology and Immunology 
Infection and Immunity Research Forum 1st Place Oral 
Presentation Award 
2017 
 
International Atherosclerosis Society (IAS) 
Young Investigator Fellowship 
2018 
 
Department of Microbiology and Immunology 
Dr. Frederick W. Luney Graduate Travel Award 
2018 
 
The University of Western Ontario 
London Health Research Day Feature Platform Presentation 
Award 
2018 
 
The University of Western Ontario 
Nellie Farthing Fellowship in Medical Sciences 
2018 
 
Public Service Alliance of Canada, Local 610 
Scholarship for Outstanding Research Contributions 
2018 
 
Department of Microbiology and Immunology 
Infection and Immunity Research Forum Poster Award 
2018 
 
Society for Leukocyte Biology (SLB) 
Presidential Award 
2018 
 
Network of Immunology Frontier Winter School on Advanced 
Immunology 
Travel Fellowship 
2019 
 
Canadian Society for Immunology (CSI) 
Travel Award 
2019 
273 
 
 
Department of Microbiology and Immunology 
Dr. Frederick W. Luney Graduate Travel Award 
2019 
 
Department of Microbiology and Immunology 
John A. Thomas Award 
2019 
 
Canadian Resident Matching Service (CaRMS) 
Sandra Banner Award for Leadership 
2019 
 
The University of Western Ontario 
London Health Research Day Feature Platform Presentation 
Award 
2019 
 
Canadian Institutes of Health Research (CIHR) 
Canadian Student Health Research Forum Travel Award 
2019 
 
Related Work  Teaching Assistant – Microbiology Laboratory 3610F 
Experience   The University of Western Ontario 
2016-2017 
 
Publications: 
Law, J. and C. Yin. (2015). A day with an orthoptist. University of Western Ontario 
Medical Journal. 84(1):23-24. 
 
Armstrong, S.M., Sugiyama, M.G., Fung, K.Y.Y., Gao, Y., Wang, C., Levy, A.S., Azizi, 
P., Roufaiel, M., Zhu, S.-N., Neculai, D., Yin, C., Bolz, S.-S., Seidah, N.G., Cybulsky, 
M.I., Heit, B. and W.L. Lee. (2015). A novel assay uncovers an unexpected role for SR-
BI in LDL transcytosis. Cardiovascular Research. 108(2):268-277. 
 
Yin, C. and J. Law. (2015). Community-acquired pneumonia and pneumococcal 
vaccination in the elderly. University of Western Ontario Medical Journal. 84(2):23-25. 
 
Novakowski, K.E., Huynh, A., Han, S., Dorrington, M.G., Yin, C., Pelka, P., Whyte, P., 
Guarne, A., Sakamoto, K. and D.M.E. Bowdish. (2016). Naturally occurring transcript 
variants of macrophage receptor with collagenous structure (MARCO) reveal that the 
scavenger receptor cysteine rich (SRCR) domain is critical for ligand binding and uptake. 
Immunology & Cell Biology. 94(7):646-55. 
 
274 
 
Yin, C. and S. Danby. (2016). A review of housing-first strategies in reducing rates of 
substance use amongst people experiencing homelessness. University of Western Ontario 
Medical Journal. 85(1):35-37. 
 
Danby, S. and C. Yin. (2016). A review of issues concerning implementation of cardiac 
rehabilitation programs. University of Western Ontario Medical Journal. 85(2):66-68. 
 
Yin, C., Kim, Y., Argintaru, D. and B. Heit. (2016). Rab17 mediates differential antigen 
sorting following efferocytosis and phagocytosis. Cell Death and Disease. 7(12):e2529. 
 
Yin, C., Daoust, K., Young, A., Tebbs, E.J. and D.M. Harper. (2017). Tackling 
community undernutrition at Lake Bogoria, Kenya: the potential of Spirulina 
(Arthrospira fusiformis) as a food supplement. African Journal of Food, Agriculture, 
Nutrition and Development. 17(1):11603-11615. 
 
Yin, C., Steadman, P.E., Apramian, T., Zhou, T.E., Ishaque, A., Wang, X., Kuzyk, A. 
and N. Warsi. (2017). Training the next generation of Canadian clinician-scientists: 
charting a path to success. Clinical and Investigative Medicine. 40(2):E95-E101. 
 
Novakowski, K.E., Yap, N.V.L., Yin, C., Sakamoto, K., Heit, B., Golding, G.B. and 
D.M.E. Bowdish. (2017). Human-specific mutations and positively-selected sites in the 
macrophage receptor with collagenous structure (MARCO) confers functional changes. 
Molecular Biology & Evolution. 35(2):440-450. 
 
Yin, C. and B. Heit. (2017). Armed for destruction: formation, function and trafficking of 
neutrophil granules. Cell & Tissue Research. 371(3):455-471. 
 
Evans, A.L., Blackburn, J.W.D., Yin, C. and B. Heit. Quantitative efferocytosis assays. 
In: Botelho, R., ed. Phagocytosis and Phagosomes. New York: Springer. 2017. p25-41. 
 
Yin, C., Blom, J.N. and J.F. Lewis. (2018). The 2nd annual clinician scientist trainee 
symposium, August 22, 2017, London, Canada. Clinical and Investigative Medicine. 
41(1):E34-E36. 
 
Taruc, K., Yin, C., Wootton, D.G. and B. Heit. (2018). Quantification of efferocytosis by 
fluorescence microscopy. Journal of Visualized Experiments. 138:e58149. 
 
Yin, C., Barra, L., Nagpal, D. and B. Heit (2018). Gene expression profiling of lesion-
resident macrophages in human atherosclerosis. Atherosclerosis. 32:106. 
 
Yin, C., Argintaru, D. and B. Heit. (2019). Rab17 mediates intermixing of phagocytosed 
apoptotic cells with recycling endosomes. Small GTPases. 10(3):218-226. 
 
Wavell, C., Sokolowski, A. Yin, C., Klingel, M. and A.D. Nagpal. (2019). Clinical 
effectiveness of durable continuous-flow left ventricular assist device (LVAD) therapy in 
275 
 
non-ischemic versus ischemic cardiomyopathy: a systematic review and meta-analysis. 
Canadian Journal of Surgery. Accepted. 
 
Yin, C., Moszcyznski, A.J., Blom, J.N., Johnson, T.P.E. and D.L. Jones. (2019). 
Advancing the understanding of research in medical education through collaborative 
learning: the Collaboration of Practitioners and Researchers Seminar Series. BMC 
Medical Education. In Review. 
 
Yin, C., Vrieze, A.M., Akingbasote, J., Pawlak, E.N., Jacob, R.A., Hu, J., Sharma, N., 
Blackler, G., Dikeakos, J.D., Barra, L., Nagpal, A.D. and B. Heit. GATA2 Expression by 
Intima-Infiltrating Macrophages Drives Early Atheroma Formation. bioRxiv 715565. 
 
Levit, A., Yin, C. and J.F. Lewis. (2019). The 4th annual clinician scientist trainee 
symposium at the Schulich School of Medicine & Dentistry. Clinical and Investigative 
Medicine. Submitted. 
 
